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children’s children. I will be joining you soon, baby, there are just a few things daddy
needs to do first.
The words of the teacher…Meaningless! Meaningless! Utterly meaningless! Everything is meaningless.
What do people gain from all their labors at which they toil under the sun?
Is there anything of which one can say, “Look! This is something new?”
So I applied my mind to study and to explore by wisdom all that is done under the heavens.
What a heavy burden God has laid on mankind!
I have seen all the things that are done under the sun;
all of them are meaningless, a chasing after the wind.
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Then I applied myself to the understanding of wisdom, and also of madness and of folly,
but I learned that this, too, is a chasing after the wind.
For with much wisdom comes much sorrow; the more knowledge, the more grief.…
So I saw that there is nothing better for a person than to be happy
and to do good while they live…and to enjoy their work…
The Book of Ecclesiastes
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QUALITATIVE REPORTS OF MICHIGAN MEDICAL MARIJUANA
PATIENTS AND CAREGIVERS INCLUDING
REDUCED OPIATE USE, DISPENSARY OPERATIONS,
LEGAL CONCERNS, AND MARIJUANA STRAINS
Chapter 1: BACKGROUND

Introduction:
The use of marijuana has been a particularly contentious issue in the United
States for many decades. This is unexpected since, until the 1937 Marijuana Stamp Act
(P.A. 238, 75th Congress, 50 Stat. 551, Aug. 2, 1937) marijuana was common and
grown throughout the country as a commodity that provided oil, fiber, food, and
medicine.

Marijuana use in world history is also extensive, predating the written

historical record by many thousands of years. This substance, once commonly used by
physicians for a variety of medical treatments, has gone from a commodity used across
the globe for a number of purposes, including for medicinal purposes as a medicine, to
totally banned in almost every country. A resurgence in the use of marijuana in the
1960’s was met by the counter-force of U.S. federal law and a variety of international
treaties instigated by the United States government which legislated in 1970 that
marijuana was a “schedule I drug” with “no legitimate medical use and a high propensity
for abuse” (P.A. 91513, 91st Congress, 84 Stat. 1242, Oct. 27, 1970).
Despite marijuana prohibition, recently there has been an increase in claims
about potential medical uses for marijuana. By 2013, the perceived efficacy of medical
marijuana as a palliative for a number of diseases and conditions and even as an actual
treatment prompted 17 States and the District of Columbia to legalize the medical use of
marijuana in opposition to federal law while two States, Washington and Colorado, have
legalized marijuana for all purposes. These diverse views on marijuana have caused
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numerous conflicts on the political scene, as well as confrontations between extremists
on both sides.
Although much has been written about marijuana use in contemporary popular
media, these have tended to focus, until very recently, on validating the governments
unambiguous anti-marijuana position. A calmer, more reasoned and balanced analysis
of the different perspectives of individuals who have specific concerns regarding the use
of marijuana is needed. The major problem is that until very recently the perspective of
marijuana users has not been the focus of the media, academia, medicine, and
scientific research. Meanwhile, the courts, law enforcement, and other government
agencies have used harsh tactics to subject marijuana users to penalties and thereby
marginalize them and made research on the population of users, and on the banned
substance itself, extremely difficult.

As a result, there has been no almost no

dispassionate analysis, almost no research, no funded clinical studies, and little
research whatsoever since the 1950s on the people who have committed themselves to
the use, provision, and supply of marijuana or the people claiming a medical need to
use medical marijuana.
The researcher of this study is medical marijuana patient in Michigan his
physician approved certification card was issued by the State in 2008, the same year
the Michigan Medical Marijuana Act was enacted into law by public referendum. For this
dissertation, the initial idea was to explore one central question: is medical marijuana a
legitimate medicine or a ruse to legalize marijuana? This question encapsulates the
societal dialectic on the issue of marijuana use with a clear split between users and
supporters of Marijuana and non-users and detractors.
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However, it quickly became apparent, the data being collected from medical
marijuana patients was decidedly one sided and was going to strongly affirm the
efficacy of marijuana as medicine. Thus the research question developed into a
advocacy oriented approach with the search for finding the “ruses” in medical marijuana
use changing to the more grounded, exploratory task of presenting the less researched
side of the marijuana question; the perspective and views of marijuana users. Thus,
there is no representation that this data is unbiased. In fact, this data collected for this
dissertation were all collected from patients and providers and is decidedly one-side of
this complicated issue that should be read in that context. In presenting the views of
medical marijuana patients and caregivers, the aim of this paper became, and is, at
least in part, a vehicle for the purpose of claims making and legal reform in favor of the
pro-medical marijuana position and against the anti-marijuana position.
The methodology of the data collection employed in this study arose primarily
from an assumption that two distinct and polarized groups are represented by pro- and
anti-marijuana social forces and that this societal split has been exacerbated by the
increasing number of states that have legalized or allow the use of medical marijuana.
The historical and social literature research led to this assumption even before the
earliest collection of data which is that the pro-marijuana forces have not been given an
equal voice in the ongoing social debate about marijuana. Literature research very
quickly and unambiguously revealed that little is known about the medical marijuana
using population of the United States and less about the medical marijuana population
in the state of Michigan. Then, from the very earliest collection of data, it became very
obvious that the answer to the initial question: Is medical marijuana a “ruse” to legalize
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marijuana or is marijuana actually being used as a medicine by some patients was
going to be very clear: Despite the claims of federal law, the popular media, political
figures, and law enforcement, marijuana was and is being used as medicine, by at least
some individuals, at least some of the time. However, since the pro-marijuana forces
have not been given an equal voice in the ongoing social debate about marijuana, there
has been insufficient research on the topic of medical marijuana use and on the medical
marijuana population.
Therefore, the primary purpose of this study was to identify the unique
perspectives of the marijuana using population, including the producers.

Despite

considerable research on the negative effects of marijuana in the journals and
presented in the media, there is, by comparison, almost no research on medical
marijuana and even less research on the opinions and feelings of the population of
marijuana users who feel that it is medically necessary. Therefore, uncovering the
perceptions, concerns, thoughts, ideas, and words of an understudied segment of
society, the medical marijuana population in Michigan was the main objective of this
study.
In addition, the imbalance in the available research between pro and antimarijuana views within the government, law enforcement, popular culture and media
became a primary driving force for this research.

The observation that the pro-

marijuana forces have not been given an equal voice in the ongoing social debate left a
great deal of room for research of this topic. Very little effort has been expended to
discover the positive aspects of marijuana or the perspective of medical marijuana
users and producers whose unique perspective about legal enforcement, organizational
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structures, and the use of marijuana as medicine is relevant to the debate. While there
is certainly considerable research on the negative effects of marijuana in the journals,
presented in the media, and funded by various federal agencies, there is almost no
research on medical marijuana, and even less research on the opinions and feelings of
the population of marijuana users who feel that it is medically necessary. This creates
an unbalanced split in society between the “pro” and “anti” marijuana groups.
The Cannabis Dialectic:
The dialectical form of argument is an attempt to resolve a highly polarized
dispute by reasoned debate of the two sides and the formation of a generally agreed
upon, logical conclusion. Hegel (1831, The Science of Logic), as later popularized by
Kant and Marx, termed one side the “Thesis” and the other, the “Antithesis,” with an
ultimate “Synthesis” usually resulting from a reasoned Socratic debate. A Hegelian
Dialectic requires an intractable dispute not readily resolved, either because the
premises are not predicated on logic, or there is not a single, logical conclusion. This
true polarization of perspectives results because each side is convinced of the
righteousness of their position this certainly describes the longstanding arguments
about medical marijuana. The characteristics and views of patients and caregivers on
the legalization and medical marijuana debate are important to a better understanding
this “cannabis dialectic.”
The two sides in the social debate about marijuana have predictably had very
different responses to the legalization of medical marijuana in California. It was ratified
by ballot initiative (Proposition 215, Nov. 5. 1996). It was passed by the electorate with
approval from 56% of California voters. Rolling Stone magazine argued in response to
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the proposition that the war on marijuana exists for “political purposes” and was
“completely outside of medical considerations” (Akhavan 1997). On the other hand,
The New Republic argued that Proposition 215 serves as a front for drug legalization
advocates and that medical cannabis clubs are populated by a "sorry lot of smokers
who are not sick" (Akhavan 1997).
Because of this dialectical social split, public perception about the actual
characteristics of patients is extremely polarized with each side crafting an image of the
marijuana population. On one side, pro-medical marijuana activists characterize the
issue using broad, largely unsubstantiated claims about the medical efficacy of
marijuana and heart breaking stories of desperately sick patients who just want access
to their “medicine.” They claim to see a group of desperately ill patients who want to be
left alone, so they can die in peace. The other side claims to see a group of
malingerers, criminals, and drug addicts, who need to be regulated and controlled. They
highlight the demonstrated dangers of marijuana, deny the efficacy of marijuana as
medicine, and respond with loud cries of fraud alleging that the entire movement is a
covert strategy to legalize all drugs for recreational purposes.

Despite the starkly

contrasting images each side portrays, there is no academic research describing the
Michigan medical marijuana population from the perspective of patients and providers,
and almost no research attempting to describe the patient population in other States.
The perspective of actual medical marijuana patients in this ongoing and widely
commented upon public debate about marijuana has been almost completely
overlooked despite the vitally important, albeit biased, views of this selected population.
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Meanings Attached to Marijuana Use:
The social group of medical marijuana users and suppliers, and the meanings
they assign to the role of being a medical marijuana user have therefore gone through a
dramatic transformation in the last few years. The search for meaning in this group has
not been completely overlooked and has been a topic in sociology since Becker’s
“Becoming a Marijuana User” in the 1950’s (Becker 1953).

Becker used a

dramaturgical approach derivative of Ervin Goffman’s methodology to describe how
participants adopt the role of marijuana users. The goal of this dissertation was similarly
to present an interpretive structure that describes the meaningful social actions and
interactions of legal medical marijuana use and reveals the meanings that users attach
to the use of different types of medical marijuana. Though it would be fascinating to
study the country as a whole and look at the regional differences associated with the
meanings of medical marijuana, the focus of this study was limited to Michigan.
Clearly, in the minds of the medical marijuana community, there is a strong belief
that marijuana is a valid, safe medication that helps a number of conditions. While,
those who believe in continued universal prohibition perceive marijuana as a dangerous
drug with significant adverse health consequences and its potential use leads to the
abuse of even more dangerous drugs. Thus the ultimate question for “medical
marijuana” is whether marijuana is actually being used as a medicine or being abused
as an intoxicant. The validity, safety and efficacy of marijuana as medicine is the pivotal
issues for medical marijuana. If marijuana is a safe and legal drug that treats a number
of medical conditions then the arguments of the anti-marijuana groups becomes
substantially compromised. On the other hand, if marijuana is a dangerous drug with
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significant side effects that do not actually treat or ameliorate the symptoms of several
medical conditions then the arguments of the pro-marijuana groups becomes
substantially compromised.
The topics of the data collection were greatly influenced by the narrow time frame
and the unique social and legal climate in which they took place. Data collection was
done during the time when the medical marijuana dispensary distribution network in
Michigan was active and concluded one month before the Michigan Supreme court
decision in People vs. McQueen outlawed dispensaries in Michigan. Therefore, much
of this study sheds light on a period of time prior to the current interpretation of the law.
This data is still valuable insofar as it provides a social and legislative model for legal
marijuana distribution in Michigan after McQueen.
The marginalization of marijuana users is a relatively modern development. In
many social/political circles, marijuana is considered criminal and distasteful for any
reason medical or otherwise. However, the use of marijuana is as pervasive and as
persistently stubborn as the discrimination against marijuana users. The war on drugs
continues even as many of the leaders of our society defend their experiences with
marijuana. While there is a clear trend towards marijuana use being less and less of a
scandal for political figures, it still creates a media frenzy when people who must have
transparent social backgrounds and ideologies are discovered to have used marijuana
purely for recreational purposes:
-Current President Barrack Obama Who stated at a debate in 2007: “Of course I
inhaled, that was the point” (Venkataraman, 2007);
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-Former President Bill Clinton who admitted in 1991: “I did smoke marijuana, but
I never inhaled” (Kurtzman, 2000);
-Former Vice-President Al Gore who stated in 1987: “When I was young, I did
things young people do. When I grew up I put away childish things” (Gore, 1990);
-Former Speaker of the House and former Republican candidate for President
Newt Gingrich who stated in a column: “[smoking marijuana]." was a sign we were alive
and in graduate school in that era” (Gingrich, 2010).

He was joined by countless

doctors, lawyers, professors, and engineers, among others.
The history of Marijuana as a plant with Medicinal properties reaches back
through thousands of years of history, moves up through the very foundations of our
nation, and has played a surprisingly important part in U.S. history. The current state of
marijuana use as a federal crime, when there is evidence it has a possible legitimate
medical usage, is an interesting and unique social phenomenon. The modern social
stigma on users, including those who use it for relief of suffering, has developed over
time. Its development in history itself frames the current dichotomy in opinion about this
controversial plant.

One side of this social debate has dominated popular culture,

media, and government efforts for many years. This paper is one answer to these
many years of efforts to demonize marijuana users and is committed to presenting the
perceptions and views of users and suppliers of medical marijuana in Michigan.
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Chapter 2: LITERATURE REVIEW
Introduction:
The history of hemp began thousands of years ago, long before the start of
recorded history. Before it was a target in the War on Drugs, hemp was an important
cash crop, with many uses and many products were derived from the plant. The
cultivation and use of marijuana in both World and American history is startling when
the contemporary stigma of marijuana is dissected. Today’s legal issues, in particular
the entire history of the War on Drugs and the more recent issue of medical marijuana,
when viewed in historical context, provide some unexpected insight. One of the keys to
better understanding the population of medical marijuana users, including obtaining a
preliminary understanding of the demographics, the social and economic correlates and
the meanings that patients attach to the use of marijuana, requires an exploration the
meanings attached to marijuana and hemp use, both by the users and by those who
stigmatize the users.
There is little modern research on the medical marijuana population and that
which exists has employed qualitative interview designs (Chapkis 2008). There has only
been one study (published in a non-peer reviewed journal) detailing the demographics
of the marijuana population in California (O’Connell 2007) and no such study has been
published on the Michigan medicinal marijuana population. This lack of research is a
consequence of a long and complicated history of hemp and cannabis in the United
States. Therefore, to understand the status of research and how the current legal
climate affects the type of data that can be collected in support or refutation of “medical”
marijuana. It is important to review the status of this substance in our history.
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The History of Hemp:
Marijuana has been used in many ways for thousands of years and may even
have been the first plant cultivated by hunter-gatherer groups (Herer 2000, Sagan
1986).

“Primitive” hunter-gatherer bands did not wander aimlessly through the

wilderness, but often completed a yearly circuit of their ranged habitat, returning to
various areas during the times wild crops were ready for harvesting. Primitive humans,
therefore, picked berries in one area. Then, when the supplies were depleted, they
would pick wild rice in another, and it is likely they did the same thing when the
marijuana plants were in bloom (Diamond 1998). Hunter-gatherer groups eventually
settled in areas such as the Nile River Valley and the Fertile Crescent region of modern
day Iraq located in the valley between the Tigris and Euphrates rivers. Each of these
river valleys which are often called the ‘cradles of civilization’ overlap with the natural
range of cannabis. This fact, considered in light of the ease of marijuana cultivation, the
multiple uses of the plant, and the substantial increase in yields that can be achieved
with minimal cultivation intervention, gives considerable weight to the notion that
marijuana may have even been the first crop ever cultivated.
Marijuana is a dioecious plant which means it has clear and obvious male and
female genders that are quite unlike any other cultivated or wild-type crops. In
particular, the mature (female) flowers of the marijuana plant are eagerly consumed by
practically every mammal and even some birds (Begg 2005). There is no doubt the
attraction of these flowers would have made the plants useful for lure as “baiting” which
is still practiced today.
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The strongest evidence that marijuana was actively cultivated in this way by early
humans is indirect but persuasive.

As with any plant, active cultivation, regular

weeding, fertilizing, protection against predation and so on will dramatically increase
yields, but marijuana is unique in this regard. Only a small amount of attention and
cultivation work results in an increase in crop yield, especially yield that is not lost to
predation that is remarkable (Rosenthol 2010). In addition to this fact, anthropological
evidence suggest that hemp was the first plant to be domesticated for human use, and
these claims certainly abound at a number of activist web sites. This contention is
supported by one of the earliest pieces of agricultural evidence ever discovered. A
hemp cord imprint on a shard of pottery was discovered in Central Asia dating back to
25,000 B.C. (Herer 2000). This suggests the cultivation and use of hemp in central Asia
has been pursued for at least 27,000 years.
The earliest evidence for the use of marijuana as a medicine was found in
ancient Egyptian excavations dating from as early as 1600 B.C. One recovered
document claimed that marijuana was used for pain relief, Asthma, and Gout. Ancient
Hebrew excavations confirm this text and provide other texts, recommending the use of
marijuana in childbirth around this same time (Herer 2000).
The idea for using marijuana in a recreational manner does not appear in the
historical record until the Greek historian Herodotus described the Scythians communal
use in 440 B.C. Herodotus noted that the nomadic culture sat around the fire, “creeping
under the felt booths.” They threw collected cannabis tops into a dish placed atop red
hot stones: “Immediately it smokes, and gives out such a vapor as no Grecian vapor
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bath can exceed.” This activity “delighted” the Scythians causing them to “shout for joy”
(Id).
By 1492, each of Columbus’ three ships carried some 80,000 pounds of hemp,
primarily in the sailings, ropes and riggings (Booth 2005). In the United States, hemp
was an important cash crop for the Colonies. The first law on agriculture ever
promulgated in the New World was in America’s Jamestown Colony, Virginia in 1619
ordering all farmers to grow Indian hempseed. There were several other “must grow”
laws over the next 200 years (farmers could be jailed for not growing hemp during times
of shortage in Virginia between 1763 and 1767), and during most of that time, hemp
was legal tender. Citizens could even pay their taxes with bales of hemp (Id).
Throughout history, Hemp has been a constant part of the growing and
expanding global society and was used for clothing, rope, medicinal purposes and
paper. The Magna Carta and the U.S. Constitution were written on hemp paper,
although this has been recently disputed. In 2006, the tour guides who present the
Declaration of Independence and the U.S. Constitution at the National Archives claimed
the original documents were written on hemp paper. However, the National Archives
web site now claims that hemp paper was not used and that copies of the documents
were transcribed onto parchment rather than hemp paper (National Archives 2013).
This recent change of the historical record by the National Archives in Washington D.C.
scrubbing cannabis from U.S. history is interesting in light of the marginalization of
marijuana that affects medical marijuana users and which is particularly interesting in
light of the fact that historically marijuana was not merely considered useful but
essential. This idea, strange to contemporary perception of marijuana, is exemplified by
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two of the men that our society holds up as examples of what a citizen of the United
States should emulate.
Thomas Jefferson, the drafter of the Declaration of Independence and 3rd
President of the United States was a strong advocate of hemp growing. In one speech
Jefferson said, “Hemp is of first necessity to the wealth & protection of the country.” In
his Garden Book Jefferson writes, “An acre of the best ground for hemp, is to be
selected and sewn for a permanent hemp patch" (Jefferson 1849). According to
presidential historians another quote has been misattributed to Jefferson, “Some of my
finest hours have been spent on my back veranda, smoking hemp and observing as far
as my eye can see" (Monticello 2011). The authoritative cite for these Jefferson quotes
was

provided

in

an

earlier

draft

of

this

paper

at:

www.wiki.monticello.org/mediawiki/index. php with a copy of the full speech given by
Jefferson and a complete scanned copy of his “Garden Book.”

However,, the

information was apparently altered after 2011 by the webmasters at Monticello. The
above link is now broken, and all references to “hemp” use have been removed from the
site except a link that redirects the above link (which was last available in 2011)
containing a paragraph denying that Jefferson ever said anything about smoking hemp.
Despite the (apparent) rewriting of the historical record, there is even better
evidence that President George Washington, the first President, grew (and smoked)
marijuana for its psychoactive properties. A scanned copy of Washington’s handwritten
diary from the library of Congress states:

(the slaves working his farm) “began to

separate the male from the female hemp plants rather too late” (Washington 1765).
This strongly suggests Washington was growing hemp to use in smoking preparations
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since keeping the female hemp plants from being seeded is only important if the
intention is to smoke the female flowers. A grower would want seeds if he were
extracting various food products or oils and the grower would not care whether there
were seeds if the intent was to grind the seeds and stalks into rope or textiles
(Rosenthal 2010). The use of marijuana was not remotely marginalized during the
youth of the United States but was considered useful and productive.
Similarly, the medical use of hemp products was commonplace in Colonial and
early America. Over 100 articles recommending hemp for medicinal purposes were
published between 1840 and 1900 alone (Herer 2000). Hemp was an important part of
the pharmacopoeia from 1870 up until 1937, when the Marijuana Tax Act effectively
banned the plant from public consumption regardless of its intended use (Chapkis
2008). Hemp extracts were used by physicians as a painkiller during childbirth, as a
palliative for gonorrhea symptoms and to effectively treat asthma and anxiety patients.
The medical uses of hemp were very well-documented in standard pharmacological
texts. The question then remains why there is such a social stigma and strong legal
prohibition on users of marijuana in the United States today. How did this plant go from
being used as legal tender and a common medical treatment to a criminal and tightly
regulated product?
Racist Origins of the “War On Drugs?”
After the early 1900’s, the story of marijuana in World History took a turn, making
it even more accessible to analysis using the sociological lens and, in particular, the
conflict paradigm. As in contemporary America, the South-Western states developed
increasing problems with the huge influx of “undocumented” Mexicans following the
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Mexican revolution of 1910. With the Depression, which hit the United States about 20
years later, the problems became more severe as jobs and welfare resources became
scarce. The people began to elect representatives who promised to solve the problem
and marijuana use among Mexican immigrants was a useful foil.
As early as 1905, newspapers began a campaign to negatively portray marijuana
as a drug used by the lower classes. One column claimed marijuana was linked to
“super-human, soul-bursting feats of valor by Latin American revolutionaries” (Gieringer:
28, 1999 quoting: “Terrors of Marihuana,” in the Washington Post, Mar 21, 1905 p. 6).
The desire to clear the country of illegal Mexican immigrants became more important
than the desire to continue using a plant that was claimed to be commonly used by
those immigrants. California passed the first State marijuana law, outlawing
“preparations of hemp, or loco weed.” Other states quickly followed with marijuana
prohibition laws in Wyoming (1915), Texas (1919), Iowa (1923), Nevada (1923), Oregon
(1923), Washington (1923), Arkansas (1923), and Nebraska (1927) (Herer, 2000).
Commentaries about the dangers of marijuana became increasingly common in
years leading up the 1937 Marijuana Stamp Act as the anti-marijuana claims makers
built their case. Many popular newspaper articles at the time described the violence
caused by marijuana. One columnist wrote:
Hasheesh will turn the mildest man in the world into a blood-thirsty murderer.
The man who takes hasheesh ‘runs amuck’ with his bloody knife in one hand
and his strangling cloth in the other, and he kills, kills, kills, until the hasheesh
has burnt out its deadly flame (Gieringer 29, 1999).
In the Eastern States, the “issue” of marijuana use was attributed to “negro” jazz
musicians from New Orleans, to Detroit, Chicago and Harlem. One 1935 newspaper
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editorialized: “Marihuana influences Negroes to look at white people in the eye, step on
white men’s shadows and look at a white woman twice” (Abel, 1980).
This sentiment of degradation and marginalization toward the Mexican classes
was often promoted in the media at the time.
Marihuana is a weed used only by people of the lower class and
sometimes by soldiers, but those who make larger use of it are prisoners
sentenced in long terms…[we are seeing]…the increasing use of marihuano
[sic] or loco weed as an intoxicant among a large class of Mexican laborers,
(Gieringer: 20, 1999).
And while there is no doubt that Mexican immigration increased greatly after the 1910
Mexican revolution, it was not until the late 1920s and 1930s with the Great Depression
that this became classified as a ‘social problem.’ Significant anti-Mexican sentiment
quickly developed as competition for scarce jobs became fierce.
However, other research has refuted the ‘racism’ meme. The argument that
marijuana was used as foil against Mexicans is undercut by the fact that none of the
major anti-Mexican groups concerned with Mexican labor and crime problems
mentioned their use of marihuana at the time (Meier and Ribera1993).
The Campaign Against Marijuana:
The claims of anti-marijuana crusaders at the time, like the contemporary claims
that marijuana is “medical” were not substantiated by any scientific research or medical
testing. This allowed the propagation of patently ridiculous claims such as: “People
who smoke marihuana finally lose their mind and never recover it, but their brains dry
up and they die, most of the time suddenly” (Gieringer, 1999). The papers of the time
also claimed that the marijuana was more potent than morphine and that “the habitual
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user of mariahuana [sic] finally loses his mind and becomes a raving maniac”
(Gierenger 1999).
The campaign against marijuana was accelerated by the campaign of Harry
Anslinger, head of the federal Bureau of Narcotics from the 1930’s to the 1960’s.
Anslinger claimed that police officials in cities of those states where it [marihuana] is
most widely used estimate that “fifty per cent of the violent crimes committed in districts
occupied by Mexicans, Spaniards, Latin-Americans, Greeks or Negroes may be traced
to this evil” (Chapkis 2008). While this may well have been the case, there was no
research supporting the claims. Separating the forces that marginalize groups such as
poverty, unemployment, and maladaptive social influences from the propensity to turn
towards mind-altering substances can be very difficult. Rather than asking whether
illegal marijuana use was co-incident with other crimes and if those tending to be violent
criminals might also be more prone to violate the law and use marijuana, Anslinger and
the media claimed that marijuana was the “cause” of violent crime: “[H]abitual users of
the drug are said eventually to develop a delirious rage after its administration during
which they are temporarily, at least, irresponsible and prone to commit violent crimes
(Id).
Anslinger’s 1961 Book:

The Murderers: The Story of the Narcotics Gangs

describes the alleged physical effects of marijuana creating misconceptions about the
effects of the drug that are pervasive even today and which include “vivid kaleidoscopic
visions… and an increased feeling of physical strength and power.” (Anslinger 1961)
Hollywood also entered the battle at this time with iconic films like “Reefer
Madness,” in 1936, which was originally a serious attempt at propaganda against
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marijuana (Sloman 1998). This film was used as a scare tactic and includes scenes
where the use of marijuana use causes a hit-and-run accident, murder, suicide and
insanity. The climax of the movie features a young woman “high on marijuana”
inexplicably leaping to her death through the window of a high rise while her boyfriend,
a wild eyed, twitching man in a courtroom is sentenced to an asylum for the “criminally
insane for the rest of [his] natural life.” The movie ends with the camera zooming in on
the announcer who sternly warns while pointing his finger at the audience:
If their stark reality will make you think, will make you aware that something
must be done to wipe out this ghastly menace, then the picture will not have
failed in its purpose....Because the dread Marihuana may be reaching forth
next for your son or daughter....or yours....or YOURS!
With these powerful images, it is not surprising that the drug was soon considered the
“Assassin of Youth” (another 1930’s era anti-marijuana film), and that it had to be
stopped. The anti-marijuana campaign and the claims making by government, law
enforcement, and other interests worked. The 1937 Marijuana Tax Act passed
Congress and instituted an elaborate set of rules that effectively made hemp cultivation
illegal in the United States (Marihuana Tax Act, Public Law 238, 75th Congress, 50 Stat.
551 (Enacted: Aug. 2, 1937).
Meanwhile, the medical use of marijuana was suddenly claimed to be nonexistent. Anslinger himself stated:

“The medical profession after many such

experiments was forced to drop the narcotic as a possible analgesic because of this
unpredictable quality” (Id: 27-28). This claim contradicted the physicians who testified
before federal committees in defense of medical marijuana and the position of The
American Medical Association (AMA) which came down strongly against the removal of
marijuana from the physician’s tool chest in the 1930’s (Chapkis 2008). However, the
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medical uses of cannabis could not withstand the concerted onslaught of negative
associations with marijuana and political motivations overshadowed medical concerns.
The sudden and severe public reaction to this "new" drug in the 1930’s was
intense considering that no one in America had even heard the word "marijuana" until
the late 1920s. The very word “marihuana (later spelled "marijuana") was invented in
the early 1930s to “confuse Americans who had positive associations with hemp, a
major cash crop, and cannabis, a well-known medicine and mild intoxicant” (Chapkis
2008). The federal strategy was to assign various social problems to the “new” drug
“marijuana” which permitted legislation banning an otherwise commonly known and
accepted substance (Herer, 2000).
Nixon and the Modern War on Drugs:
In the 1969 case of Leary vs. United States, a critical part of the 1937 Act was
ruled unconstitutional. The government quickly responded with the Controlled
Substances Act of 1970 which declared marijuana a schedule 1 drug with “no legitimate
medical purpose” (21 USC 81 et seq) and instituted severe penalties for the use and
possession of marijuana.
Despite the federal position, the 1960’s saw a time of greatly increased use of
marijuana, primarily by those in the anti-war movement as a counterculture response.
With this increasing influence of the “Hippy Culture” and the “Peacenicks” use of
marijuana, President Nixon ordered the Shaffer Commission on Marijuana and Drug
Policy to issue a report. The Commission studied the issue and concluded:
Marijuana users are essentially indistinguishable from their non-marijuana
using peers by any fundamental criterion other than their marijuana
use….Neither the marijuana user nor the drug itself can be said to
constitute a danger to public safety (Nixon1972).
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President Nixon ignored his commission and instead began America’s longest and most
costly war, the War on Drugs.
In contrast to the caricatures about violent marijuana users, the War on Drugs
has led to real violence involving marijuana. Unlike the faux stories in the papers during
the 1930s, today people really are dying on an almost daily basis over a drug that has
few side effects, has never caused a substance related death, and may even have
medicinal properties. The War began as most wars do with relatively minor skirmishes
in the earliest part of the 20th century with State actions in response to Mexican
migration. The War grew and today it does not respect territory or nationality. In August
of 2010, Mexican National Security Director Guillermo Valdes Castellanos claimed that
28,000 people have been killed since 2006 when President Felipe Calderon began
cracking down on the drug cartels (Brice 2010). Daily shootouts at the Mexican border,
mass graves (Reuters 2011), and the increasing violence of the drug gangs are adding
to nativist fears which are hardly unfounded. The killings regularly spread across the
border.
The cost in lives taken by law enforcement and rival gangs delivering a product
that is both illegal and popular is not the only cost of the war on drugs. A 2010 study by
Harvard economist Jeffrey Miron estimated that legalizing marijuana would inject nearly
$7 billion a year into the U.S. economy through tax revenues and decreased
incarceration costs (Miron, 2010). However, an argument could be made that as an
economist, rather than a sociologist, Miron underestimates the savings and the ultimate
societal costs of prohibition. In 2008 alone, there were over 800,000 arrests for
marijuana. With costs of $27,000.00 per year per inmate the total cost potentially related
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to those arrests amounts to more than $22 billion (Bureau of Justice Statistics, 2010). It
is easy to see how the massive amount of money spent on hunting down marijuana and
incarcerating marijuana users influences the perception that marijuana, and its users,
are criminal and a menace to society.
The unintended consequences of the anti-marijuana law and policies also include
more than mere financial costs. As a trial lawyer for several years, this researcher has
witnessed some of the adverse consequences of marijuana prohibition, particularly
among minority populations. In my observations, even before beginning this research, it
is beyond doubt the persecution of those who use marijuana diminishes that
population’s confidence in the police and governmental institutions and causes
increased racial, ethnic, and socioeconomic polarization with the widely held perception
that disadvantaged groups are disproportionately targeted.

By allocating societal

resources towards military, police and prison operations and away from medical, mental
health, and private/public charitable endeavors, this problem has become greatly
compounded with an ever increasing prison population (Peters 2010). These problems
reflect the current societal and legal stigmas on the use of marijuana and any medical
use of marijuana is tainted by the war on drugs. The perception created by the media
and the government may be relatively new and contrary to the earliest history of the
United States, but it is now pervasive and causes considerable legal and emotional
problems for medical marijuana users.
The anti-marijuana view has been promoted by the fact that scientific research
on marijuana is strictly limited by the government. The research acquisition process is
so cumbersome that few scientists have been able to successfully navigate it. The
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Marijuana Stamp Act of 1937 outlawed the growing of hemp unless the grower
possessed a stamp, but then the government never issued the stamp. Similarly today,
the government today claims that scientists are free to conduct research on marijuana
while at the same time denying legal research marijuana.
The appropriately dated written statement of Robert Meyer, Director of FDA
Office of Drug Evaluation before the House Subcommittee on Criminal Justice and Drug
Policy on April 1, 2004 is illustrative of the government position on marijuana research:
Researchers who wish to conduct clinical studies of marijuana must first
contact NIDA to make an inquiry to NIDA to determine the availability and
costs of marijuana. If NIDA determines that marijuana is available to support
the study…If the researcher is proposing a study in humans, after obtaining
the right of reference to the DMF, the researcher must proceed through the
FDA process for filing an IND application under 21 CFR part 312…In
addition, all researchers must obtain from DEA registration to conduct
research using a Schedule I controlled substance (Meyer 2004).
In order to better understand the gravity of complying with this overlapping web of
regulations and hurdles, a very brief overview of the process put in place by the DEA
just to obtain the licensing that is required is germane.

Issuance of a controlled

substances license, the last requirement listed in the above quote, enables a researcher
to submit an application to obtain marijuana from the National Institute of Drug Abuse
(NIDA). However, just the Table of Contents from this section in the Code of Federal
Regulations on what is needed to “obtain from DEA registration to conduct research
using a Schedule I controlled substance” comprises 35 statutory sections and runs for
more than six pages of single spaced type. Nor are bureaucratic hurdles the only
obstacle.

The main barrier to marijuana research is the NIDA policy which openly

admits they will only grant a controlled substances license and the legal marijuana on
which to conduct research, to individuals who are studying the harmful effects of
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marijuana. Studies using research marijuana on the potential beneficial effects are
stymied in the United States
The War Against Marijuana Research:
There are several instructive case studies that illustrate the anti-marijuana bias in
research approval and funding. In 1994, Dr. Abrams of the University of California
received the first marijuana from NIDA for medical research in more than 10 years.
However, to get funding for his study which had been approved by the FDA more than 2
years before, he was forced to reframe the research questions. The FDA approved
study called for an investigation into the safety and efficacy of marijuana for AIDS
related wasting syndrome. However, NIDA is only interested in studying the harmful
aspects of drugs (NIDA 2011). In order to get the marijuana from NIDA, Abrams had to
reframe his research questions to investigate whether marijuana interfered with the
protease inhibitors used to treat HIV (Chapkis: 2006 at page 66 citing Abrams, 2004).
Despite the manipulation of his research, Abrams was able to “sneak a peek” and show
a significant weight and BMI gain for AIDS patients using medical cannabis (and no
effect on protease inhibitors). At the same time, drug Czar Barry McCaffrey publically
stated that “Drug policy must be based on science, not ideology” (Chapkis).
In another example of federal drama that began in 2001 and recently ended in
total victory for the government, Dr. Craker of the University of Massachusetts applied
for a license to produce alternative cannabis for medical research (Chapkis 2006). This
is a critically important issue in medical cannabis research because all research in the
U.S. is limited to the few strains grown at the University of Mississippi by NIDA (NIDA,
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2011). Craker hoped to establish a second production facility where actual medical
grade cannabis could be cultivated for scientific research.
The DEA first claimed to have lost his petition. One year later as the professor
was assembling all the documents to resubmit the proposal (they would not accept a
photocopy of the documents they had lost and demanded originals) he received a copy
of his original application sans any cover letter but time stamped with the original
application date a year before. He resubmitted the application and more than 20 months
later received a response requiring “credible evidence” that researchers were
insufficiently served by NIDA marijuana. In other words, the federal government was
now demanding proof of a negative which is almost like demanding proof of non-divinity.
How could Craker possibly prove the researchers were not served by NIDA marijuana
when the absence of available marijuana limited the number of researchers in the field?
Nevertheless, the evidence was submitted and once again DEA held his application for
more than a year. Finally, three full years after the initial application, Dr. Craker sued the
agency in federal court alleging in 2004:
They always say we need more research, but at the same time, they block it.
The government is placing ideology above the health and safety of patients”
(Abrams 2004).
On December 6, 2009 in the waning days of the Bush administration, a DEA
administrative law judge issued a ruling GRANTING Craker’s application. However, this
decision was overruled by the DEA Administrator in an Order which became final on
January 14, 2009, just six days before President Obama was inaugurated. A Motion For
Reconsideration was timely filed and (leaving no opportunity to extend the time for this
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litigation) the DEA granted permission to file a Brief In Support of Reconsideration by
March 11, 2011 (Craker 2010). At this point, the 70 year old Craker finally gave up.
For the reader not schooled in the Federal Rules of Evidence, it is important to
understand precisely what the DEA and NIDA did in this case. First, the agencies
delayed responding to a request for more than 3 years. Then when the applicant filed a
case in federal court alleging undue delay, the agency claimed a “final disposition” had
not been granted at the administrative level (Federal Rules of Appellate Procedure,
Number 15). This means the applicant’s court case must be dismissed because only a
final order and action of an administrative agency can be appealed to the federal district
court. Then, once the federal case is safely dismissed they delay again, and again,
extending the litigation for more than 11 years (Craker 2011). On March 3, 2011 Dr.
Craker announced he was finally giving up his quest to grow medical grade cannabis for
research (Miga 2011).
This calculated lack of ability to study medical grade marijuana has hampered
both the understanding of the substance and its acceptance. The legal permutations
that Dr. Craker endured are ubiquitous when dealing with medical marijuana and
attempting to conduct research on medical marijuana. The lack of research on medical
marijuana has caused many people searching for relief to turn to a synthetic, and legal
form of THC, Marinol.
Synthetic THC (tetrahydrocannibinol), Marinol:
Not only did NIDA seal off access to marijuana for clinical trials in the 1970’s, in
1986, the government diverted 90% of the funding for marijuana research to the
development of synthetic THC (Chapkis 2006).

Marinol is a synthetic THC drug
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approved by the FDA for use as a palliative for nausea and vomiting associated with
cancer chemotherapy. The synthetic THC in Marinol is purified and does not contain
any other cannabinoids. In contrast, cannabis contains dozens of separate chemicals,
many of them psychoactive. Users claim this combination of chemicals creates a
different reaction in patients than synthetic, purified THC.
This observation launches the authors of Dying to Get High into a detailed
description and a general demurer to the federal agency preference for “purified”
compounds delivered by a pill to “botanical” compounds delivered by a plant. “[Drug]
warriors are left with little more than an appeal to the superiority of the man-made over
the natural and of the pharmaceutical over the botanical” (Chapkis, 2006). The authors
observe there is an almost “preternatural” belief in the superiority of purified
pharmaceuticals over naturally occurring botanicals which:
…is not a scientific fact, but rather part of an ideological apparatus used to
create an imaginary line separating safe and effective pharmaceuticals from
crude and dangerous botanicals (Chapkis, 2006 at page 71).
The federal government has spent billions of dollars to purify THC by funding the drug
Marinol. In favoring a patented pill over a naturally occurring botanical, the government
ignores the physical and psychological buffering characteristics of various cannabinoids,
rejects the synergistic effects of isomerically and stereo chemically related naturally
occurring compounds, dismisses potential benefits of ingesting other compounds and
chemicals resulting in better regulation of bioavailability. All of this is done in order to
favor a synthetic compound and a valuable patent with only a few years of research
over a natural compound to which humans have had thousands of years of experience.
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Purified, concentrated, synthetic THC does not occur in nature and the majority
of patients who have experience with both Marinol and medical marijuana favor the
naturally occurring compound as easier to regulate and for producing far fewer side
effects (Armentano, 2005). For example, Grinspoon (2001) stated:
I have yet to examine a patient who has used both smoked marijuana and
Marinol who finds the latter more useful; the most common reason for using
Marinol is the illegality of marijuana. If patients were legally allowed to use
marijuana relatively few would choose Marinol.
The odd result of Marinol containing concentrated, synthetic THC being approved
by the FDA as a “safe and effective” Schedule III drug while diluted natural, organically
grown cannabis is unsafe and has no known medicinal use as a Schedule I drug is an
interesting comment on how our society views “drugs” versus “pharmaceuticals.”
Corporate interests and large drug manufacturers with profitable patents are greatly
preferred over smaller operations even when the corporate product is more dangerous.
When Marinol was finally synthesized, the side effects of the concentrated product
that contained only THC, and none of the other modulating chemicals in natural
cannabis, were found to be dramatic. The package insert of Marinol states that the drug
“may be habit forming…may cause side effects such as:
“feeling high" (i.e. easy laughing, elation, and heightened awareness),
abdominal pain, dizziness, confusion, depression, nightmares, speech
difficulties, chills, sweating, psychological and physiological dependence.” In
case of accidental overdose, a potentially serious oral ingestion, if recent,
should be managed with gut decontamination. In unconscious patients with a
secure airway, instill activated charcoal via a nasogastric tube. A saline
cathartic or sorbitol may be added to the first dose of activated charcoal.
Patients experiencing depressive, hallucinatory or psychotic reactions should
be placed in a quiet area and offered reassurance (Marinol 2011).
While more dangerous and less tolerated, Marinol is not even as effective as medical
marijuana: “In practice it has been found that extracts of cannabis provide greater relief
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of pain than the equivalent amount of cannabinoid given as a single chemical entity
[such as Marinol]” (Whitle 2001).
Since almost all marijuana research in humans has used this form of synthetic
THC delivered orally, in pill form, there are very few reported studies on the use of
smoked marijuana.

For example there is only one reported study using smoked

marijuana in Multiple Sclerosis (M.S.) which is a condition which considerable anecdotal
reports suggest may be improved by the use of marijuana. In fact, 97% of M.S. patients
reported that smoked marijuana improved their condition (Consrue 1997). Despite the
growing evidence, no blinded, randomized clinical study using smoked marijuana has
ever been approved in the United States for problems associated with M.S. Grant,
Atkinson, & Gouaux (2012) provide a recent review on the accumulating anecdotal
reports on the potential medical benefits of marijuana. However, the lack of proof for the
medical benefits of marijuana remains a hurdle for those who feel they could benefit
from using cannabis for treatment.
Due to NIDA’s Policies The Medical Claims about Marijuana Remain Unproven:
As new medical uses for marijuana have been discovered, people suffering from
illnesses have illegally medicated themselves. By the early 1970’s, treatment of
glaucoma, chemotherapy induced nausea, spastic disorders, AIDS wasting syndrome
and other less severe illnesses were being illegally treated by the therapeutic use of
marijuana (Chapkis 2008). There have also been claims that marijuana relieves pain,
nausea, swelling, inflammation, and seizures, decreases ocular pressure in glaucoma
(c.f. MCLA 333.26421 et seq), helps regulate blood sugar (Izzo 2009) and can even
treat cancer by shrinking metastatic brain and breast cancer tumors (Angelo 2009).
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Authorities responded partially to growing demand for medical marijuana in 1969 by
supplying a few selected patients and researchers with government-grown marijuana
originally slated for use in scientific experimentation. The University of Mississippi in
Oxford raised thousands of cannabis plants behind a twelve foot tall barbed wire fence
for the National Institute of Drug Abuse (NIDA).
Evaluating medical marijuana research is almost impossible because only this
particular marijuana grown by NIDA at this facility can be used for research involving the
actual use of marijuana in the United States. NIDA openly admits that their task is to
study only the harmful effects of drugs, and they will not provide funding- or research
marijuana- for any study that does not support this proposition (Craker 2005, testimony
of NIDA Administrator day 2).
While maintaining these strict barriers to research, the regulatory agencies claim
that marijuana research is not actually being blocked. On February 16, 2011, Drug
Czar Gil Kerlikowske was interviewed by The Daily Caller’s Mike Riggs. Kerlikowske
claimed “there are over 100 groups doing marijuana research.” In fact, according to
clinicaltrials.gov as of February, 2011 there are presently only six FDA-approved trials
taking place anywhere in the world involving subjects’ use of actual cannabis. Of these,
two are completed, one is assessing the plant’s pharmacokinetics, and one is assessing
pot’s alleged harms (Armentano 2011). Limitations on marijuana research means that
little current usable data on the effectiveness of medical marijuana can ever be
collected in the United States.
Immunosuppression:
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Research on medical marijuana is important for several reasons including safety.
There have been claims of reduced immune function with heavy marijuana use which, if
true, are important to explore before recommending marijuana to patients who are
already ill and immune compromised. The “fact” that “marijuana weakens the immune
system” has become a much touted quote by the anti-marijuana groups and the
government. For example, theologian and Pastor James Dobson (head of the
conservative Christian organization “Focus on the Family”) in a Washington Times oped piece stated his medical opinion categorically that “marijuana weakens the immune
system” (Adams 2006). While there is certainly evidence for this interesting line of
study, selectively suppressing immune function is also an important medical protocol for
many types of disease (Earlywine 2002) because an overactive immune system may
cause diseases as harmful as a weakened immune system.
This creates a striking nexus between medical marijuana and the claims of
immune suppression insofar as auto-immune diseases and many long term debilitating
diseases appear to align with the diseases and conditions that advocates claim is
treated by medical marijuana. Autoimmune diseases that advocates claim are treated
by marijuana include:

Type 1 diabetes (in which the immune system attacks and

destroys the insulin producing Islets of Langerhorn cells in the pancreas); Rheumatoid
Arthritis (in which the immune system attacks the connective tissue in the joints);
Multiple Sclerosis (in which the immune system attacks the myelin sheaths lining the
nerves that innervate skeletal muscles) and many others. A more complete list of
diseases caused by the immune system misidentifying various parts of the body
includes more than 50 conditions (List 2011).

Immune function is a double-edged
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sword that is critically important to human life, but the immune function can also be
harmful and suppression of immune function can be beneficial.
Thus, the question framed in this way becomes whether the immunosuppressive
effects of cannabis are beneficial or harmful. In contrast to human studies, there is a fair
amount of experimental data from experiments on cell lines. However, these results
have been inconsistent on whether the immunosuppressive effects of marijuana are
beneficial or harmful. Some studies suggest that cannabis decreases immune function
by decreasing T-lymphocyte, and Natural Killer T-Cells (NTK’s), in healthy subjects
(Pacifici 2003). T-Lymphocytes and NTK’s are important immune system cells
responsible for developing immunity and resistance to viral infections, and a decrease
suggests the impairment of normal immune function. However, the authors note that
they were only allowed to experiment on various cell lines so “the clinical relevance of
these findings in humans has not been established” (Id). Other studies contradict the
findings in cell assays and also suggest the reduction of these important immune
system cells is associated with a dramatic reduction in IL-2 and an increase in IL-10
levels (Croxford 2005). Interleukin-2 cells are associated with cell mediated
inflammation and apoptosis (programmed cell death) which is strongly implicated in
diseases of the immune system such as Alzheimer’s disease, Multiple Sclerosis and
Diabetes (Croxford Id). Il-2 cells (decreased by marijuana) promote inflammation and
death of deficient cells while IL-10 cells (increased by marijuana) are anti-inflammatory
cells. In other words, although there is good evidence immune function is impaired by
marijuana there is also good evidence that what is impaired are primarily the
inflammatory modulators responsible for auto-immune diseases caused by an

33
overactive immune system. With little current research, it is difficult to pinpoint what
components of medical marijuana create precisely what effects.
Chemical Components and Effectiveness of Marijuana:
Of the more than 100 components of marijuana, only two have ever been studied
in any significant way: Cannibidol (CBD) and Tetrahydrocannibinol (THC). The most
widely noted Cannabis effects include both euphoria and sedation and both occur
simultaneously in the user.

However, these effects appear in different proportions

depending on the strain and cultivation techniques. (c.f. Rosenthol, 2002). Some of
these effects are what users claim makes marijuana an effective treatment of certain
conditions by easing the suffering that is caused by certain diseases and by providing
palliative comfort. These effects also depend on the social context in which the
marijuana is consumed, the experience of the user, and the psychoactive and
physiological effects of various components in the marijuana (Id).
When considering the effectiveness of medical marijuana, the specific effects of
the individual chemical components are important. According to experienced users and
a variety of non-systematic reports, high THC content is associated with euphoria while
higher CBD (Cannabidiol) is associated with sedation (Rosenthal 2010). Delta 9-THC is
a moderately psychoactive cannabinoid receptor with a relatively low affinity for
endogenous cannabinoid receptors (CB1 in the central nervous system and CB2
distributed in the gut and throughout the body). The CB1 Cannabinoid receptor is found
widely distributed throughout the brain and is activated by exogenous (from outside the
body) THC and endogenously (from inside the body) by the neurochemical anandomide
(Vincenzo 1994). In contrast, to THC, CBD is not very psychoactive at all but appears to
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modulate various physiological processes (Santos 2010) including the effectiveness of
THC. When the CB1 receptor is activated, this decreases GABA availability in the brain
(Pagott 2006). GABA is an inhibitory neurotransmitter, so the net effect of consuming
THC is a decrease in inhibition. In short, the effect of THC in decreasing the inhibitor is
thought to be responsible for the increased euphoria and the selective enhancement of
attention, concept formation and sensory awareness reported by users while CBD
modulates this interaction and may also have other effects.
Although CBD does not bind, inhibit, or activate CB1 receptors, it may increase
receptor permeability with a net effect of enhancing the effect of THC. Perhaps even
more important for medical marijuana, CBD does weakly activate the 5-HT receptor
which is the target of the widely prescribed anti-depressant selective serotonin reuptake
inhibitors and may activate other cannabinoid receptors that have not yet been identified
(Ryberg 2007). Therefore, CBD works as a long-term anti-depressant and also has anticholinergic (blocks acetylcholine), anti-pyretic (reduces fever) and anti-inflammatory
effects (Id).
The key point is that the two primary components: THC and CBD are found in
widely varying quantities depending on the particular strain of marijuana and the harvest
techniques (Gonzoles 2007). Medical marijuana growers, seed banks, and many
experienced users claim that the ratio of THC to CBD determines the effect of the
medical marijuana, and that the early harvest of a particular strain results in lower CBD
to THC content while a later harvest results in higher CBD to THC content. The
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www.michiganmedicalmarijuana.org)1 and contains detailed forums for “Collective
Growing” (with 120 topics, 1200+ Replies), “The Grow Room” (924 topic, 1800+
Replies), “General Growing Information” (454 Topics, 1600+ Replies) and “Seeds,
Strain Clones” (700 Topics, 1800+ Replies) (MMMA, 2011). This information helps
growers create the “best” and most potent combinations of chemical compounds in the
plants.
A product with higher THC content is reported to have a more uplifting effect and
is thought to impart some other effects such as:

increased imagination enhanced

selective sensory and cognitive awareness, increased laughter and even euphoria
(Gonzales 2007). Because there is no regulation in the growth of medical marijuana in
Michigan with the current system, the level and potency of cannabinoids in marijuana
varies considerably, not only in ratio, but also in potency. Very detailed information
about growing marijuana and the claimed effects of different strains are available on
many internet discussion boards and seed banks, but there is almost no clinical
research supporting or refuting these claims (c.f. Rosenthal 2002).
This lack of research is one of the central problems with marijuana research in
the United States and is irredeemably compounded by the fact that the very limited
supplies of marijuana available for clinical research is much less potent than the
marijuana available to the typical medical marijuana patient. As we have seen, NIDA
has the sole right to supply marijuana for research purposes in the United States and
operates the only federally authorized marijuana grow operation at the University of
Mississippi (21 USC. 801 et seq).
1

NIDA research marijuana has a THC content

The Michigan Medical Association (MMMA) is not to be confused with the other MMMA (Michigan
Medical Marijuana Act).
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between 1.5% and 8.37% with 99% of that supply falling in the 1.5% range (FOIA 2005)
compared to the 25-30% THC levels commonly available at dispensaries. These figures
on the quality of research marijuana available in the United States have remained
unchanged up to the present time, even while strains available on the street have
become considerably more potency, because NIDA has not grown any additional
research marijuana since at least 1998 (Pro-Con 2008).
The fact that research on different strains is so limited was confirmed by a 2009
NIDA Request for Proposal (RFP (No. N01DA-10-7773) seeking competitive bids on a
production facility to produce research marijuana). The proposal states that NIDA
wanted to produce “125,000 marijuana cigarettes in four potencies from "placebo" (0%
THC) to "high" (3.5-5% THC), plus 500-1,000 cigarettes at greater than 5% THC. In
other words, NIDA is, or at least was, planning that less than 1% of marijuana available
for research in the United States will be greater than 5% THC2 even though the
marijuana commonly used in the United States is at least 5 times as potent. Therefore,
research on the perceived effects of potent medical marijuana currently being used by
medical marijuana patient population is clearly warranted.
In addition to the potency levels of THC and CBD in marijuana, there is another
complication in studying the effectiveness of medical marijuana. There are 100 plus
components in marijuana, but only a few have been studied beyond characterizing them
2

This RFP was located on a private job site and the author investigated further. Government officials
referred me to the NIDA Request For Proposal (RFP) page which does not contain any information
whatsoever about this RFP. Another advised me that this RFP was currently under review. There was no
reply to my follow up query on whether the proposal was public information subject to FOIA . The
private job search site was located at: https://www.fbo.gov/index?s=opportunity&mode=
form&id=13b43512c37e45befa6e8f9556d276b0&tab =core&_cview=1 but the RFP has now been
apparently scrubbed from government sites.
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in chemical essays or introducing them to various cell cultures. Further, NIDA does not
measure or report the level of CBD or other cannabinoids in its research marijuana
Thus CBD and other THC’s beyond delta-9 (delta-8, delta-7, etc.) have had almost no
research at all and none in humans even though they are also psychoactive, albeit with
considerably less affinity for the cannabinoid receptor than delta-9. Other Cannabinoids
such as Cannabinol (CBN) are also psychoactive but have not been investigated in
humans in even a single study. CBN is a degradation byproduct of THC (McParland
2001). Since the widely varying compounds in cannabis are found in different quantities
depending on the particular strain of marijuana and the harvest techniques (Gonzoles
2007) this makes any research on marijuana as a medical compound extremely difficult.
Research with NIDA marijuana is akin to studying a drug using sub-clinical doses and a
product more likely to cause a headache than to produce any medicinal or therapeutic
effects (Armentono, 2010).
Neuroimaging studies provide further evidence for the suggestion that marijuana
is highly heterogeneous with findings of activation patterns throughout the brain
apparently depending on what type of marijuana is ingested. However this hypothesis
has never been tested since there is such heterogeneity of compounds in marijuana, it
is not surprising that both the perceived effects and the neuroimaging results would also
be heterogeneous. The most common findings from brain activation studies includes
increased resting prefrontal, insular (responsible for emotion regulation and homeostatic
mechanisms) and anterior cingulate (responsible for emotion, attention, motivation and
error detection) (Santos 2010). These findings are very inconsistent which,
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paradoxically, makes them consistent with the theory that a diversity chemicals in
marijuana is responsible for different reported subjective effects of marijuana.
If marijuana is a legitimate therapeutic agent, then a widely divergent set of
claims about the type and quality of the efficacy of medical marijuana would suggest
that some varieties of marijuana may be more therapeutic for some conditions and less
therapeutic for other conditions. For example, there may be marijuana strains best
suited for treating muscle spasms, and other strains best suited for treating pain.
In addition to the effects of euphoria and sedation, there are other effects to
marijuana. In particular the Cognitive and Clinical Psychology Genre primarily funded by
the National Institute of Drug Abuse (NIDA) has outlined many negative effects from
using marijuana. This line of research focuses on “a motivational syndrome,” the
problems of addiction, how marijuana suppresses the immune system, potential longterm cognitive deficits, and the Gateway Hypothesis. These potentially negative effects
have been repeated in well-funded study after well-funded study and are important
because they are the primary reason why marijuana, medical or otherwise, has such a
negative social image.
Marijuana and Diminished Social Function:
Demographic studies of marijuana users have long shown a fairly strong
correlation between cannabis use, particularly early cannabis use, and diminished
social activities, lower educational attainment and decreased monetary success. The
hypothesis is that poor social skills, smaller academic potential and/or membership in a
relatively lower social class is connected to greater cannabis consumption. The
interpretation favored by anti-marijuana groups is that cannabis use causes lower social
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performance (Kandel 1986). This perspective has been supported by longitudinal
studies which attempt to adjust for variables such as family income and other
confounding covariates (Fergusson 1997; Elickson 1998). These studies on a
motivational syndrome were primarily approved and funded in the 1980’s and used
large national databases purporting to show a negative correlation between marijuana
use and educational attainment (Lynsky 2000). Although these studies attempt to adjust
for covariates, suggesting the problem is consequential rather than contributory, they
cannot rule out the possibility of an underlying common factor. In other words, despite
decades of well-funded research attempting to pathologize cannabis use, it still is
possible that youth who use an illegal substance carrying extraordinary social and legal
penalties may have a lower regard for educational attainment and other measures of
success used by our society. This contributes to the stigma of marijuana usage,
including the self-selected group of medical marijuana users even though they are
usually older and suffering from specific diseases which are not necessarily predicted
by socio-economic class or social attainment.
Cognitive Functioning:
The literature is also muddled in the area of cannabis induced cognitive decline.
Some studies claim a “small but apparently permanent effect on memory, information
processing, and executive function” (Kalaunt 2004). Others claim TCH causes “minimal
cognitive deficits” and is a “minimal confounder in experienced marijuana users” (Chait
1990). One author found a “significant difference in cognitive function between longterm users and short-term/nonusers of marijuana” (Solowji 2002), but this study had
several methodological problems. First, it did not control for age-related differences in
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memory and cognitive function, suggesting that the “difference” between long-term and
short-term users was due to the older population of long-term users. Second, it only
included patients who were “seeking treatment for long-term cannabis addiction.” Third,
the short term duration (overnight) between administration and testing could have been
confounded by the lingering presence of cannabinoids in the subject’s system (Nyquist
2002). The conclusion of Pope on the alleged cognitive deficits of long-term cannabis
use is particularly illuminating:
Cognitive deficits may be caused or exacerbated by withdrawal effects from
the abrupt discontinuation of cannabis; these effects typically peak after 307 days of abstinence. It is less clear, however, whether heavy cannabis use
can cause neurotoxicity that persists long-term after discontinuation (Pope
2001).
The fact the academic debate continues decades after the government and news media
has reported the long-term cognitive effects of cannabis as fact supports Pope’s summary
conclusion: “long-term effects, if they exist, are subtle and not clinically disabling” (2001).
This leads to another fact that the media and government have continually promoted, the
addictive quality of marijuana.
Addiction:
Another widely claimed effect that greatly contributes to the negative image of
marijuana in our current society is the claim about addiction. Though an addiction risk in
humans has never been conclusively shown with marijuana use, there are varying
claims including that cannabis dependence is the most common type of drug
dependence after alcohol and tobacco (Anthony 1991). One study claims that 2% of the
entire adult population is currently “addicted” to marijuana while 4% of the adult
population is now or was in the past “addicted” to marijuana (Swift 2001). The risk of
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such dependence is claimed to be 6% for any persons who have ever tried marijuana
and 9% for those who tried marijuana for the first time in adolescence and rising to one
in three for daily users (Anthony 2006). With more than 40% of the U.S. population
admitting to having smoked marijuana at least once, 5% of the population admitting to
daily use, and a national population of 300,000,000, this equates to some 15,000,000
patient beds.
However, one of the most important criteria in establishing that a substance is
“addictive” is evidence for the presence of physical withdrawal symptoms. “Dependent”
cannabis users who have been abruptly withdrawn from high daily doses of THC report
decreased mood, increased irritability, anxiety, appetite disturbance and depression
(Budney 2004). Some writers have characterized these effects as similar to caffeine
withdrawal (Grinspoon 1997). Anyone who has suffered a “caffeine headache” must
agree that caffeine is addictive, yet on the scale of addiction it is quite low. Similarly,
the withdrawal effects of marijuana are low enough that most medicinal marijuana users
experience few withdrawal symptoms and what is experienced is usually much less
than with many pharmaceutical compounds and even less than with caffeine. Yet, the
purported addictive properties of marijuana have fueled government law enforcement,
the drug treatment industry, and movie producers of government sanctioned
propaganda (c.f. Budney, 1999- funded by NIDA grant R29DA08655; Hughes, 2002funded by NIDA grant DA00490 inter alia).
Here again is the difference in our society between criminalized marijuana and
the accepted pharmaceutical. The medical studies suggest that marijuana activates the
same dopamine reward system as heroin (Wichelgren 1997), but that since the
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metabolites of marijuana leave the body slowly there are very mild withdrawal issues
comparable to denying an “addict” his daily cup of caffeine and primarily manifesting in
restlessness, irritability, and some insomnia which invariably disappears after a few
days (Grinspoon 1997). Most patients do not refuse a medicine that can help with
suffering because of a side effect (withdrawal). Indeed a huge portion of pharmaceutical
drugs have much more addictive properties than marijuana. Alcohol is well known to be
highly addictive as are stimulant drugs frequently forced on young children (almost
exclusively young boys) and opiate narcotics which are widely accepted in
contemporary society. The negative is perhaps not that medicinal marijuana might be
addictive, but instead that it is marijuana.
The Gateway Hypothesis:
There are numerous studies on the “Gateway Hypothesis” that the use of
marijuana leads to use of “hard” drugs like heroin and cocaine (DiSimone, 1998, Mills &
Noyes, 1984 et al).

The “Gateway Hypothesis” could even be viewed as the

centerpiece of the government campaign against cannabis and whether marijuana use
leads to the use of “hard” drugs or whether there might be a different, precisely opposite
claim, was a central topic of the data collection in this paper. The DEA claims:
Marijuana is a frequent precursor to the use of more dangerous drugs and
signals a significantly enhanced likelihood of drug problems in adult life...
Marijuana use in early adolescence is particularly ominous. Adults who were
early marijuana users were found to be five times more likely to become
dependent on any drug, eight times more likely to use cocaine in the future,
and fifteen times more likely to use heroin later in life (DEA, 2011).
Some studies have found that regular or heavy cannabis use is associated with an
increased risk of using other illicit drugs, abusing or becoming dependent upon other
illicit drugs and using a wider variety of other illicit drugs. Again, almost all of these
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studies are funded by NIDA. Even though such risks decline with increasing age, a
number of studies conclude the findings support a general causal model on the
cannabis gateway hypothesis (Fergusson 2006) while others dispute the methodology
and interpretation of these findings (Kandel 2006). Most reviews acknowledge the
interesting correlation but reach an inconclusive result.
The state of the current data on the issue of the Gateway Hypothesis in cannabis
use is highlighted in a 2009 review article (Hall). Hall and his colleagues attempted to
reconcile the well-known fact that cannabis use usually precedes the use of other illicit
drugs, and that earlier and heavier cannabis use is more predictive of future illicit drug
use. They examined three theories that explain these findings:
1) that the relationship is due to the fact that there is a shared illicit
market for cannabis and other drugs which makes it more likely that
other illicit drugs will be used if cannabis is used;
2) that they are explained by the characteristics of those who use
cannabis; and
3) that they reflect a causal relationship in which the pharmacological
effects of cannabis on brain function increase the likelihood of using
other illicit drugs (Hall).
Hall concluded that the evidence from longitudinal epidemiological studies, simulation
studies, discordant twin studies and animal studies indicates pre-existing traits along
with social and peer influences caused by early and/or heavy entry into the drug culture
are the primary influences in later abuse of other illicit drugs. Although this article does
not dismiss the evidence from animal studies suggesting regular cannabis use may
have pharmacological effects on brain function that increase the likelihood of using
other drugs, the authors conclude that this “minor” effect is a secondary concern in
human subjects.
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These findings are supported by other studies, including a 2007 paper about
using marijuana to decrease alcohol intake suggesting that chronic alcoholics may use
marijuana to substitute for alcohol (Lenza 2007). Another very early study used
synthetic THC with a group of psychiatric patients that happened to include some
alcoholics in the acute phase of recovery and found improvement in alcohol withdrawal
symptoms in 85% of the cases (Thompson and Proctor 1953). One writer to the
American Journal of Psychiatry claimed he had clinical experience suggesting
marijuana is a viable treatment for alcoholism (Scher 1971). He also claimed that
marijuana and alcohol are “mutually exclusive agents.” In other words, he argued that
greater use of marijuana is associated with less use alcohol.
In contrast to the “Gateway Hypothesis”, there have also been claims to the
opposite effect, in particular the claim by patients that marijuana reduced opiate use
which is contrary to many previous studies on marijuana use and abuse (Golub &
Johnson 1994). As an increasing number of states allow the use of medical marijuana,
the conflict between advocates and detractors of marijuana has only intensified.
State Medical Marijuana Laws:
As the first state to outlaw marijuana, California was also the first state to pass a
medical marijuana law. The California medical marijuana resolution, Proposition 215
was known as the Compassionate Use Act and was passed by the voters in November,
1996. Since then, a cottage industry has grown up to service the marijuana industry and
well over a billion dollars in taxes have already been collected by the State of California
(Stateman 2009). California could have been the first state to completely decriminalize
marijuana in November, 2010, but the referendum narrowly failed. Instead Colorado and
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Washington State first legalized marijuana in 2012. However, federal prohibition
continues and the States have come increasingly into conflict with the central
government.
Michigan Medical Marijuana:
On November 4, 2008, the people of the State of Michigan passed a referendum
that enacted a medical marijuana law. Until this law, users of marijuana in Michigan
were unanimously labeled as criminals. The medical marijuana population was officially
created when the State of Michigan joined a growing number of states, 15 (17 by 2013),
and the District of Columbia, that have that openly defied United States federal law by
permitting the use of marijuana for medically certified patients. The Proposal 1 ballot
initiative in Michigan passed with the approval of 63% of the electorate and effectively
became part of the State constitution that can only be overturned by a two-thirds
majority vote in both houses of the State legislature (Michigan Constitution Article 2,
Section 9).
After passage by the people, Proposal 1 became the Michigan Medical Marijuana
Law creating two new categories of people: “Patients” are certified by a medical doctor
to use marijuana and “caregivers” may register up to five patients and supply them with
marijuana. These are not arbitrary statistics, but are carefully defined by the state.
A medical marijuana patient must be certified by a doctor to have a:
Serious and debilitating medical condition…[such as]… Cancer, Glaucoma,
positive status for Human Immunodeficiency Virus, Acquired Immune
Deficiency Syndrome, Hepatitis C,Amyotrophic Lateral sclerosis, Crohn's
disease, agitation of Alzheimer's disease, nail patella, (MCLA 333.26421 et
seq).
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Not only must the patient be suffering from one of these conditions, but the state of the
illness must serious enough that they are currently in treatment and that the condition is
causing:
cachexia or wasting syndrome; severe and chronic pain; severe nausea;
seizures…epilepsy; or severe and persistent muscle spasms, including but
not limited to those characteristic of multiple sclerosis (MCLA 333.26421 et
seq).
These medical conditions create a difficult living environment and the groups of people
suffering from these conditions are often already marginalized by society due to their
illness and poor health even before attaining the status of medical marijuana user.
Under the Michigan Medical Marijuana Act (MMMA), a medical doctor with a
physician-patient relationship may provide the patient with a signed statement that in
the physician’s professional judgment, the patient has a debilitating medical condition
and that the medical use of marijuana is likely to provide palliative or therapeutic
benefits for the symptoms or effects of the applicant’s condition (MCLA 333.26424(f)).
Michigan initially regulated this process through the Michigan Department of Community
Health, but the responsibility was passed to the Michigan Regulations Bureau in 2011
by the new Republican Governor Rick Snyder (Cleary 2013, Ramsdel 2012).
The status of caregiver is also regulated and carefully defined by the Michigan
Medical Marijuana Act. A caregiver is a person who grows or supplies marijuana to a
patient he or she has registered with the Regulations Bureau. A caregiver may register
up to 5 patients with the bureau and may grow up to 12 plants and possess up to 2 ½
ounces of marijuana for each patient registered. This means a caregiver who is also a
patient may grow up to 72 plants (6 X 12) and possess up to 15 ounces (6 X 2 ½) of
marijuana.
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Presidents Clinton and Bush (H.W.) actively tried to subvert state laws through
raids on state approved marijuana dispensaries and grow operations. The Supreme
Court decision in Gonzales v. Raich affirmed the right of the federal government to
conduct operations based on federal law alone even when there was a conflict with
state laws. In response, medical marijuana states began withdrawing support from
federal police agencies and setting the stage for increasing conflict between state and
federal government not seen since the 1950’s desegregation battles. The standoff
continued for several years with state law enforcement withdrawing support and
cooperation from federal law enforcement and growing public support for medical
marijuana with each DEA raid (Pew 2013, Gallup 2012).
Finally acting in response to the majority, the federal government backed off.
With national polling data showing support for medical marijuana as a favorable
percentage in the mid 80’s (Langer 2010), the only surprise was that it took over a year
for President Obama to fulfill one of his campaign promises to end raids on state
sanctioned medical marijuana patients. President Obama made at least five statements
on medical marijuana during the 2008 campaign (Laugesen 2011). Taken together, they
promise tightly regulated medical marijuana at the federal level and state that
prosecution of state sanctioned patients is “not a good use of federal resources”
(Venkataraman 2007). In February of 2009, the Obama administration, through Deputy
Attorney General David Ogden, sent letters to all U.S. District Attorneys directing:
As a general matter, pursuit of [drug enforcement] priorities should not focus
federal resources in your States on individuals whose actions are in clear and
unambiguous compliance with existing state laws providing for the medical
use of marijuana (Ogden 2009).
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Marijuana operations not in clear compliance with state laws continue to be subjected to
federal law enforcement raids.
Despite the apparent release of many legal prohibitions, there is still no published
literature on the Michigan Medical Marijuana patient population except the following
very basic statistics published on the Michigan Licensing and Registrations Bureau web
site as of May 31, 2013 (LARA 2013):
402,688 original and renewal applications received since April 6, 2009.
128,441 active registered qualified patients.
26,875 active registered primary caregivers.
25,788 applications denied -- most due to incomplete application or
missing documentation.
Michigan is one of the few States to even keep official records. The statistics from most
•
•
•
•

States are not available from official sources. Nor are statistics describing the
population of users of medical marijuana
Distribution of Marijuana Under The Michigan Medical Marijuana Act:
As the interpretation of the Act continues to unfold in Michigan, a variety of
medical marijuana distribution methods appeared almost organically and spontaneously
to fill the new demand. They appeared even though regulations concerning medical
marijuana

centers

were

left

conspicuously out

of

the

referendum

because

“dispensaries” were not polling well (MPP 2013). The story of medical marijuana centers
in Michigan is interesting but a story with consequences for the people impacted by the
deliberate ambiguities left in the law to insure passage and by how the case law
developed in Michigan.
Therefore, before proceeding further, the context in which the data was collected
needs further elucidation. This study did not take place in a laboratory with carefully
isolated and controlled variables that were carefully separated from the natural
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environment. The data was collected from real people, with real life problems and real,
legitimate concerns.

During the time of the interviews, the patient and caregiver

participants were confronted with a constantly changing legal environment, a State
Attorney General who was and is anti-marijuana, and an erratic, often unclear and
conflicting series of appellate court decisions. A myriad of legal, legislative and policy
decisions affected the participants and determined the topics covered in the interviews.
In particular, several of the major themes and issues in the interviews depended on the
dynamic interaction between the topics being discussed and the developing case law.
The issues pertaining to the access and use of marijuana were particularly sensitive to
the changing legal interpretations. Therefore, it is necessary to conduct a thorough
review of the Michigan Medical Marijuana Act and the case law as it developed during
the course of the interviews.
The theme of interactive responses to changes in the law was actively sought
from the beginning of data collection in order to explain and describe how patients and
caregivers adapted to the changing interpretations of the Michigan Medical Marijuana
Act. Particular attention was given to the structures and functioning of the alternate
medical marijuana distribution centers that arose in Michigan following passage of the
Act. The principles of reciprocal change have rarely been as obvious as in the
responses from patients and caregivers and from law enforcement and prosecutors to
the Michigan Medical Marijuana Act. Therefore in order to set the stage for the interview
data, a review of the law and legal environment created by the Michigan Medical
Marijuana Act along with the case law that developed around the Act is provided. As
well as, a discussion of alternate interpretations of the Act, and an investigation as a
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purely legal issue into the rise, variable fortunes, and ultimate fall of alternative medical
care provider distribution networks in Michigan following enactment of the Michigan
Medical Marijuana Act.
People vs. McQueen: The Supreme Court outlaws dispensaries in Michigan:
By the fifth year of enactment of the Michigan Medical Marijuana Act, the
Supreme Court of Michigan had given minimal guidance until deciding People vs.
McQueen in February of 2013. In McQueen, the Supreme Court voted 4-1 against
allowing medical marijuana dispensaries to operate in Michigan. The court quoted
section 4e in full twice during the opinion without providing any legal analysis of the
section. Then, in a very unusual move, the court put the ruling on dispensaries in an
Appendix at the end of the opinion after the judge’s signature. This avoided any need
for the court to provide an analysis of Section 4e. In general, courts organize the rulings
or decisions in a “Holdings” section or at least in a conclusion section prior to the
judge’s signature on the opinion. However, in this opinion, in the Appendix, after the
judge’s signature the court stated:
Section 4 does not offer immunity to a registered qualifying patient who
transfers marijuana to another registered qualifying patient, nor does it offer
immunity to a registered primary caregiver who transfers marijuana to anyone
other than a registered qualifying patient to whom the caregiver is connected
through the MDCH registration process.
This statement is unsupported by any legal reasoning or analysis and was apparently
placed in an “Appendix” for the sole purpose of avoiding the provision of any legal
analysis to support the court’s position. Use of an Appendix to issue a “Ruling” is an
extraordinary move not supported by any known precedent. In fact, an analogy may be
drawn to the Marijuana Stamp Act, where marijuana cultivation was allowed, but only
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with a stamp that the government then refused to issue. The Supreme Court of
Michigan in McQueen effectively issued a Judicial Stamp Act by ruling that the Michigan
Medical Marijuana Act permits patients to legally purchase marijuana, but anyone
selling or even providing the patients with that marijuana except the narrowly defined
“caregiver” to whom they are registered with through the State, commits a felony.
In the legal analysis that the court avoided Section 4e clearly states:
“A Caregiver may assist a patient in the medical use of marijuana.” (MCLA
333.26424 section 4e, emphasis added).
In other words, the plain meaning of the statute that was relied upon by each of the
“Caregiver” interviews and most of the “Patient” interviews is that “A” Caregiver may
assist “A” patient in the medical use of marijuana. The word “A” does not precisely
mean “any” but obviously refers to a larger and broader classification than “THE
(emphasis added) caregiver” connected through the caregiver registry system. The
preceding sections 4a- 4d state that: “The caregiver (shall not be criminally liable) for
assisting a qualifying patient to whom he or she is connected through the department's
registration process (MCLA 333.2624 section 4a-4d, emphasis added). Unless the
legislature clarified this term, then the plain meaning of the statute is that “A” or “Any”
Caregiver can assist “A” or “Any” patient in the medical use of marijuana. In case there
was any doubt what this passage means and precisely what is covered in the meaning
of “medical use,” the law explains in the next sentence:
“Such assistance shall not be considered the sale of a controlled substance.”
(MCLA 333.2624 section 4e).

52
In other words, the plain meaning of the law clearly states that a caregiver, may sell
marijuana to a patient and such assistance “shall not be considered the sale of a
controlled substance.”
The decision of the Michigan Supreme Court was viewed with universal outrage
by the participants in this study, several of whom complained that the decision does not
enhance the Court’s stature among the several States with one referring this researcher
to the below cited University of Chicago study. The Michigan Court has long had a
reputation nationally as a political entity with few legal scholars on the bench, low
standards and a marked lack of judicial independence. According to a University of
Chicago study, the Michigan Supreme Court ranks at the very bottom, number 52 out of
52 in the survey:

“Which States have the best (and worst) Supreme Courts?”

(University of Chicago 2008).
In People vs. McQueen, the court ruled that the plain meaning of Section 4
provides for immunity from arrest or prosecution for the use of marijuana by patients
registered with the State of Michigan though the caregiver registry system.
Notwithstanding the language in section 4e, the court further “ruled” (in an Appendix)
that caregivers are only protected if they are providing marijuana to the patient to which
they are registered under the caregiver system.
Section 4 also provides specific guidelines to patients and caregivers on
allowable plant counts and usable marijuana weight limits.
Section 8 provides different and less comprehensive protections for transactions
and patients which occur outside of the section 4 caregiver registry system. The
Supreme Court in People vs. Kolanek held previous to McQueen:
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The stricter requirements of section 4 are intended to encourage patients to
register with the state and comply with the act…if patients choose not to
abide by the stricter requirements of section 4 they will not be able to claim
this broad immunity but will be forced to assert the affirmative defense under
section 8 (at page 2).
The affirmative defenses are asserted after arrest, before a court, and provide
protections for the use or possession of marijuana in a quantity that was not more than
“reasonably necessary to ensure the uninterrupted availability of marijuana” (Kolanek,
id) but which is not otherwise protected under Section 4. In other words, if a caregiver
has too many plants under Section 4, engages in any transaction outside the caregiver
registry network protected by Section 4, or a patient possesses to much usable
marijuana under Section 4, the caregiver or patient may still assert the medical
necessity defense under Section 8 before a court and have the case dismissed if the
amount was “reasonably necessary to ensure the uninterrupted availability of
marijuana” for the patient.
The Supreme Court cases of McQueen and Kolanek are, in one sense, the “end”
of the story. Given the status of marijuana under federal law, any appeal to the United
States court system would be ridiculous. Although there are legislative efforts underway
in Michigan to change the law to allow dispensaries, the interpretation of the current
iteration of the Michigan Medical Marijuana Act has finally been clarified. Dispensaries
and all transfers of marijuana, except in a few very narrowly prescribed circumstances,
are now illegal in Michigan. This was not the case during the data collection in this
paper, and the progression of legal cases that led us to McQueen is a necessary
predicate to understand the context of the interviews.
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Michigan Medical Marijuana Act Case Law and History 2008 – 2013:
While the Michigan Medical Marijuana Act was enacted in November 2008 by
public referendum with the support of 63% of Michigan voters, very few Michigan
Supreme Court cases have clarified the law in the last five years even while
contradictory appellate court decisions continue to be issued. In short, the case law in
Michigan on the question of medical marijuana has not developed in a straight line of
logical or legal reasoning.
Thus the legal realities for Michigan medical marijuana was constantly changing
during the course of the interviews, providing an opportunity to employ two related fields
of study. “Sociology of the Law” and “Law and Society” are related interdisciplinary
programs that incorporate theoretical paradigms from sociology, law, science, and the
humanities. “Sociology of the Law” is the use of sociological techniques and theory to
study the legal system or portions of the legal system as an integrated, but discretely
defined, social institution while “Law and Society” explores the reciprocal relationship
between the effect of the law on the overall social system, or a segment of that social
system, and the impact of the social system on the development of the law (Sutton
2004). Changes in society cause changes in the law and this causes further changes in
society. Similarly, changes in law cause changes in society which causes further
changes in the law. The changing laws affected the patients and caregivers and heavily
influenced the open ended interviews as participants adapted to the constantly
changing interpretations of the Michigan Medical Marijuana Act.
Therefore, an understanding of the changing legal analyses of the Michigan
Medical Marijuana Act is necessary to fully understand the personal and professional
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views of Michigan medical marijuana patients and caregivers as they developed over the
course of the interviews used in this study. Further, a full legal review requires a detailed
history of the case law that developed around the Act, a discussion of alternate
interpretations of the Act, and the investigation of the rise, variable fortunes and ultimate
fall of medical marijuana dispensaries and alternative medical care provider distribution
networks in Michigan following enactment of the medical marijuana act in 2008 and the
2013 decision in People vs. McQueen outlawing dispensaries and any transfers of
marijuana outside the limited number of patients connected to a caregiver through the
state registry system.
People vs. Feezel No 138031, June 8, 2010 (Michigan Supreme Court)
effectively reversed the 0-tolerance provisions of People vs. Derror 475 Mich 316 (2006).
The issue was whether a metabolite of THC (11-Carboxy-THC), which is often measured
in blood tests, was a “controlled substance” and thus subject to Michigan’s 0-tolerance
policy barring any Michigan driver from operating a vehicle ‘in the presence of’ a
controlled substance.’ The court overruled Derror thereby providing considerable
protections for Michigan medical marijuana patients from the 0-tolerance policy.
Many of the rulings from this time forward, until 2012, were in the appellate court.
As with many statutes, the first set of questions dealt with by the court was the issue of
retroactivity. In People vs. Campbell (Case no. 291345, decided:

July 13, 2010,

approved for publication August 26, 2010, Michigan Court of Appeals), the court held
that the Michigan Medical Marijuana Act is not retroactive and that any physician’s
recommendations used in a Section 8 defense must have come before any arrest or
prosecution for possession or cultivation of marijuana. See also People v. Reed, Case
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No. 296686, August 30, 2011 (Michigan Court of Appeals). This is a common ruling on
statutes that do not specify they are retroactive.
Next, the Michigan Appellate court attempted to interpret the section 8 defense:
In People v. Redden, Case No. 295809, September 14, 2010, the Michigan Court of
Appeals held that an assertion of the Section 8 affirmative defense requires a bona-fide
doctor-patient relationship and that the Defendants have to see the physician for good
faith medical treatment and not merely to obtain marijuana under false pretenses. This
case included a controversial concurring opinion by Judge O’Connell and was
remanded to the trial court where an order of dismissal is pending Supreme Court
decisions on the Section 8 and Section 4 defenses.
In People vs. King Case No. 294862, February 3, 2011, the Michigan Court of
Appeals held (in obvious contradiction of the plain meaning and wording of the statute)
that Section 4 and Section 8 required the same plant counts and weight limits and that
only those complying with the Section 4 limits could assert the Section 8 defense. This
was overturned by the Michigan Supreme Court (King, supra).
In People vs. Anderson Case No. 3000641, June 7, 2011, the Michigan Court of
Appeals upheld the longstanding rule that courts have discretion to impose summary
disposition on any case where there is no genuine issue of material fact (MCR 2.116
C(5)). In other words, although patients and caregivers may assert the Section 8
defense for a jury, a judge may still deny the use of the defense where no reasonable
juror could find on behalf of the party asserting the defense. This has been longstanding law in Michigan as reiterated in King.
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In the first direct case impacting the issues of access to marijuana and the
delivery of that access in the context of alternate provider organizations, the Michigan
Court of Appeals in State of Michigan vs. McQueen (Case No. 301951 Decided: August
23, 2011) held the “medical use of marijuana” does not include patient-to-patient sales
of marijuana under the Michigan Medical Marijuana Act.” This was the same case that
became the definitive Supreme Court case of People vs. McQueen.
In People vs. Koon (Case No. 301443, Decided: April 17, 2012) the Michigan
Court of Appeals distinguished Feezel which had held 11-Carboxy-THC in a driver’s
body (this is different from the metabolite that was judged by the Michigan Supreme
Court) was not evidence of a violation of the 0-tolerance of drivers using controlled
substances policy in Michigan. Medical marijuana patient Koon had active THC in his
blood and the court held that the 0-tolerance for controlled substance use in a driver
was applicable. In effect, this decision means that medical marijuana patients may not
legally drive in Michigan since almost all patients regularly and chronically have
measurable levels of THC in the blood. The case is also being appealed to the Michigan
Supreme Court.
In People vs. Bylsma (Case No. 302762), Decided: September 27, 2011, the
Michigan Court of Appeals held that the defendant could not assert a Section 8 defense
because he had violated an Attorney General opinion that each set of twelve plants
permitted under the Act must be kept in an enclosed, locked facility that can only be
accessed by one individual. This was overruled by the Supreme Court on December 19,
2012, Supra. However two months later in People vs. Danto, November 8, 2011, the
Michigan Court of Appeals held that “marijuana” and “plants” were identical in the

58
medical marijuana statute which states: “for each registered qualifying patient who has
specified that the primary caregiver will be allowed under state law to cultivate
marijuana for the qualifying patient, twelve marijuana plants kept in an enclosed, locked
facility.” The court held this requires that both dried marijuana and plants must be kept
in a “locked enclosed facility” and denied the defendant the right to assert the medical
marijuana affirmative defenses at trial. This case is also on appeal to the Michigan
Supreme Court.
The second medical marijuana case decided by the Michigan Supreme Court
was People vs. Kolanek and King Case No. 142695, (Michigan Supreme Court, May 31,
2012). These two cases were decided on the narrow grounds of whether the assertion
of the Section 8 affirmative defenses in the Michigan Medical Marijuana Act also
required a defendant to comply with the requirements of Section 4. Despite an appellate
court opinion to the contrary (c.f. People vs. King Michigan Court of Appeals), the
Supreme Court held that the plain meaning of the statute established two different
sections and two different sets of requirements and protections to assert a medical
defense to the use of marijuana. This was viewed as extremely positive in the medical
marijuana community and several interviews conducted in the May, 2012 time frame
included discussions about this case.
The Michigan Supreme Court ruled in Kolanek and King that there are two
separate sections of the Act, and that the caregivers who fall outside the weight or plant
count limits may still assert the section 8 affirmative defenses at trial. Both King and
Kolanek were remanded for further action consistent with the opinion but only Kolanek
was permitted to assert the Section 8 affirmative defense because King was held to
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have lost the argument of whether a material fact for the jury existed since the lower
court ruled as a matter of law that no reasonable jury could have found in his favor.
Kolanek is currently at the trial court again while King filed for another appeal and the
case is again working its way through the legal system.
On December 19, 2012, the Michigan Supreme Court unanimously overruled
People vs. Bylsma in part stating, that although Bylsma had more plants than permitted
to him under the Section 4 immunity defense, he was still entitled to assert the Section 8
affirmative defenses. Bylsma will have to show he possessed the marijuana in a
quantity that was not more than “reasonably necessary to ensure the uninterrupted
availability of marijuana.” The court remanded the case for the trial court to conduct an
evidentiary hearing on that issue. This case was also extensively discussed during the
interviews, particularly in the caregiver interviews involving growers and medical
marijuana facility operators who were very concerned about allowable plant and weight
counts.
These laws on medical marijuana have confused many patients, including the
participants in this study. During the time before the Supreme Court rule in McQueen,
there were several unanswered questions about the appropriate interpretation of this
referendum. The Michigan attorney general has been critical of the Act while various
circuit court jurisdictions have exercised their discretion in vastly different ways. Several
Oakland County Circuit Court judges have added their own interpretations to the
Michigan Medical Marijuana Act and the court is known to be very anti- medical
marijuana. Therefore it is not surprising that not a single volunteer came forward to be
interviewed who lived in Oakland County. One court ruled against patient-to-patient
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transfers (People v. Nater, Case No. 10-234179-FH, January 12, 2011 (Oakland
County).

Another ruled directly against dispensaries and other alternative medical

provider delivery services People v. Vlasenko 11-236616-FH, August 17, 2011
(Oakland County) stating that: “There is no language in the Michigan Medical Marijuana
Act that provides protections for dispensaries.” In People v. Hicks, Case No. 2010232705-FH, March 15, 2011 (Oakland County), the court held that the defendant did not
have a sufficient medical history to justify his use and possession of marijuana, and that
his medical marijuana card was thus invalid. Therefore, he had no right to present a
section 8 defense. In People v. Prell, Case No. 2010-233008-FH, March 4, 2011, the
court refused to accept the testimony of the defendant’s certifying physician in support
of his Section 8 defense.
Gaps in The Literature and Rationale:
As we have seen, in a very real sense, the bulk of the literature on medical
marijuana research is a giant gap. There is little research about the medical marijuana
population nationwide and no published research about the Michigan population. There
has been no clinical research approved in the United States using medical grade
marijuana and very few randomized controlled studies in the entire world on the effects
of marijuana. In fact, more than 95% of the studies purporting to investigate marijuana
are not studies of natural smoked marijuana but of synthetic, oral pharmaceuticals such
as Nabilone, Dronabinol, or Levonantradol (Armentono 2011, Earleywine 2002). There
is no published research on the impact of marijuana use on prescription medications or
the hypothesis that marijuana might reduce prescription opiate intake except a single
publication derived from this dissertation (Peters, 2013). There is no research on the
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operation of medical marijuana dispensaries in Michigan and almost no research on the
topic in other States. There is no research on the opinions of the Michigan medical
marijuana population and almost no research in other States. The Michigan Medical
Marijuana Act (MCLA 333.26421 et seq) was passed in November 2008 and, to date,
there are no published studies on the medical marijuana population in Michigan. The
state of California was the first to pass a medical marijuana statute in 1996, and there
are still only a handful of peer reviewed studies on this population and no controlled
clinical studies.
There are dramatic claims from seed manufacturers, trade publications, and
growers about the different types and strains of marijuana, but there is no controlled
scientific research on them. More research is warranted on the population of medical
marijuana patients and on the perceived positive and negative effects of medical
marijuana.
Delta-9 tetrahydrocannabinol (THC) which binds to endogenous cannabinoid
receptors (CB1 and CB2) and cannabidiol (CBD) which modulate various neurochemical
and physiological processes (Santos 2010) have been studied to some extent, but the
ratio of THC to CBD and the subjective effects of each is a potentially important piece of
the medical marijuana research puzzle; the investigation of which has been grossly
deficient. As we have seen, NIDA will only supply research marijuana which averages in
the 1.5% THC range while medical marijuana dispensaries often provide products with up
to 25% THC. There are some studies using CBD in human subjects (Mechoulam 2002,
Kowel 2013) and quite a few using synthetic THC (Lile, 2013) but almost no studies on
the combined effects of THC and CBD.
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Most of the studies on the dozens of psychotropic agents in marijuana beyond
CBD and THC have been limited to characterizing them in chemical assays or introducing
them to various cell cultures. Research into the other psychoactive THC’s (delta-8, delta7 etc.) along with cannabidiol (CBD) and cannabinol (CBN) is currently lacking in the
cannon of work on medical marijuana (McParland 2001). There is even less work on the
potential effects of other cannabinoids, terpines, and flavinoids of the cannabis sativa
plant as it is found in nature.
Despite the relatively large size of the population, medical marijuana patients
have not been extensively studied by any measure. The dramatic lack of research on
the topic is highlighted by comparing it to other sociological topics that have been a
focus of research. For example, a search of the sociological abstracts for the term
“transgender” reveals over 1,000 hits while a similar search for “medical marijuana”
reveals 25 hits, most addressing policy issues like drug legalization or the neurobiology
of marijuana use. Only 6 studies directed at the population of medical marijuana
patients could be found in the sociological abstracts (Boudrias 2004, Chapkis 2007,
Chapkis & Webb 2005, Goode1970, Hathaway & Rossiter 2007, and Lenza 2007). In
contrast to medical marijuana, the population of transgendered individuals in the entire
United States is estimated to be only between 3,000 and 10,000 (Paisley 2006). In other
words, with 17 States now participating in some form of legalized medical marijuana,
and a medical marijuana population that is at least 100 times larger than the
transgender population, there has been at least 100 times less research on the group
that is the topic of this paper. Clearly more research is warranted.
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There are only about 69 peer reviewed randomized controlled medical studies
involving the actual use of marijuana and investigating the effects, benefits and
dangers. This could be put into perspective in many ways. This warrants further reviews
of the benefits dangers and social effects of marijuana.
More than 90% of the studies that purport to investigate marijuana are actually
studies investigating purified pharmaceuticals such as Nabilone (Schedule II Synthetic
THC), Dronabinol (Schedule II Synthetic THC isomer), and Levonantradol (Schedule I
Synthetic Analog NOT used in clinical applications but widely used in medical research;
the isomer is some 30 times more powerful than pure THC). Several excellent and
detailed bibliographies referencing marijuana studies are available online. The most
comprehensive is some 60 pages long and categorizes all the human cannabis
research ever done with links to the full study (Clinical Studies 2011). The categories
include:

(1) The medical condition studied (i.e. nausea and vomiting- cancer

chemotherapy, nausea and vomiting- radiotherapy etc.); (2) the modality of the study
(i.e. controlled, uncontrolled, case reports and surveys); and (3) the substance studied
(i.e. Nabilone, Dronabinol, Levenantradol, sublingual tinctures, and Smoked marijuana)
(Id). Further study is warranted on actual cultivated marijuana in actual human subjects.
Another reason to study marijuana as it is actually used in situ is the fact that
health care, mental health, drug policy concerns, and criminal law issues can be
informed by better understanding the perspective and demographic characteristics of
the medical marijuana population. Better understanding will also guide important social
and government policies. The conflict between pro-medical marijuana activists and antimedical marijuana regulators is one of the most polarized debates in our society
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touching on major public policy decisions.. While pro-medical marijuana activists claim
that medical marijuana patients are desperately sick and desperately in need of their
“medicine,” anti-medical marijuana regulators claim that marijuana patients are
malingerers, drug addicts and frauds who just want to get high. The former has an
incentive to prevaricate and even fabricate in order to gain access to their favored
intoxicant while the latter is motivated to expand their power, scope, and influence as is
characteristic of most bureaucracies according to many observers who have variously
described them as “imperialistic” or “expansive” (Weber 1922). The question of whether
the individual should have the freedom to endanger one’s life or health by taking an
intoxicant or medication is a legitimate social concern; and at least as much so are the
antisocial consequences of government action. There is an argument that the tendency
for expanding bureaucratic influence is arguably counterproductive to the civil society.
Current anti-drug policies and laws provide government workers with an expanding
client base via increasing prison, parole, and drug treatment populations (Peters 2010).
In short, deciding whether marijuana is a legitimate medication or if the patient
population is composed of malingerers and frauds aids the decision making process on
several much larger questions such as projections and staffing for prison, health care,
and rehabilitation populations.
Research on the population will also inform pending and future legal disputes.
Medical marijuana has already generated significant and important case law on the
Commerce Clause and State’s Rights issues.3 Some fundamental constitutional and

3

The two most prominent cases so far are U.S. vs. Oakland Cannabis Buyers Cooperative 542 U.S. 483
(2001) which rejected the common law necessity defense for a medical marijuana buy clubs and Gonzales
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federal principles have not yet fully been decided by the Courts such as the scope of
States rights and the 10th Amendment, along with related and wholly unresolved conflict
of laws issues between the State and federal government. California’s Proposition 215,
Michigan’s Ballot initiative and all the other State laws that have legalized and regulated
medical marijuana stand in opposition to federal law which specifically categorizes
marijuana as a Schedule I drug with no legitimate medical use and a high propensity
for abuse (21 USC 811). A better understanding of the perspective of the medical
marijuana population may aid the legislative and judicial decision-making process in
these matters by assessing the dangerousness, criminal history and propensity for law
breaking in the population.
Conclusion of Literature Review:
From the time long before humans began settling into villages and towns, to the
Magna Carta and to the 80,000 pounds of hemp on the Nina, Pinta, and the Santa
Maria, hemp has played a pivotal role in world history. From the time of the U.S.
Constitution, to Washington and Jefferson, all the way to the present day, hemp (which
was renamed “marijuana” in the 1930’s) has continued to be of critical importance to the
nation. In the late 1920’s, southwestern States began outlawing marijuana as an attack
on Mexican immigration and “negro” jazz singers. Meanwhile, the claims makers in the
media, law enforcement, and in Hollywood began making the case against marijuana in
earnest and by 1937, culminating with passage of the Marijuana Stamp Act. By the
1960’s more and more people began using marijuana again as a counter-culture protest
which was answered first by the Controlled Substances Act of 1970 and then by Nixon’s
v. Raich 545 U.S. 1 (2005) which upheld the commerce clause power of the federal government to regulate
intra-State distribution of medical marijuana despite contrary State laws.
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1972 declaration of a “war on drugs.” The “war” continues even today and despite
federal obstacles to research, and the massive effort expended to show the harms of
marijuana, there are increasingly compelling claims that marijuana can be used
medicinally. Medical marijuana laws in Michigan and 16 other states are challenging
federal jurisdiction and developing a body of case law that will have unpredictable
interactions for many different people, social groups, and institutions. Further research
on the population of medical marijuana patients is warranted.
Since there is little or no ability to study medical marijuana using double blind,
clinical paradigms used in most pharmaceutical drug studies because the United States
government has limited medical studies on the efficacy of marijuana as medicine using
a variety of procedural and regulatory obstacles. This study, therefore, pursues a
different modality of inquiry. When ethical, moral, practical, or legal concerns prevent
scientists from employing the entire scientific method, social scientists can still
investigate matters such as the efficacy of a claimed medical procedure or drug by
systematically obtaining the perspectives of the patient’s themselves (Westfall, 2004).
In August, 2013, Dr. Sonjay Gupta, CNN’s Chief Medical Correspondent aired a
special known simply as “Weed.” Dr. Gupta has long been an opponent of medical
marijuana, claiming that “the scientific research does not support the use of marijuana
as medicine.” He held this view until he took the time to interview some actual patients
and review the actual medical marijuana research in the United States and around the
world. That was when he finally realized why there is so little research supporting
medical marijuana.

His epiphany was discovering that there is so little research
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supporting marijuana use as medicine because the U.S. government has deliberately
created a self-fulfilling prophecy by preventing this research since the 1960’s.
We have been terribly and systematically misled for nearly 70 years in the
United States, and I apologize for my own role in that. I had steadily reviewed
the scientific literature on medical marijuana from the United States and
thought it was fairly unimpressive. Marijuana does not have a high propensity
for abuse and it does have legitimate medical uses. In fact, sometimes it is
the only thing that works. There were in fact hundreds of journal articles,
mostly documenting the benefits. Most of those papers, however, were
written between the years 1840 and 1930 (Gupta 2013).
This ‘new’ information caused him to revise his original conclusions and his
documentary describes in detail the federal obstacles to marijuana research already
reviewed. His biggest objection, and the reason he changed his mind about medical
marijuana, is the fact that NIDA will only approve a drug study on the harmful effects of
marijuana which does indeed create a ‘fairly unimpressive’ body of research on the
beneficial effects of marijuana, which is a gap this dissertation attempts to begin to fill.
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CHAPTER 3: METHODS

Introduction:
This study employed in-depth, recorded interviews of medical marijuana patients.
A total of 31 medical marijuana patients gave recorded interviews with twenty recorded
participants who were “regular” patients and eleven who were patients and also
producers or “Caregivers” under Michigan law so that all Caregivers interviewed for this
study were also card holding patients.

Several dozen shorter, often impromptu

discussions were also conducted but not recorded for various reasons. Pursuant to IRB
protocols, all persons who gave interviews from which data was collected via handwritten
notes during or afterwards, or who were recorded and transcribed were provided IRB
approved information sheets. Often impromptu discussions took place while awaiting the
scheduled recorded interview or while visiting various marijuana vendors, seminars, and
political rallies around the State of Michigan.
Sociology of Medical Marijuana:
Sociology is a discipline that explores the social interactions between people,
groups and institutions as the primary unit of study. In almost all scientific disciplines, the
goal is to reduce the object of study to the most basic components. That is, the goal of
science is usually to focus the “lens of inquiry” as finely and as detailed as possible and to
“zoom-in” on what is being studied. However, Sociology “zooms-out” the lens of inquiry
and attempts to take in the larger picture to include the social forces that affect human
social behavior. The focus is not only on human behavior but also the larger focus of the
social influences on that behavior using what C. Wright Mills called the “sociological
imagination.” Engaging the sociological imagination teaches us to step back from the
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most typical unit of study, individual human behavior, and consider the broader social and
group influences on that behavior. Thus, sociologists study the social interactions of the
organism, not the organism itself. In this case, the unit of study was the newly created
group of Michigan medical marijuana users and informed producers.
The qualitative sociological methods of in-depth interviews and observation used in
this study started with anthropological research on primitive and exotic cultures (Neuman
2006). Beginning with the Chicago School “Field Work” in the 1920’s and accelerating
with conflict theorists in the 1960’s, particularly the feminists, qualitative methodologies in
anthropology began to be applied to the study and understanding of contemporary
cultures and groups (Creswell 2008). The goal of anthropological research is to “grasp the
native’s point of view, his relationship to life, to realize his vision of the world” (Malinoski
1922). Thus, the goal of qualitative research is often expressed as an impressionistic or
interpretive task of finding individual meaning that empowers “certain agents to create
representations and thereby to authoritatively pronounce on the shape and structure of
the world” (Hess-Biber & Levy, 2004). The interpretive researcher is encouraged to view
the world as the participants view the world and to see what the participants see. In short,
the fundamental characteristic of qualitative research, whether used to study “primitive”
cultures or contemporary cultures and groups, is the “commitment to viewing events,
actions, norms and values from the perspective of the people being studied (Bryman
1988).
Interpretive research is the “systematic analysis of socially meaningful action…in order
to understand the interpretations of how people create and maintain their social worlds”
(Hess-Biber & Levy 2004 page 88). Hermeneutics is the dominant interpretive paradigm
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which advises the researcher to discover the meaning embedded in the text. The text in
this study came from recorded and transcribed interviews of medical marijuana patients
and caregivers and from memoranda prepared following some of the unrecorded
interviews. Objectivity is not completely discarded in interpretive research; however, it is
often understood that all value points are equally valid and that nobody has a superior
position, value or point of view that is better than any other (Hess-Biber & Levy 2004 page
94).
Interpretive research is used frequently in research on traditionally oppressed groups
such as African-Americans and women, especially where such research can be used to
identify the roots, causes and forms of oppression. Critical theorists and researchers see
their role as destroying the myths and empowering people to change society. This is
achieved by bringing forward the ideas and perspectives of the oppressed group and by
giving them a voice (Rubin & Rubin, 2005). The paradigm used in this research with
medical marijuana patients is construed as a critical perspective since one primary goal
was to report on the perspective of a group that has been legally and socially
discriminated against. Society has created meaning for them that includes labeling them
as deviants, drug abusers, and criminals. The users of marijuana for medical reasons
have been arrested and vilified in print and visual media since before the 1930’s. In fact,
one would be hard pressed to find another group in the United States who has
experienced more legal and social discrimination than marijuana users over the last 90
years. Thus, the research methodologies, the analysis of socially meaningful interactions
and the goal of providing an understanding of a disenfranchised social group provide a
better understanding of human behavior and social interaction.

71
Recruitment:
Recruitment of prospective participants was an ongoing venture and a particularly
difficult and delicate job for a group like medical marijuana patients. IRB approved flyers
were posted at Compassion Clubs and other sites where medical marijuana patients were
known to congregate. IRB also permitted referrals from medical marijuana producers and
suppliers including compassion club owners and operators, growers, certifying physicians
and others who become known to the researcher. During the course of the research,
potential referral sources were presented and utilized. These sources included various
Compassion Clubs who held monthly public meetings, medical marijuana certification
physicians, and contacts with various producers. Making contact with several owners and
operators of compassion clubs, dispensaries, growers, and caregivers greatly simplified
participant recruitment and resulted in substantially more referrals for interviews than
were actually conducted.
Table 1 Interview Recruitment Sources

Number
n=7
n=7
n=26

Interviews
1-3, 7, 8, 20-21
6, 11, 16,19, 23, 24, 30, 31
4, 5, 9, 10, 12-15, 17, 18, 22,
25, 26, 27, 28, 29-31

Method of Recruitment
Flyers (not purposive)
Personal contact with the PI during the
research (Purposive)
Referrals (Purposive)

A total of seven participants, and the first three participants who provided recorded
interviews, were obtained by posting flyers at medical marijuana dispensaries,
compassion clubs and other areas where medical marijuana patients were known to
gather. Additional contacts were requested at the conclusion of each interview and the
remaining

24

participants

were

recruited

using

a

partially-purposive

snowball
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methodology. This means that efforts were made to obtain a recorded interview sample
population that roughly looked like the Michigan medical marijuana population on gender
and qualifying medical condition. However, proper caution must be taken in interpreting
these results since the sample in no way represents a probability sample.
Table 2: Internal Referrals of Interviewees by other Study Participants
Referring source
Participant by Identifying
No. Participants
Number
Referred
Non-referenced
4,5
2
Participant
Non-referenced
30, 31
2
Participant
11
9, 10, 12, 13, 14, 15, 17
7
16
25, 26
2
24,26
18, 22, 27, 28, 29
5
Interview number 4 and 5 were referred by one of the early respondents who
functioned as an information source. Interviews 9, 10, and 12-15 and 17 were referred by
interview 11, a delivery service operator. Interviews 25 & 26, a couple who operated a
dispensary, were referred by interview 16, another dispensary owner. Interviews 18, 22,
27, 28, and 29 were referred by interviews 25 & 26. Interviews 30 and 31 were referred
after a discussion with one of their work associates at the dispensary operated by
interviews 25 and 26.
The initial research protocol to interview five medical marijuana patients and
caregivers, advertising flyer, and participant information sheet was approved on February
16, 2011 by the Institutional Review Board at Wayne State University. Amendments
expanded the number of participants and added additional prospective interview slots for
activists and other knowledgeable persons who did not need to be carded patients.
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The interviews were a convenience sample but “partial purposive sampling” was
used because the interview sample group quickly diverged from the known population
parameters, especially along the domains of gender and qualifying condition to use
medical marijuana. The percentage of female patients and the occurrence of very serious
conditions in the patient population are known from government sources in Michigan and
comprise just 30% of the card holding patients in Michigan and less than 5% of patients
with stage IV cancer or multiple sclerosis (LAR 2012).

Therefore, the sampling

methodology is characterized as “partial” purposive. Because although there was not a
clear defining exclusion principle, there was a strong counter-resistance to the tendency
of being primarily referred to the sickest patients. The referral sources and participants
were repeatedly told we were looking for “the common and regular” medical marijuana
patient. Therefore, due to selective exclusions, and with a goal from the beginning on the
goal of obtaining a somewhat representative sample, the majority of the female
volunteers and referrals were not interviewed and only two cancer patients and 1 Multiple
Sclerosis (M.S.) patient were interviewed.

Considerably more female patients

volunteered or were referred to be interviewed than males even though only 30% of the
population is female (LAR, 2012). Therefore 35% of the sample (11 of 31) chosen to be
interviewed were female even though significantly more females volunteered to be
interviewed than males. Similarly, while the actual population of patients is less than 5%
cancer or multiple sclerosis fully 20% of interview volunteers and over ½ the referrals had
one of these conditions. However, slightly less than 10% of the sample chosen to be
interviewed had cancer or M.S. (3 of 31).
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In short, considerably more women than men volunteered to be interviewed even
though women are a minority in this population while a disproportionate number of cancer
and M.S. patients were referred or volunteered to be interviewed. The initial goal was to
determine if medical marijuana was a “ruse” or whether people were actually using
marijuana as medicine. As stated previously, this soon changed to a more interpretive
structure with a goal of finding the views and perspective of the “regular” medical
marijuana patient not just to provide evidence for the efficacy and utility of medical
marijuana by interviewing a population that was unbalanced on gender and qualifying
condition. Therefore after the first couple of interviews and a larger number of volunteers
and referrals began to come forward, the rejection criteria became more selective and
there was a deliberate effort to over-sample certain categories such as qualifying
conditions like chronic pain which is over 70% of the population (LARA 2012) and undersample other categories such as females which is just 30% of the population, so that the
final sample was more qualitatively similar to the known population parameters.
This was not always a simple task because there was a very strong tendency for
medical marijuana patients, particularly activists with a financial incentive in the medical
marijuana industry, to refer the most serious patient cases. However, while the sample is
not a random sample, it was not a pure convenience sample either with gender, severity
of medical condition, and type of medical condition all roughly balanced in proportion to
the known population parameters. Interviewee characteristics are shown in Table 3.
Table 3: Interviewees by qualifying medical condition
Medical Condition
Interviewees
Severe Pain/Post-Surgical Trauma
Cancer
Multiple Sclerosis
Minor Back, Neck or Muscle Pain

8
2
1
2

Percentage
(25%)
(6%)
(3%)
(6%)
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Arthritis
Minor Headaches
Severe Headaches (Cluster/Migraine)
Minor Knee pain
Severe Knee or Hip Pain
Other

7
1
2
3
3
2

(23%)
(3%)
(6%)
(10%)
(10%)
(6%)

Consenting Procedure:
Participants who volunteered for interviews initiated contact and were then
provided information about the study. Those who agree to a taped interview and provided
contact information were provided the information sheet before any data was actually
collected or recorded. Consent to participate in the study was obtained verbally once the
participant read the information sheet and any questions or concerns were addressed.
Unsigned Information Sheets were used because the main risk of the study was a breach
of confidentiality and the use of an Information Sheet protected the anonymity and
confidentiality of the respondents. Participants were given the opportunity to review the
transcript of the interview and explain or supplement the answers although only one
participant took advantage of this opportunity.
Creating the Questions, Gathering Information:
During the course of two years of research, dozens of patients, caregivers,
dispensary principles, growers, lawyers, professors, reporters, public organizers,
lobbyists, and physicians shared opinions and feelings on the use of medical marijuana
and the implementation of the Michigan Medical Marijuana Act.

In most of these

impromptu discussions actual data was not collected, but, the information was often used
to formulate the themes for the recorded interviews. When notes were not taken during
or after an informal interview an Information Sheet was not always provided. When the
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Information Sheet was not provided to individuals and notes were not taken during or
immediately after the interview, the information gained was not used in the final report of
findings since this data was insufficiently systematic to warrant reporting as “Findings.”
Further, the prospective participants were insufficiently informed of their role as research
participants to justify using this as primary data. However, the transcripts of the recorded
interviews are filled with prefaced questions such as: “I had heard that…” Thus, this data
from the discussion where an Information Sheet was not provided was formative in
refining the Interview Guide and the topics to be discussed with the recorded participants.
There were also several dozen unrecorded discussions where notes were taken
during, or memoranda were drafted or dictated after, the discussion. These individuals
were considered interview participants and were given an information sheet, and freely
gave consent for their information to be used as data in the study. Some of these were
short conferences, perhaps while in the waiting room at a dispensary or before the start of
a conference or political rally while other information was gathered over multiple
conferences and some even lasted several hours. Over 100 pages of handwritten and
dictated notes and memorandum were accumulated during the information gathering
process and reviewed during the writing and hypothesis formulation process for this
paper. However, the primary use of this information was to help develop the formal codes
for the transcribed, recorded interviews and not as a separate, systematically collected
set of data points.
Study Procedure:
Interviews took place at a location of the patient’s choosing.

Approximately a

quarter of the interviews were in a public location such as the library (n=2) or a restaurant
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(n=4). The majority of the interviews took place in the participants home (n=18) while the
rest (n=7) took place at a medical marijuana center. Six of the interviews were tandem or
dual interviews with two married couples and a long-time intimate couple.

In these

interviews, both members of the dyad were medical marijuana patients and both were
interviewed concurrently.
Interview Guide
The interviews were conducted using an eight page Interview Guide as a template
(Appendix 1). However, these interviews were not heavily structured. Instead. they were
guided by the Interview Guide and developed as semi-structured qualitative interviews
whose purpose was to learn the patient and caregiver perceptions about the effects, use,
acquisition, and provisioning of marijuana. Therefore, the format of each interview was
unique and the topics ranged depending on the participants interests and knowledge.
Each participant had areas of interest and stronger feelings about certain topics than
others. After the first few interviews, when it became manifestly clear that the originating
question about whether marijuana is actually being used as medicine was going to be
affirmative, the interview format changed slightly to provide more room for the participants
to express their individual concerns, perceptions and experiences. The interviews were
recorded and transcribed. Most of the patient interviews took approximately an hour
while most of the caregiver interviews took one to two hours.
Each recorded interview began with the question:

“What is your qualifying

condition to use medical marijuana in Michigan?” This was followed by a detailed medical
history, and then the participant’s perception about his or her use of medical marijuana,
including beneficial and harmful effects, method of use and frequency of

medical
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marijuana use, as well as, an interactive discussion of the certification process, and each
individual’s visit to the medical marijuana doctor. The topics of stigma, dealing with the
children of patients, use of different medical marijuana strains, and initiation into the use
of marijuana and medical marijuana were added later to the interview guide. Finally,
demographic information such as income, class, political affiliation, work and school
history, and religion were briefly discussed.
Some topics were not even considered as a research theme or question until
several transcripts were reviewed. They showed a clear theme. For example, almost
every participant spontaneously provided detailed stories of social isolation, and the loss
of family, friends and significant others over opposition to the participant being a medical
marijuana user or patient. Therefore, the Interview Guide was changed to add the topic
of stigma. Similarly, a review of the transcripts revealed a clear tendency of several
participants to revert to euphemistic expressions about the efficacy of marijuana that took
a few readings to identify. Participants extemporaneously described marijuana as an allnatural remedy, and some talked about marijuana as an almost sacred herb that
promotes peace and harmony. Ultimately in a few cases, the participants began extolling
the benefits of free love and sex that the individual participants felt were fostered by the
use of marijuana. This topic was recognized as a similar ideology to that expressed by
hippie culture. Thus discussions in this genre were coded under the heading “Hippie
Talk.”
Four topics were chosen to present as findings for this paper: reduced opiate
usage, unequal enforcement and stigma, availability, and quality. Each chosen topic or
theme (as well as subtopic and themes) is given a separate Chapter in the “Results”
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section. Narrative passages from the transcripts provide multiple perspectives that were
used in a discussion of the interconnected themes (Creswell 2003).
Data Analysis:
The interview transcripts were subjected to a first pass of open coding followed by
more tight and specific codes at the conclusion of data collection (Creswell, 2003). The
initial categories were the twelve main topics listed in Table 4 and were covered in the
interview guide which was constantly revised as more information was discovered:

1
2
3
4

5
6
7
8
9
10
11
12

Table 4: Initial Categories of Discussion in Interview guide
Perceived adverse effects of marijuana;
Perceived beneficial effects of marijuana;
Certification procedure including fraud in the process and experiences with medical
marijuana physicians;
Children of medical marijuana patients
whether they know of patient status, whether this affects them, and how they were
told;
Patient Demographics;
Initiation into the use of marijuana and medical marijuana;
Patient views on the cannabis dialectic;
Patients qualifying medical condition;
Strain specific effects of marijuana as perceived by the user;
Qualifying medical condition;
Stigma experienced by medical marijuana users;
Use of medical marijuana such as frequency, modality etc.

The process of qualitative data analysis involves making sense out of text data, preparing
the data for analysis, and interpreting the larger meaning of the data (Creswell 2005).
The process is iterative and reflective which means that data analysis is circular with new
information feeding back and causing the researcher to change tone and the questions
for the next interview.
Preparation for data analysis begins even before the researcher begins collecting
data with narrowing of the research topic and a literature review of previous data points
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that have been collected on the topic. Once data collection begins the process of analysis
continues and deepens.

As data is collected from qualitative interviews, this new

information is used to refine the existing themes and questions and even formulate
entirely new themes and questions through a continual process of data collection and
reflection. Data is collected, interviews are conducted and the information is used to
modify the existing questions and themes.
The process continues until saturation of the data is achieved.

Some of the

findings reported in this study were obvious almost immediately and saturation of the data
occurred relatively quickly.

For example, the first four interviewees spent some time

talking about the fact that marijuana use let them decrease their opiate use and this
continued throughout every single one of the thirty one interviews where the patient’s
complaint was chronic pain. However, it was not until very late in the interview process
(specifically interviews 25 and 26) that the structure of dispensaries and alternate
marijuana delivery organizations came into focus. Complete saturation of the data on this
topic did not occur until the final two interviews. Saturation of the data for different strains
of medical marijuana did not occur during this study and this report is very preliminary.
This subject is strongly recommend for further interview studies that focus on comparing
patients with more serious qualifying conditions to those with less serious conditions.
Development of Interview Themes:
In Qualitative Research, the themes are often said to ‘jump out’ of the interview
transcripts or observation notes (Rubin & Rubin 2004). In this study, over 1,200 pages of
interview transcription was completed and typed over the course of 31 interviews. During
the course of the interviews, the Interview Guide was further developed via hand-written
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notations, memoranda and further research. The interviews were then transcribed and the
relevant portions of the transcript were coded under 19 major themes that had been
discussed during the interviews.

Four categories in the major themes were later

collapsed from the 19 categories into a total of 15 thematic categories that are listed and
described in Table 5 Final Codes below along with the pages of transcript devoted to that
topic over 31 interviews.
The quotations, discussions, and questions from the transcripts were included in a
“Qualitative Data Analysis” directory which was used in the analysis and comprises the
portions of transcript cited in the results section as shown in Table 5 :

Table 5: Final Codes and Interview Themes by Volume of Data Collection
Code
Description of Discussion
Pages of Transcription
Adverse
Consequences
Beneficial Effects
Cannabis Dialectic

Children
Demographics
Doctor’s Visit
Dispensaries

Fraud

Reverse-Gateway

Negative effects from use of
marijuana
Positive effects from use of medical
marijuana
Social split between pro and antimarijuana groups including discussion
of larger social issues like legalization
and the effect government control
Explaining patient status, diversion
issues, use by children
General demographic questions
The Medical Marijuana certification
process
Formation, operation and structure of
medical marijuana centers in
Michigan
Evidence for fraud in the certification
process and no legitimate medical
need
Medical marijuana reducing opiate
usage

30
25
57

40
172
41
63

41

47

82
Hippie Talk

Initiation
Michigan Marijuana
Act
Stigma
Strains

Use of marijuana

Discussions of free love, peace,
communal living, open sex practices,
new age, Eastern religions including
references to ‘all natural’ or ‘chemical
free’ life while using.
First time using marijuana and
medical Marijuana
Implementation, rule changes, case
law
As experienced and perceived by
users
Discussions about different types of
marijuana including modality of use
such as concentrated oils and
tinctures
A catch-all category including types
and modalities of the use of
marijuana

28

14
12
6
59

117

Using MS Word, each of these themes was given a separate directory name and
the transcript excerpts were labeled, and then cut and pasted into the appropriate file.
Because of the fluidity of the qualitative interview process, this was by necessity a flexible
process. For example, the section on the “Certification Process” was collapsed entirely
into “Doctor’s Visits.” Similarly, sometimes a transcript excerpt was placed into more than
one file. For example, discussions about the “Doctor’s Visit” often segued into “Fraud”
because the physician’s certification is closely related to the seriousness of the patient’s
qualifying condition and because some patients claimed the doctor’s visit was itself an
example of “Fraud.”
Some categories were not used in the final analysis of the results:

“Adverse

Consequences” had 30 pages of transcription, but most of it was questions about any
adverse consequences from marijuana use followed by a denial of any adverse
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consequences although a few patients complained about coughing and headaches from
“smoking too much.”
The topic of “Children” was fascinating and was almost chosen as one of the four
to present in this dissertation, but space constraints prevented this. Questions about the
children of medical marijuana patients were not pursued until later in the interviews,
beginning with interview 18 and most of the 40 pages of transcript devoted to this topic
were from just 4 interviews.

This topic is strongly encouraged as a future area of

research.
The topic of “Demographics” was not an important topic for a qualitative study
except insofar as it revealed the participant population which was 99% white (30 of 31)
and 35% female (12 of 31). The interview population was also highly educated (see
Table 9).
The most significant

results were

collapsed

into four main

categories

corresponding to the four sections in this dissertation on “Findings.”
Table 6: Findings Reported In this Study
Final Findings
Reduced Opiate Use

Unequal Law Enforcement and
Legal Concerns

Medical Marijuana Distribution
Strains of Medical Marijuana

Original Questions Category
• Beneficial Effects
• The Cannabis Dialectic
• Reverse-Gateway
• Hippy Talk
• Cannabis Dialectic
• Doctor’s Visit
• Michigan Marijuana Act
• Stigma
• Dispensaries
• Dispensaries
• Michigan Marijuana Act
• Use of Medical Marijuana
• Strains

84

Therefore, the Results section was primarily derived from the data that was copied
into the 15 Thematic Categories (Table 5) and then interpreted and condensed into the
final findings (Table 6).
Patient and Caregiver Interview Characteristics:
There were two categories of interviews:
Table 7 :Interview Types
Regular patients
Caregivers

n=20
n=11

A “regular” patient was an individual with his or her certification card from the State of
Michigan who had been approved to use medical marijuana by a physician who judged
he or she had a serious or disabling medical condition, the symptoms of which could be
helped by the use of marijuana. These interviewees did not have any significant contacts
with the medical marijuana industry in Michigan except as consumers and their interviews
took approximately one hour.
The remaining interviews (n=11) were with patients who were also individuals
classified as caregivers under Michigan law.

The Caregiver interviewees were all

producers and activists in the medical marijuana community. Proposal 1 under Michigan
law allows each patient designate a caregiver who may grow, purchase, or otherwise
obtain marijuana for his or her patient and legally receive remuneration from the patient.
These interviews took approximately two hours, and included the personal observations
about the categories and types of patients they had observed.
Table 8: Caregiver Interviewees by medical marijuana experience
“How many patients have you personally observed or advised about the use of medical
marijuana?”
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Number of Caregivers
1
4
2
2

Number of Patients claimed to have advised others about the
use of medical marijuana
A few dozen
Lots…too many to count
Hundreds
Thousands

The Caregivers interviewed were not representative of the population of medical
marijuana patients as they were mostly highly educated producers, leaders, and activists
in the medical marijuana community. Only three Caregiver interviewees did not have a
college degree, two of these were young females recently graduated from high school
who intended to go to college while the 3rd was a middle-aged, self-identified hippie who
had a tie dyed shirt and rainbow pony tail. Three of the eleven recorded Caregiver
interviews held a Master’s Degree.
Table 9: Interviewees by Education
Interviewee Characteristics:
High School

College

Masters

Patient Interviews (n=20)

11 (55%)

7 (35%)

2 (10%)

Caregiver Interviews (n=11)

3 (27%)

5 (46%)

3 (27%)

Interviewees Previous Experience with Marijuana:
Twenty-eight of the Thirty-one respondents (both Patient interviewees and
Caregiver interviewees) reported using marijuana before they developed their qualifying
condition. Two others were born with their qualifying medical condition and began using
marijuana before age 15. This convenience sample is too small to provide a meaningful
average (mean) age of entry into the use of marijuana and this was certainly not the
purpose of this study. However, the median (middle number in the range) and mode
(most common number in the range) is interesting:

According to the interviewees, both
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the median and mode of entry into the use of marijuana was age 15. Four respondents
reported first using marijuana at age 9, two at age ten, and one at age six.4 All but two
had been smoking regularly on a daily or weekly basis since their initiation. Several
claimed they started smoking marijuana at age 18. Only one first tried marijuana at age
25 and one stated she was in her 60’s the first time she used marijuana. Five patients or
caregivers were unclear on the age they began or did not wish to divulge this information.

Observations of “Medical Marijuana Dispensaries” as Alternate Medical Care Providers:
The interview process provided a number of opportunities to physically inspect
approximately twenty medical marijuana centers across the State of Michigan including
visiting facilities located in Lansing, Flint, Detroit, Grand Rapids, Ann Arbor, Northeastern
Michigan, and Northern Michigan. The results included personal observations, formal
recorded interviews, and the ability to gather information from lawyers, medical marijuana
center principles, and employees working within the medical marijuana industry in
Michigan.

Personal observations backed up by formal recorded and unrecorded

interviews were used in specific circumstances particularly in order to describe the
physical operation of medical marijuana centers in Michigan.
Methods- Conclusion:
This study employed in-depth interviews with a non-probability sample of Michigan
medical marijuana patients and caregivers which is a unique and little studied population.
A total of thirty one medical marijuana patients gave recorded interviews for this study
including twenty “regular” patients and eleven producers or “Caregivers.” Several dozen
4

This interviewee grew up in a “hippie commune” and believed her initiation may have been several years earlier
but listed age 6 because this was her first memory of smoking marijuana.
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short, information sessions were also conducted and used to modify the interview guide
and refine the initial codes into the final codes that were used. The recorded interviews
were then transcribed and the interview guide codes (Table 5) were developed in a highly
iterative process into the final codes (Table 6). Each transcript was then read and the
relevant excerpts from the transcript were copied into the appropriate final code category
for data analysis.
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CHAPTER 4: USE OF MARIJUANA DECREASED OPIATE USE:
THE “REVERSE GATEWAY EFFECT”5
The most prominent and earliest theme uncovered was the almost universal
claim by patients and caregivers that medical marijuana reduced or eliminated use of
prescription painkillers, in particular orally administered opiate narcotics. This claim is
at odds with previous studies on marijuana use and abuse.

In fact, there are

numerous studies on the Gateway Hypothesis that the use of marijuana leads to use
of “hard” drugs like heroin and cocaine, but very limited research on the potentially
beneficial effects of marijuana. The Gateway Hypothesis is the centerpiece of the
campaign against marijuana. The Drug Enforcement Administration (DEA) argues:
Marijuana is a frequent precursor to the use of more dangerous drugs…
marijuana users are five times more likely to become drug dependent, eight
times more likely to use cocaine, and fifteen times more likely to use heroin
later in life (DEA 2011).
However, proving the Gateway Hypothesis has been problematic. There is no
question the use of marijuana is associated with later use of more dangerous drugs in
specific cases, but it has not been proved that these individuals were not influenced by
other factors. Some studies find support for a general causal model that marijuana use
leads to use of “hard” drugs (Fergusson 2006) while others dispute the methodology
and interpretation of these findings (Kandel 2006).

Most reviews acknowledge the

interesting correlation but reach an inconclusive result. One of the more convincing
recent studies used a meta-analysis of longitudinal, animal, epidemiological and twin
studies to determine causality of the gateway effect claims (Hall 2009). Hall showed

5

An earlier version of this Chapter was published by the author as “Patients and Caregivers Report Using Medical
Marijuana to Reduce Prescription Opiate Narcotics” Humbolt Journal of Social Relations Issue 35:29-41 (2013).
The term “reverse-gateway” was coined by an early physician participant who was not recorded.
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that pre-existing traits, along with social and peer influences caused by early and/or
heavy entry into the drug culture are the primary influences in later abuse of other illicit
drugs. He concluded that regular cannabis use may have pharmacological effects on
brain function that increase the likelihood of using other drugs, this “minor” effect is a
“secondary concern” in human subjects (Hall 2009).
The claim that marijuana use decreases the use of other drugs was called the
Reverse-Gateway Hypothesis” in several conferences including all four discussions with
medical marijuana certifying physicians in Michigan. All the physicians agreed with the
Reverse Gateway Hypothesis and claimed that the “overwhelming majority” of their
patients seek marijuana in order to decrease their prescription use, especially opiate
narcotics.
Therefore, since the primary aim of this paper was to present the patient
perspective and perceptions about the effect of medical marijuana, the effect of
marijuana use on prescription drug use was the first finding. All patients and caregivers
who had experience with opiate narcotics expressed the view that medical marijuana is
not a Gateway Drug that increases the likelihood of illicit drug use but a Reverse
Gateway Drug that permits a decrease in concurrent opiate narcotic drug utilization.
No studies were located on the issue of using marijuana to substitute or
decrease opiate narcotics or any prescription medicines. However, there is a growing
body of research showing marijuana may reduce the negative side effects of various
symptoms and signs associated with narcotics use and withdrawal, especially nausea
(Todaro 2012) and headaches (Robbins 2009).

Thus, the additional untested claim

that marijuana use may also decrease opiate narcotic consumption by acting (like
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alcohol) as a mutually exclusive agent cannot be ruled out.

A claim that greater

consumption of marijuana is associated with less consumption of opiates appears to be
plausible. This paper is the first to report the medical marijuana patient’s claim that
marijuana acts as a mutually exclusive agent with opiates and thereby decreases the
use of opiates with greater use of medical marijuana.
Finding 1 on Decreased Opiate Use is an example of Applied Medical Sociology:
Medical sociology is an application of sociological methods and theory to the
evaluation of the role of social factors in the development of disease and illness.
“Sociology of medicine” is the study of the organization, structure, relationships, norms,
values, and beliefs of medical practice as a form of human social behavior (Cockerham
2010). Medical sociology is also interested in the causes and consequences of social
effects on the health of particular groups and the larger society which is often referred to
as “sociology in medicine” (Cockerham 2010). Medical sociologists often collaborate
with physicians to study the social cause and determinates of diseases or conditions
and tend to be motivated by a medical problem, rather than a direct social consequence
(Cockerham 2010). This study primarily focuses on Medical sociology, or the sociology
in medicine. These interviews are examining the social effects on the medical marijuana
users of Michigan.
The interview results from this study are reported in two sections as outlined
above in the “Interview Types” section. Results from “Patients” are reported in Section
One while results from “Caregivers” (Producers and activists) are reported in Section
Two. Eleven of nineteen patients and eight of nine caregiver interviewees who talked
about the topic had experience with opiate narcotics. All patients and caregivers who
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had experience with prescription opiates made sweeping claims that they personally
reduced opiate consumption and/or had personally observed patients reducing opiate
consumption as a result of using medical marijuana. Many provided personal, specific
and detailed examples of patients using medical marijuana to substitute for other drugs,
particularly prescription opiate narcotics.

The only patients who did not claim they

substituted marijuana for opiate narcotics were patients who were not originally taking
opiates.
PATIENT RESULTS
A. Patients reported completely eliminating prescription opiate narcotics by
substituting medical marijuana.
Several patients claimed they had been able to completely eliminate narcotics by
substituting marijuana.

One participant, a male P8 in his 40’s with dual hip-

replacements and severe arthritis described months of his life in a “complete daze”
taking Darvon, Oxycodone, and sublingual Codeine. He mentioned several times that
he was only able to completely discontinue these drugs because of marijuana:
I:

You mentioned, and I want to just get it out on the record, you have been
able to decrease or discontinue narcotic medications because of having
medical marijuana?

P:

That’s exactly right.

I:

You have been able to completely discontinue?

P:

Yeah.

Many patients were almost unable to contain their glee when they reflected on their
drug use before and after access to medical marijuana. One male, in his 50s, a College
Graduate was suffering lumbar pain post-surgery after he broke his back at work. The
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medical history was consistent with low back herniated discs and lower right side
peripheral neuropathy:
I:

Are there other drugs that you are not on now that you might be if you
didn't have marijuana?

P:

Yes I no longer take, the… frankly, I want to jump up and dance
because of that. You know. I took those pain pills and all those other pills
for so long. But, no more Tramadol [a prescription opiate pill] for me! I
don't have to see the doctor at the prescription mill for any pills, so no.

I:

So, no antidepressants, no pain medications, no Tramadol just marijuana.

P:

That is correct

Four of eleven patients who claimed experience taking opiate narcotics agreed they
were able to completely eliminate the pharmaceutical opiates by using medical
marijuana.
B.

Patients reported reduced use of prescription opiate narcotics by
substituting medical marijuana.

Other patients whose condition was more life altering claimed they had been able
to reduce their use of opiate narcotics by substituting marijuana.

Seven of eleven

patients reported they were able to reduce the number of pills taken, but did not
completely eliminate the use of opiates because the pain was still existent.
In two interviews, the respondents claimed they had significantly reduced opiate
narcotics use while simultaneously claiming they had recently added a morphine pump
to their medication regimen. The morphine pump was described as considerably less
psychoactive and did not have the side effects associated with opiate pills.6 During the
interviews it became clear that the participants believed the medical marijuana in
conjunction with the morphine pump made it possible to decrease opiate usage.
6

An intrathecal pump delivers morphine at about 1/300 the dose used for oral administration.

93
In an interview with P12, a female in her 30s with Multiple Sclerosis it was
disclosed:
P:

When I was on oral meds I was just not with it. You could talk to me and
have a conversation with me and 10 minutes later I wouldn't remember
what you said, and then I'm on the liquid morphine it's like a whole new
world to me.

I:

Is that because it is a steady supply and not an up-and-down situation?
what do you attribute that to?

P:

They said when you're taking oral meds it has to go through your whole
entire body…head to toe. When they put the pump in, it goes to my back.
I don't have to swallow. It doesn't have to go through my whole entire
body. I don't feel high all the time like I did when I had to take the orals
every six hours, every day

She claimed her ability to get off some of “the orals” was directly related to use of
medical marijuana:
I:

Have you been able to reduce or discontinue any of your medications as a
result of your use of marijuana?

P:

Yes, absolutely. I used to be on probably about 20 different pills, and I am
down to I think 7 or 8.

I:

So by two-thirds?

P:

Oh, absolutely yes, yep
A male patient in his 40s, P14, who suffered severe post-surgical lumbar trauma,

also related a history of taking “handfuls” of narcotic pain medications. He described
taking large numbers of narcotic pills every day and claimed a dramatic reduction in his
pill use due to the availability of medical marijuana:
I:

Is it your claim you have been able to reduce or discontinue some of your
narcotics and high schedule medications because of your use of Medical
Marijuana?

P:

I was taking 20 pills a day, almost 20 pills a day and now I am down to 12
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Patients frequently provided specific and detailed quantitative information
about their reduction in opiate use based on their perceptions and
memories. This patient believed his morphine pump was particularly
effective in conjunction with medical marijuana to reduce oral narcotics
use.
I:

So, do you think you would have graduated to the morphine pump
earlier if you had not had access to medical marijuana?

P:

Of course. The pump and the pot work together a lot better than
the pills. It takes out the pain, but it doesn’t mess up your mind.
The combination of morphine and medical marijuana, in the perception of several

patients allowed a reduction in prescription opiates, allowing them to function more
clearly. This preference was obvious not just with back pain, but also with other
maladies, such as Cancer.
Both Cancer patients interviewed were Stage IV with severe pain and mental
distress. They spent some time describing their experiences with prescription narcotics.
Medical marijuana was literally their last stop, and both talked extensively about the
importance of being able to reduce their narcotics intake and about the amounts of
narcotics they were prescribed. First was PP22, a 60s aged female cancer patient.
I:

Well, let’s talk about that what kind of drugs were you taking?

P:

I was taking Vicodin extra-strength three times a day backed up by an
Ultram which is an anti-inflammatory, and also a Duragesic patch with 50
micrograms that I change every three days. It gives me a constant flow of
medicine.

I:

Have you had to take a lot of narcotics?

P:

I had to take a tremendous amount of narcotics.
tremendous, tremendous amount

Tremendous,

Both cancer patients claimed they were able to significantly reduce their narcotics use
by substituting marijuana. P60s was able to take less of the “tremendous” amounts of
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narcotics that she had as part of her treatment. This was echoed by P27a female
cancer patient in her 50s :
P:

When I use the oil and smoke, I find it. I realize – wow. It is two hours past
the time when I would've normally taken my Fentanyl [a potent opiate and
general anesthetic]. I have two 100 milligram patches Fentanyl that I use
at a time. As well as, 40 or 50 milligram of Oxycodone [a/k/a Oxycontin, a
potent oral opiate] immediate release on top of that.

I:

Were you able to decrease any of your treatments since you started using
medical marijuana?

P:

Well, that I have been able to do, yes, absolutely. Like I said before, be,
be less dependent on those pills…which makes me happy. But as far as
changing any protocol like at the cancer center, then no.
Results were consistent across several medical conditions. Of the eleven patient

interviewed who were prescribed opiates/narcotics for their condition, regardless of
whether the medical condition was trauma, Cancer, Multiple Sclerosis, Arthritis, or some
other pain inducing condition, they unilaterally made nearly the same claim. If the
patient had a history of prescription narcotics utilization, after integrating medical
marijuana into their treatment they had been able to reduce or eliminate opiate narcotic
pills by using medical marijuana.
C. Caregiver Results: Caregivers agreed that medical marijuana is routinely
substituted for prescription narcotics.
In addition to 20 patients, eleven caregivers (producers, activists and patients)
were also interviewed. They were also asked about their observations on the use of
marijuana in order to reduce opiate use.
One of the 11 caregiver interviewees (P19) was a male in his 20s who worked as
a medical marijuana dispensary operator did not agree that medical marijuana regularly
decreased opiate use.
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I:

[of the “thousands” of people you have talked with about medical
marijuana] How many people have you personally witnessed able to
reduce or discontinue medications, pharmaceuticals, because they started
using medical marijuana?

P:

Personally, about 10.

He thought this was a fairly low percentage of patients because narcotics addiction is so
powerful.
His position involved in administrative matters, and he did not routinely talk to patients
about their
medical condition. His personal history did not include personal experience with opiate
narcotics
P:

I would say about sixty percent [of medical marijuana patients] are taking
pharmaceutical pills still.

I:

So well over half you think?

P:

Oh, yeah.

I:

And, how many of these sixty percent have been able to reduce the
number of pharmaceuticals they’re taking?

P:

Probably not many, I would say probably five percent. The rest are still so
hooked on it; that it is really hard.

The other 10 other caregiver interviewees reported they had experience talking to
patients specifically about their medical conditions and also had personal experience
taking opiate narcotics. They all claimed that medical marijuana was used to decrease
opiate narcotics.
The interview with Participant 1 was indicative of many of the users. She was a
young white female in her early 20s a High School Graduate, who suffered fibromyalgia
and Scheuermann's disease (mid-back kyphotic or “hunchback” changes that are often
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very painful) and worked as a medical marijuana dispensary employee in a medical
marijuana dispensary in Northeastern Michigan.

She and her parents were both

caregivers who worked at the medical marijuana facility. Her specialty was baking THC
candy and other edible medical marijuana preparations (“medibles”). She described her
condition as including extreme and disabling pain that caused her to miss a significant
amount of high school and develop an extensive medical history. She talked for some
time about her medications that included “huge amounts” of Vicodin, and several other
narcotics, anti-depressants, Flexerol, and non-steroidal anti-inflammatory medications.
Both her personal experience, and her broader experiences working with the patient
population supported the hypothesis that marijuana might be useful to “decrease”
narcotics intake:
I:

Have you been able to decrease other treatments since you started
using medical marijuana?

P:

I use nothing but medical marijuana.

I:

You don’t use any narcotics?

P:

Nope. Nothing.

The young woman’s observations about the patient population matched her personal
medical history:
I:

I have heard some doctors mention that perhaps marijuana is a reversegateway drug, that is. It doesn’t cause you to try other drugs, but it helps
you get off some of the drugs you are already on.

P:

Oh, yeah. Especially working, you know at a Compassion Club. I, well,
have seen that a lot. People will are coming to us mostly because they
don’t want to be on any more, or so many. I mean I started [using medical
marijuana] because I didn’t want to be on those pills.
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P1’s experience with “Wanting to get off those pills” became one of the most common
themes
in the interviews.
The second caregiver interview (P2) was a female in her late teens that suffered
from chronic knee pain and worked as a medical marijuana employee had the least
experience in the medical marijuana industry of all the interviews classified as
“Caregiver” interviews.

She had only worked in a dispensary for six months, but

extemporaneously set the tone for later interviews despite critical questions and pointed
probes:
I:

Have you ever seen anybody use marijuana as a gateway to use harder
drugs?

P:

I have because I feel like that’s what we’ve been told our whole life, and
so that’s just how it is. That’s what we’ve been told, but I mean they don’t.
It is not true.

I:

Can you be more specific what did you see? What have you heard?

P:

I mean, my whole life going to D.A.R.E. classes for instance? That
marijuana is a gateway drug, and then I believed that for the longest time
you know, and then I previously worked at [Medical Marijuana Center
name withheld] in [City name withheld] and I saw everybody coming in
there for it, and just like especially the old people. It really touched me
because they come in complaining mostly about Vicodin, and ‘how they
put me on this and that, and it was killing me.’ Lots of older people would
come in and tell me about how medical marijuana saved their life by letting
them get off that stuff.

Both groups of interviewees, Patients and Caregivers, used very similar language such
as “saving their life” or “lets me live my life” or “lets me function in my life” in describing
how medical marijuana is used to substitute for opiate narcotic pills.
Participant 11 was a Master’s level college instructor in his 50s who had back
pain. He worked as a medical marijuana delivery service provider and a medical office
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consultant. He reported, when asked about his experience with patients and narcotics
usage before and after medical marijuana:
P:

I may have personally processed four hundred doctor certifications. I am
the one the person talks to the longest...doing their case prep [for the
doctor’s office] And through these hundreds of patient encounters, I would
say about ninety percent of them have already been taking doctor
prescribed narcotic and opiate pharmaceuticals and…the side effects of
these are so onerous and debilitating themselves they are not able to
function in their normal capacity, and they are seeking to get off the
zombie effect of the pharmaceuticals. That is where medical marijuana
really
works
well.

His statement about the “zombie effect” of opiate narcotics is one that many suffers of
pain find difficult to combat, without narcotics they are in pain, with narcotics they are
numb. Their reports of medical marijuana making life bearable and still being able to
function is both interesting and promising for the Reverse Gateway Hypothesis.
A medical marijuana dispensary owner and operator, P 16, was a male in his 30s
who was an avid activist and lobbyist for medical marijuana. He personally suffers from
back pain. In his interview, he continued the assertion of the earlier participants, using
an even larger sample. He is a prominent political activist, the president of a statewide
medical marijuana advocacy group, a caregiver, and a ‘bud tender.’ He owned a large
medical marijuana center in the State of Michigan. “Bud tender” is a California term.
Because of legal ambiguities there is no commonly accepted term for the retail vendor
in Michigan who actually hands the cannabis samples to patients and advises them
about the properties and expected effects of the available types of cannabis. Many in
Michigan prefer the title “Cannabis Counselor.” All of the caregiver interviewees were
“Bud tenders” except the first interviewee quoted in this section who did not agree that
marijuana commonly substitutes for opiates. P16 had considerable direct access to the
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patient population that included “several thousand” sit-down interviews and discussions
with patients specifically about their medical condition:
I:

How do we compare cannabis to other drugs that are available? We start
off with Tylenol and Motrin, and most people tell me oh no it (medical
marijuana) is better (at killing pain) than Tylenol and Motrin. And then we
get into Tylenol with codeine, and they tell me they don’t want to take it.
And then we get onto Vicodin, and then Percodan, and a Morphine drip.

P:

We will help everybody but sometimes they need to supplement and cut
down on a bunch of the pills that they are taking and use cannabis
instead, but then still have to take those from time to time because the
combination, or at certain times of pain, it’s just, you have to go there
when it gets too bad. And that’s fine, everybody is different. Sometimes
people eliminate them all together which is better. And sometimes—

I:

You mean the pharmaceutical?

P:

Right. And then sometimes people eliminate one or two pills a day, and
that’s it. But over a period of time the amount of stuff you are putting in
your body, and the amount of cost, health costs, [of] those things is
realized, even if it is just a couple of pills a day, you know. So there’s,
there’s a combination of everything. Just reduce it a little bit, reducing it a
lot, and eliminating it. But either way, if you interject marijuana in there, it
makes things a little bit better

Like Interview 1, his personal experiences were similar to his broader observations:
I:

And you know what a gateway drug is of course?

P:

Yeah, and I know cannabis is not. Cannabis is an exit drug, it helped me
quit taking opiates, and all that crap. I’m also on over 6 years of not
drinking.

Interview P16’s personal and professional experience is interesting in light of the social
stigma that is currently on the use of marijuana and medical marijuana because of its
affiliation with crime and other harder drugs. In P16’s experience, he credited cannabis
with getting many people away from pharmaceutical narcotics, and for his departure
from drinking. He states quite clearly that it is an “exit drug.” And, he was not the only
interview with strong feelings on this subject.
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A tandem dual interview (P25 & P26) with a manager and girlfriend of a West
Michigan medical marijuana center yielded even more sweeping claims. They were in
their 30s-40s both college graduates and suffered from chronic radiating pain and
headaches. They owned and operated a medical marijuana dispensary. Both
Participants had already discussed the issue before the interview with the researcher.7
Each had talked with and advised “hundreds” to “thousands” of patients and were so
eager to tell their story the interviewer could barely complete the questions:
I:

Have either of you ever heard mentioned in your presence that maybe
somebody was able to reduce pain killers and narcotic drugs…

Female:

(interrupting) all the time…

I:

as a result of their marijuana use?

Female:

All the time.

Male:

Yes, all the time.

...Crosstalk….
Female:

Yes, yes, more people than I could list. We have people come in here,
well, all the time, every day, and talk about that. Yes, of course.

I:

Do you think that the majority of people who come in here and you talk
with you claim they are able to reduce the meds, the narcotics they're
taking…..

Male:

Yes

I:

because it is probably really only a few people who….

Male:

No!

Female:

No!

….Crosstalk….

7

The center was also participating in an investigation with the author comparing patient perceptions of blinded
strains of medical marijuana with the chromatographically revealed components and concentrations.

102
Female:

So many people. So many people, you know, text us. They thank us, this
is something we hear all the time. It is not a small thing. I mean, people
want to wash our car, or babysit our kids for free. Their so thankful, and it
really is all the time. It's every day.

Male:

Every day, and several times a day

…Crosstalk…
I:

go ahead.

Male:

I see, I mean. Yeah, I see people myself, firsthand, come in, and more
times than not, they're not happy when they come in. And every single one
of them will tell you ‘hey, I went from taking 10 pills a day to taking 2 pills
a day.’ With fewer pills, it's still a better quality life because of the medical
marijuana

P25 and P26’s enthusiasm and excitement about the help they were able to offer their
clients was touching. The two believed that the work they were doing was helpful, even
essential in the quality of life for those they were serving. Every single Caregiver
interview transcript includes consistent and numerous claims that at least some patients
were using marijuana to decrease prescription opiates.
Every Caregiver who was interviewed gave specific examples and articulated
personal observations about patients using medical marijuana to decrease prescription
drugs use, particularly opiate narcotics. Even the single Caregiver who did not have
any personal experience with opiate narcotics reported that he personally observed
about 10 patients who reduced their narcotics use by using medical marijuana. Every
Patient that was interviewed (including the 11 Caregiver interviewees) with experience
taking narcotics claimed they reduced or eliminated their prescription opiate narcotics
because they substituted medical marijuana. These findings are important in when
viewed against the social perception of marijuana mentioned by the second Caregiver
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interviewed (P6) who felt that it must be a Gateway Drug, because that is what she had
been taught, in direct contradiction of her personal experience.
PATIENTS PREFERED MARIJUANA TO PRESCRIPTION OPIATE NARCOTICS
Though pharmaceuticals are currently available for almost every ailment in a
variety of strengths, participants in this study reported they preferred medical marijuana
to narcotic opiates. There were several reasons for this preference; the most common
was that the side effects caused by opiates were pervasive and severe. There were
also claims that medical marijuana was more effective at relieving pain than some
opiates and that marijuana was a natural remedy and not a synthetic pill.
A. Opiates caused very unpleasant side effects:
Most patients described unpleasant side effects from taking opiate narcotics. A prime
example was P9 and P10, another tandem or dual interview with a husband and wife
team of patients in their 50’s or 60’s:
Female:

He simply can’t take [Vicodin] without getting sick.

I:

Now when you say you get sick, do you throw up?

Male:

Yeah, what happens is I get a severe headache, and I start feeling, I don’t
know, like fuzzy in my head, like there’s cotton all over inside my head,
and then it starts making me feel like motion sickness, is the best way I
can describe it, and then I just started getting sick and trying to throw up
and throw up and throw up (Male and female, 40’s-50’s, married couple,
college graduates, chronic pain).

Beyond physical effects, such as headaches, nausea and vomiting, another very
unpleasant side effect that was commonly reported was the claim that high doses of
opiate narcotics caused the patient to literally become disassociated with reality, or go
crazy. P27 a female in her 40s stated:
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P:

Marijuana doesn’t put me off in some world where I don’t know where my
kids are, and I don’t know what’s going on with the world.

I:

And oxycodone does?

P:

Yeah it does that. I don’t like [sic] take it. They gave it to me, and I gave it
back to them because ‘you take this, I don’t want this.’ I can’t even
remember having a conversation with my own husband or my own child.
This is bad stuff, ‘you take this I don’t want it.’ I gave it back to them,
because I refuse to take it. Give me a joint, give me a bowl, do whatever,
because I can smoke a bowl ,and then have a conversation with my
husband, or my kid, and I can still remember that conversation. Because
I’m sorry I would rather do that than to take one of those pills they gave
me because it just puts you off in a world that you don’t even know that
you’re in, and that’s scary.

The medications given to her for her torn rotator cuff were so off-putting that she turned
to medical marijuana. She was not the only one. Several of the patients with experience
taking high doses of opiate narcotics reported detailed, graphic, and apparently valid
fears about their mental health if they could not find an alternative to “the pills.” In a
humorous, but frightening, anecdote P27, a woman with end stage cancer related how
she came to make her decision to try medical marijuana:
P:

I was on almost 300 mg of oxycontin a day between the long-acting
and the short term. It was a very high dose. I was also given other
pain relievers Percocet, vicodin, Norco, you name it. I have a
drawer full of these pills. When it came to my final decision when I
decided to try medical marijuana was when I asked my dog to
make me lunch one day.

The stark reality of this situation is that she was not aware of her surroundings, and that
in trying to find relief from pain, she was losing her grasp on her life.
In addition to the complaints of nausea and insanity, some of the complaints
were frightening. Patients reported that opiate drug use was putting their children in
danger because of their lack of ability for function correctly. Opiates also caused
patients to sleep all the time as well as making them feel they were missing out on life.
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The overwhelming responses from patients were that medical marijuana returned them
to their life in a way that opiate narcotics could not.
B. Medical marijuana was perceived to be more effective at relieving pain than
some opiate narcotics but not the more powerful narcotics:
All patients and caregivers who had experience taking narcotics (n= 21of 31) in
this small sample said medical marijuana was more effective at relieving pain than
codeine. This is consistent with earlier work (Campbell 2001). In addition to being
more effective, all of the participants interviewed agreed that medical marijuana did not
have any of the negative side effects associated with codeine or narcotics. And, two
patients and three caregivers claim that medical marijuana relieved pain better than
Vicodin, which has not been previously been reported. All participants with narcotics
experience agreed that medical marijuana was not as effective at relieving pain as
stronger narcotics such as morphine or oxycontin. However, medical marijuana was
often still preferred over the more effective opiate.
In discussing with patients and caregivers the comparisons between opiates and
medical marijuana, there was some difficulty separating out the two issues of the
adverse side effects of opiates and the pain relieving effects of opiates. Although it was
clear that most patients preferred marijuana over Vicodin, it was not always clear
whether marijuana was preferred because it was more effective at relieving pain than
Vicodin or whether marijuana was preferred because it was not associated with the
adverse side effects of Vicodin which can include nausea, blurred vision, confused
thoughts, headaches, etc.
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One patient, a college educated Afghanistan Veteran in his 20s, attempted to
explain the differences including the disadvantages of opiates and the advantages of
marijuana:
P:

[Smoking marijuana]… makes my life better than when using narcotics.
Narcotics keep my back from hurting, sure, but the medical marijuana
helps me forget about the fact that I'm in pain. Narcotics, you know, I
don't have the nausea like that, and I physically feel better.

I:

I want to get very specific about what it does for your pain it doesn't work
as well as Percodan, am I right?

P:

Well, yeah, that that is that medication’s job. It is the thing that they do. Is
to kill the pain…and mess your head up a little bit, is obviously their main
purpose of life is essentially to dull pain, and they do a very good job. That
however is a Catch-22. You can be pain free, but you'll feel like garbage
with the nausea and the side effects from the narcotics that come with it.

His experience taking narcotics to help his back pain were echoed by almost all
participants who complained about “that sick nausea feeling” caused by taking opiate
narcotics.

C. Several participants refused to take opiate pills because they believed
marijuana was a “natural” remedy different than synthetic pills
Of the nine patients and one caregiver (out of a total of 31) who had no
experience taking opiate narcotics, seven claimed they never even started taking
opiates because they used medical marijuana.

One young woman, a female high

school graduate had chronic pain and reported she had never started using narcotics.
She attributed this to medical marijuana:
I:

What about other treatments, have you been given drugs?

P:

I choose not to take them. I personally, I have personal beliefs. I don’t like
to take chemicalized pills. You know what I mean?
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I:

OK, you don’t have a problem taking medical marijuana though?

P:

No.

I:

How is medical marijuana different than the…

P:

Well it is grown, it is an actual plant. So, for me it is just a natural
way to treat this.

Her belief in the natural approach to medical aid was expressed by others as well.
Another participant in her 20s was against smoking marijuana, until she suffered from
knee pain:
P:

I was against smoking marijuana for a long time for recreational use, and
then the whole medical marijuana thing started to come around, and so I
gave it a try. And I was like, wow, it really does help. And now, I have a
whole other different lifestyle now. I don’t do any chemicals, nothing like
that, it’s all natural. Everything natural, and I feel a lot better just as a
person.

I:

Can you go into that a little bit more? What do you mean you live a whole
different life style?

P:

I don’t, I mean, anything unnatural, I don’t do to my body. I don’t take any
prescription pills; I don’t drink alcohol any more, I use hash oil actually.
It’s very, very, very potent and you have to work up tolerance to be able to
vaporize a lot of it, but I mean once I’m at that level I don’t even want to
drink. I used to drink heavily and stopped when I started smoking hash
oil. I haven’t drank in two years now.

Most of the patients who had never started taking opiates, explained this by using some
version of the ‘natural remedy’ claim.
It is interesting that the natural medical marijuana was favored so highly, even
with the stigma of marijuana in the United States. The legal form of THC, Marinol was
also reviewed with four participants who had experienced both.

Three of the four

participants were ‘informal interviews’ and were not recorded while the other was
recorded but the discussion about Marinol was off the record.

Marinol, a
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pharmaceutical product that is synthesized THC has been promoted by the drug
companies as a substitute for medical marijuana. All medical marijuana patients who
have taken Marinol characterized it as negative. These comments place it closer to
opiate narcotics in the opinions of the medical marijuana users, than to grown
marijuana. The agreement and condemnation of the four participants dealt with both the
side effects and potency. They offered comments such as: “scary stuff”, “makes you
hallucinate”, “makes you jittery and paranoid”, “doesn’t help at all” and “you can’t
regulate how it makes you feel.”
The main complaint for opiates were the “sick feeling”, fear of putting their loved
ones in danger due to opiate intoxication, and fear of going crazy. Medical marijuana
patients and caregivers who volunteered to be interviewed for this study were more
positive toward medical marijuana’s effectiveness and side effects as a whole than the
effectiveness and side effects of opiate narcotics.

Consistent with previous work

(Campbell 2001) medical marijuana was thought by patients to be more effective than
codeine elixirs, but less effective than hard narcotics like oxycodone or morphine.
Some patients reported they preferred medical marijuana over Vicodin either due to the
lack of side effects from medical marijuana or from superior analgesia.

Medical

marijuana patients who did not have experience taking opiates often actively avoided
taking them even when prescribed because they preferred the “all natural” remedy of
medical marijuana.
These results should be viewed with caution given the unusual cohort that was
interviewed. Many participants had started using marijuana many years before they
developed their qualifying medical condition; so it is not clear from these results that
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novice marijuana smokers who did not begin until they developed their qualifying
condition would have the same experience of superior analgesia, lack of side-effects, or
the almost belief in marijuana as an ‘all natural’ remedy. Many of the people who turned
to medical marijuana without previous marijuana experience found they needed to
overcome the legal stigma that surrounds marijuana before being willing to try it. The
legal issues of medical marijuana in the state of Michigan are complex and frightening,
and though these participants unilaterally agree that medical marijuana helps their
condition, almost all of them expressed serious concerns about where they stand in the
legal system.
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Chapter 5: PARTICIPANTS COMPLAINED ABOUT SEVERAL LEGAL CONCERNS
IN PARTICULAR THAT ENFORCEMENT OF THE MEDICAL MARIJUANA ACT WAS
UNCLEAR, AMBIGUOUS, AND UNEVEN
Introduction:
Medical Marijuana users in Michigan have many concerns, and not just about the
legality of the medicine they have chosen. Several reoccurring legal concerns were
expressed by the participants during the course of the interviews specific to the
enforcement of the Michigan Medical Marijuana Act.

In terms of duplicating these

results with future samples, it is first important to mention that this researcher practiced
law for more than a decade as a licensed attorney in the State of Michigan so it was
probably inevitable that the interviews often covered legal aspects. There were six
primary legal issues and concerns that were addressed and expressed by the patients
and caregivers about the enforcement of the Michigan Medical Marijuana Act and the
effect of various interpretations of the act on medical marijuana patients.
Legal Issue 1: Long Delays for State Issued Card: The first and most commonly
expressed concern was about the delay in issuance of certification cards by the State to
patients. In order to obtain a medical marijuana card, first the patient would see a
physician and obtain a statement that verified the patient had a legitimate qualifying
condition. Then after issuance of the application materials to the State, the State was
supposed to issue the card within 25 days (20 days to review and reject or deny the
application and 5 days to issue the card, see MCLA 333.26426). However, at the time
the interviews were progressing, patients often had to wait up to 6-months for the State
to issue the certification card and this created problems with access, particularly their
ability to procure marijuana from dispensaries.
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Legal Issue 2: Access to medical marijuana and Dispensary Operations: Since
many dispensaries would not serve patients who did not have the ‘hard card’ from the
State, the often 6-month wait caused a loss of access to marijuana.

This was

expressed as a strong concern over and over again by the patients and was a primary
issue for every single caregiver that was interviewed.
Other Caregivers had other often very specific legal concerns. For example,
each of the Caregiver interviewees asked to go off the record and solicited the
Research Interviewers legal opinion on the issue of whether they could serve individuals
with just their paperwork rather than the hard card from the State of Michigan, and it
was clearly of primary importance for almost all of them during the course of the
interviews when providers and patients were attempting to comply with an ambiguous
law and everyone was waiting for the courts to decide.

Legal Issue 3:

Protective Measures Taken by Dispensary Operators:

The

discussion about dispensary operations very frequently included specific measures that
were taken by the operators to work with or even avoid the law. Fortunately there is a
fair amount of transcript devoted to this topic as the tape was often turned back on as
we discussed the specific steps various dispensary operators took to comply with the
law and to win allies in the community and in local government. Even though most
providers and caregivers strongly claimed they were “true believers” willing to go to
prison for their beliefs, they also inevitably adopted several protective mechanisms to
help avoid that outcome.
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The final two concerns were primarily medical in nature:
Legal Issue 4: Inclusion of other medical conditions: Just under one-half the
interview participants (14/31) mentioned the dilatory practices of the State government
in refusing to consider inclusion of additional medical conditions or convening a panel to
consider adding other medical conditions to the list of medical qualifying conditions to
use marijuana.
Legal Issue 5: Scope of a valid Medical Marijuana doctor-patient relationship.
Every single care caregiver and patient who discussed the issue of the medical
marijuana certification provided by the medical marijuana doctor thought the scope of
the doctor-patient relationship needed clarification especially about what constitutes a
legitimate physician patient relationship.
Findings on Legal Concerns of Patients and Caregivers are Sociology of the Law and a
Study in Law and Society:
Just as there is a division between “Sociology of Medicine” and “Sociology in
Medicine” there is also a division between research focusing on “Sociology of Law” and
the study of “Law and Society.” Sociology of law, like sociology in medicine is the study
of the legal system and the actors in the legal system or a segment of the legal system
that includes an analysis of social institutions or societal segments as a self-contained
entity or in relation to society as a whole (Sutton 2001). In contrast, studies of law and
society or sociology of law tend to focus on human social behavior in the context of the
legal system and regulatory structures and the impact on society.
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This research is an example of both sociology of the law and law and society.
One of the primary purposes of this work from the beginning was to better understand
the interaction between the legal and medical systems and to investigate a rarely
studied population that occupies a unique subset of both systems.

The issues of

marijuana regulation, use and abuse have been treated as legal concerns and matters
for the court and prison systems since the 1930’s while the issues of medical marijuana
are, obviously, medical issues.

The goal from the beginning was to obtain the

perspective of the patients and caregivers who are most affected by the legal,
adjudicative, penal, and medical systems.

The legal concerns of patients and

caregivers reflect a myriad of issues about the legal and medical system. These issues
reveal truths about the sociology of medical marijuana law. At the same time, this was
obviously a study that focused on human social behavior in the context of the medical
and legal systems along with the regulatory structures and as such it attempts to assess
the impact of medical marijuana on society and the impact of society on the medical
marijuana user.

Legal Concern Finding 1: State Delay in Issuing Registry Identification Cards:
The first concern was the long delay between submission of the certification
materials to the State and approval being granted by the State. Every single participant
who was interviewed expressed concerns about ambiguities in the Michigan Medical
Marijuana Act which resulted in at least a temporary loss of access to medical
marijuana. At the time the interviews were ongoing, the State of Michigan routinely
delayed the delivery and distribution of certification cards. Most participants complained
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about waiting for up to 6-months for their medical marijuana certification cards to arrive
in the mail from the State of Michigan.

The drafters of the medical marijuana

referendum, having experience with 90 years of government tactics such as the
marijuana stamp act (where marijuana cultivation was made illegal without a stamp
which the government then refused to print or distribute) wrote into the statute an
automatic certification trigger of 20 days so that: “If the department fails to issue a valid
registry identification card in response to a valid application or renewal submitted
pursuant to this act within 20 days of its submission, the registry identification card shall
be deemed granted, and a copy of the registry identification application or renewal shall
be deemed a valid registry identification card” (MCL 333.26429).
However, while this anticipated and attempted to thwart internal opposition to the
act, the problem became inextricably linked to the issue of dispensaries. At the same
time one government agency was delaying the delivery of medical marijuana cards to
qualified applicants, other government agencies

were

engaging

in selective

prosecutions of various medical marijuana centers that had sprung up in the
unregulated environment. As a result of legal pressure, many dispensaries refused to
serve patients who were waiting for their “hard card” from the State. Many patients who
only had their “registry identification application” (consisting of a 1-page application and
a 1-page physician’s certification statement) were denied service at dispensaries. Thus
a patient might not have easy access to their medication for half the year while they
waited for the “hard card.” Nearly half the interview participants (14/31) complained,
often bitterly, about this application of the law and expressed concern they had been
denied service (or in the case of Caregivers that they were unable to provide service) at
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a medical marijuana center or dispensary, and that their access to marijuana was
limited because of the delay in getting their certification cards from the State.
Whether the primary concern was about legal liability or wasted resources was
not always clear; but, the concern of the participants was both genuine and warranted.
In one interview, P8 was able to identify how much money the State of Michigan had
made, and was bitter that little of the money was being used to facilitate the legality and
legitimacy of Michigan Medical Marijuana Act.
We have given them $38 Million already and they don’t have anybody working
at Community Health8 like [sic] four employees. $38 Million in money and they
hire four employees while we have to wait six months (P 8).
The obvious distress of the participant at the wait compared to the influx of funds the
state had received due to medical marijuana appeared in many interviews.
Several patients, and every single caregiver who was growing marijuana,
expressed concerns they were exposed to legal liability in the event of police action.
I don’t understand what they expect us to do. We have pot growing in our
basement and the drug laws all say that is illegal. Then we have the Medical
Marijuana Act that says it is OK if you have a card, but they won’t issue the
cards, you know, they delay. This is the marijuana stamp act all over again. (P
6).
After

the

conclusion

of

the

interviews,

the

public

message

boards

at

Michiganmedicalmarijuaan.com began reporting that the wait for hard cards had been
dramatically reduced from 6-months to less than 2 months.

8

The Michigan Medical Marijuana Program was transferred from the Michigan Department of Community Health
to the Bureau of Licensing and Regulatory Affairs effective April 22, 2011.
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Legal Concern Finding 2: Access and Dispensary Operations:
The long wait for cards was connected to the overarching concern over a loss of
access to marijuana. Nearly one-half of the patients interviewed were concerned that
the 6-months wait to get their certification card issued by the State prevented them from
getting marijuana at some dispensaries. These dispensaries would not serve patients
until they were in possession of the hard card from the State. A Dispensary Operator
stated:
A lot of patients get upset because of our policies. Our lawyers told us we
need the hard cards if there is any problem with the paperwork. We turned
away a guy yesterday because the doctor did not check both boxes on the
certification form so it creates problems (P 11).
The interviews that were conducted were not a completely random sample, and it is not
clear what the scope of this problem was before McQueen. During the interviews the
law was changing and after McQueen there are no legal dispensaries left, so this may
no longer be an important problem for medical marijuana users, except insofar as it
illustrates the reliance on and importance of dispensaries for the distribution of
marijuana to patients in Michigan.
Some caregiver participants were less concerned because they were not
involved in the distribution chain.

The level of concern on the part of the eleven

Caregivers (dispensary owners and operators, activists, and growers) who were
interviewed apparently depended on their responsibility in the distribution chain and
their role in the medical marijuana center. Caregivers who were responsible for dried
marijuana weight quantities at the medical marijuana center or who provided direction to
patients about the products available for acquisition were particularly concerned about
getting legal direction for their activities.
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In most of the caregiver interviews, a substantial portion of the interview was
done without the tape rolling and involved this discussion and an analysis of the
effective legal interaction between Section 4 and Section 8 of the Marijuana Act. My
interpretation was always prefaced by the rather cynical (and prescient) warning that
courts tend to do whatever they want to do and interpret statutes however they choose
without regard for the clear and plain meaning of the law. I consistently offered my legal
opinion when asked (which is to say in the majority of the patient interviews and 10 of
the 11 Caregiver interviews) that the dispensaries were protected under Section 8 but
possibly not Section 4 (as was later held in McQueen) and that they could still be
arrested and held before they could even assert the “affirmative defense.” Further,
under Section 4 it did not matter whether the patient had a hard card. The only
determining factor was whether the medical condition was valid, and the marijuana was
being acquired for that legitimate medical condition. Each dispensary owner who asked
was also counseled there was a good chance of prevailing at trial under Section 4. I
also offered specific legal guidelines when asked, for example, suggesting to several
dispensary owners that they would be better protected by obtaining a notarized affidavit
of each patient each time they obtain marijuana swearing under oath that they needed
to acquire marijuana at the dispensary in order to insure uninterrupted access (from the
language of the Medical Marijuana Act section 4).

Legal Concern Finding 3: Protective Measures Taken by Dispensaries
Although most providers and caregivers strongly believe that what they are doing
is the right thing, and claim they would go to prison if necessary to continue helping

118
those who need medical marijuana, they wisely adopted several protective
mechanisms.
Local Organizing:

The first layer of protection included forming local

organizations for support. For example, all of the 11 dispensary owners and operators
who were recorded had engaged in extensive organizing with sympathetic local
government and regulatory officials. All claimed they had received local approval to
open their dispensary or alternative medical marijuana provider, and they were
confident that they were not under immediate threat of arrest because they would be
informed before any arrest warrant could be issued.
During one Caregiver interview the participant initially claimed his club had done
no local organizing, but he later admitted the reason his club did not organize was that
he had relatives well placed in the local government office who were “providing
protection.” The owner of this Compassion Club stated: “If they think they are going to
go after our place, I will know about it way before they can get a warrant. We will be
there in court ready to argue our case” (P9). Most providers and caregivers were not so
lucky as to have family who were watching out for them. Some medical marijuana
centers worked directly with the local city council, some worked with the prosecutor’s
office, and some worked with the mayor’s office. All of the owners and operators of
medical marijuana centers who agreed to recorded interviews had some branch of local
government in support of their activities.
As of the time these results were written up in summer, 2013, after the decision
in McQueen effectively barred medical marijuana dispensaries in Michigan, none of the
“caregiver” research participants who owned or operated a dispensary had been
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arrested. In fact, as predicted by the participants, each was notified by their allies in the
local government that it was time to close down any operations associated with the
transfer or sale of marijuana even before they received the official correspondence.
Only one of the dispensaries where recorded interviews took place remained open as of
summer, 2013 in defiance of the ruling
Compiling a Legal War Chest: There was one singular common theme in all the
medical marijuana centers, owners, and operators who were formally and informally
interviewed, and that was that each had a roster of retained lawyers ready to spring into
action. Every single dispensary owner who was interviewed had already retained an
attorney and had set aside money to pay for extended legal action in the event this
became necessary. When asked if they thought it was important the response was: “Oh
sure, you absolutely have to have an attorney lined up if you do this kind of work” (P19).
Another aspect of constant readiness to defend themselves came from the business
model that many chose to employ. Instead of making dispensaries a profit making
business, the dispensaries found it most beneficial to work as non-profit organizations,
to shelter under the laws that might protect non-profit organizations.
The “Donations” Model: The most popular model way in which the non-profit
model was operated was the so-called “Donations” model. The premise is that nonprofit ventures are somehow protected more than for-profit ventures. Thus any use of
the word “Sale” or “Buy” is prohibited during the entire transaction even as money is
exchanged and “recommended donations” of $15.00 to $20.00 per gram are being
quoted while precise weights are being calculated on digital scales. There is some
support for the Donations Model as the law developed in Michigan in that courts have
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consistently ruled that transfers of marijuana between patients for money are not
allowed (People vs. McQueen, L.C.) while several courts have ruled that transfers of
marijuana between patients where no money is exchanged are allowed (People vs.
Green, 2013 Court of Appeals).
The idea behind the Donations Model was that patients paid money to join a
private club. Ostensibly the patients are then able to go to the club to obtain marijuana
“for free.” In reality, they must pay the “suggested donation” each time, or they will be
kicked out of the club. The legality of the donations model was supported by the idea
that many medical marijuana centers often give away large amounts of marijuana and
marijuana-laced products to the sickest, unemployed patients while supporting their
operations by voluntary donations from members who are in better health. This model
was unequivocally invalidated by the Supreme Court case of People vs. McQueen in
2013. When McQueen clarified the Caregiver system as the only legal distribution
system in Michigan, the Donations Model became immediately obsolete.
Community and Charitable Outreach: While the Donations Model was one way
of trying to protect the distributors from legal ramifications, most medical marijuana
centers that were observed during this study were heavily involved in community
outreach and charitable work. Toys-For-Tots was one of the most common programs
supported by medical marijuana centers and almost all of them worked with local food
banks and competed very favorably with local bars and bowling alleys in providing large
amounts of charitable and needy contributions. For example, the researcher gave an
invited talk at a dispensary and followed a representative of the charitable group
“Loaves and Fishes” who was there to thank the dispensary for making the largest
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donation of any organization (except for a large multinational pharmaceutical company)
in the entire State of Michigan. Every single compassion club I visited had a donations
box for food and other non-perishables in the front door. The connection between the
caregiver and distribution network and the community was very strong before McQueen
but it is not clear whether this connection remains after McQueen.
Conclusions:
Before McQueen, dispensaries, alternate provider organizations, and advocacy
groups were formed to provide access to the newly legalized marijuana. However, the
legality of the dispensary organizations remained in question until the Supreme Court
opinion in People vs. McQueen in February, 2013 when most transfers of marijuana
were made illegal under the court’s unique interpretation of the Michigan Medical
Marijuana Act. Therefore, this is possibly the only study that investigates and attempts
to explain the social behavior of patients and caregivers during the time they were
responding to the ambiguous, but developing, case law. Those responses included the
formation of several types of organizational structures that functioned as quasi-legal
entities in order to deliver marijuana to patients. These newly formed dispensaries, and
patients at large, spontaneously formed together into several statewide organizations to
defend the right, and ability, to access medical marijuana. In response to the legal
pressure, the various dispensary organizations and provider groups increased their
reliance on “legal fictions” such as the “donations model.” They also increased their
engagement with the community and charitable organizations, while at the same time
put money aside for what they believed was the coming legal battles. Again, since this
research ended a the precise time when dispensaries were made illegal, it is not clear
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how patients and caregivers are reacting to the changes, and whether there are supply
interruptions with patients unable to obtain their medicine.

Further research is

warranted on these questions.

Legal Concern Finding 4: Inclusion of other Medical Conditions
Over half the knowledgeable patients (who possessed at least a college degree)
and were carefully following the legal developments and all but three of the eleven
Caregivers, were concerned about the refusal of government agencies to follow the act
and consider scores of petitions asking for the inclusion of:
additional medical conditions and treatments. In considering such petitions, the
department shall include public notice of, and an opportunity to comment in a
public hearing upon, such petitions. The department shall, after hearing, approve
or deny such petitions within 180 days of the submission of the petition” (MCL
333.26425).
The statute requires:
Not later than 6 months after the effective date of the amendatory act that added
this subsection, the department shall appoint a panel to review petitions to
approve medical conditions or treatments for addition to the list of debilitating
medical conditions under the administrative rules. The panel shall meet at least
twice each year MCLA 333.26432(k).
In short, the State has absolutely refused to set up the required panel despite the fact
the 6-month time period for doing so expired in August, 2009. The practice of the State
government refusing to consider adding additional qualifying medical conditions, was a
concern for most of the participants.

According to the attorney handling the case,

Michigan NORML (National Organization for the Reformation of Marijuana Laws) had a
lawsuit filed in the Court of Claims (a Michigan court with original jurisdiction over claims
against government units) alleging the department has “willfully failed to reply to multiple
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petitions for including several medical conditions such as ADD, ADHD, depression, and
GERD on the list of qualifying medical conditions to use marijuana.”

The case of

Chilcutt v. Hilfiger was dismissed on Summary Disposition motion by the State of
Michigan later that year, and the lawyers are attempting to fund another attempt at
forcing the State to comply with the law (Informal interview, ongoing conversations, and
email exchanges with lead counsel for Michigan NORML).
Most patients and caregivers who discussed the issue thought certain psychiatric
conditions needed to be added to the list of qualifying medical conditions. For example,
the first interviewee stated:
P: I do think the medical marijuana act should be expanded to include mental
conditions.
D: OK, and what types of mental conditions would you include?
P: Anxiety. I mean it is amazing for anxiety. (laughs). Umm, depression.
Definitely. I mean very effective, I mean. You hear about the effect, you know
when you get high, it makes the world good, you know (P1).
This became fairly common with several participants claiming that their main qualifying
was some type of anxiety disorder even though anxiety disorders are not qualifying
conditions under Michigan law:
D:

You mentioned panic attacks, is it your opinion that panic attacks should
be added (to the list of qualifying medical conditions)?

F:

Absolutely, I mean unequivocally, absolutely it works that well and there
are so many horrifying and dangerous side effects from the
pharmaceuticals that are able to be completely avoided.

D:

There’s a wide choice of pharmaceuticals.

F:

[overlapping]

D:

And have you tried every one of them?
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F:

I’ve tried probably a dozen over the years. I’ve had the panic disorder for
decades, and it gets worse as the years go by, but now that I’m able to
legally get medication that I can use, I don’t have a need for those things,
and my quality of life is much better.

Later in the interviews, the conditions of Depression, bipolar disorder, Gulf War
Syndrome and Post Traumatic Stress Syndrome were all mentioned as potential
psychiatric issues that might be treated by the use of marijuana.
By the 11th interview, we were able to tie down the issue of what is covered
under the Act. The delivery service operator who acted as a medical doctor’s office
manager stated:
So the (marijuana) Act requires (a medical condition to be) chronic AND
debilitating. Now chronic could be a bad lower back but she copes and
exercises and keeps good posture but it does not debilitate her. The other
key word- you’re a lawyer so you know words matter- what is the definition
of debilitating? Now there is a moving target. Debilitating is subjective
and is usually defined as something you have to do something about, to
treat it or it will get worse or at least not get any better. Go to a doctor.
Get it looked at. Take action to deal with the fact. Show objectively that it
is there. That's debilitating. a soft spectrum. Debilitating, for an athlete
who is otherwise in strong That's body but a grandmother with the same
condition might make her not be able to drive to the store to get
groceries…so debilitating is a soft definition but what is solid, clear bright
line definition is the term chronic. Under the Michigan Public Health Code
“chronic” is a condition that has existed for at least 90 days.
In other words, a hangnail, or even a sprained ankle that lasts for 89 days is not a
qualifying medical condition under the marijuana act because it is not “chronic.” Even a
broken bone that heals without further treatment is not “chronic” although it last for more
than 90 days and the patient could conceivably get a marijuana card for the time the
bone was casted and during the healing process.

However, “debilitating” is

considerably more subjective since what might be “debilitating” to one person might not
be debilitating to another. For example, a pro-athlete might ‘play through the pain’ and
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not find himself “debilitated” until years after retirement from the league. Similarly, pain
is subjective and there are few reliable ways to measure pain.

In general, at a

minimum, evidence of a “chronic” condition, including pain, requires a recognizable
condition and a minimum of three physician’s visits over a 90 day period. In our broken
bone example, this would require at least three physicians visits after the bone had
healed, complaining about ongoing pain in the bone.
No patients or caregivers mentioned diabetes, lupus, or rheumatoid arthritis as
possible conditions, but several medical marijuana physicians during informal
conversations mentioned these conditions as possible candidates for inclusion in the list
of qualifying medical conditions to use medical marijuana in Michigan.
Legal Concern Finding 5:
relationship needs clarity:

Scope of a valid Medical Marijuana doctor-patient

The Michigan Medical Marijuana Act only requires patients to get a physician
certification, or signature on the State approved certification form, and does not specify
the level of medical supervision required. This has become a particularly important
issue because of the interpretation of Section 4 and Section 8 in the Michigan Medical
Marijuana Act. If the patient and caregiver are connected through the caregiver registry
system and are below the weight and plant counts permitted under Section 4, then they
are completely immune from arrest or prosecution. As we have seen, the Marijuana Act
permits a caregiver to register up to 5 patients with the State, permitting them to grow
up to 12 marijuana plants and possess up to 2.5 ounces per patient (MCLA 333.26424).
However, to register a patient, the patient must designate a specific caregiver to provide
marijuana for that specific patient and a caregiver may only register up to 5 patients.
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Therefore, in a dispensary, for example, it would be rare for a caregiver to see the
specific patient registered to be served by the specific caregiver that he or she had
designated with the State. Rather, in a dispensary it would be much more common for
“a” caregiver to assist “a” patient in procuring marijuana without regard to whether the
patient and caregiver had registered that relationship with the State.
The problem is if this transaction takes place outside the caregiver registry
system, for example if the patient acquires medication from a medical marijuana
dispensary operated by a caregiver, or caregivers, to whom they are unconnected
through the caregiver registry system, then any transactions between them are not
immune from arrest or prosecution under Section 4 of the Act but may only be defended
after arrest and prosecution and at trial by way of an “Affirmative Defense” under
section 8 of the Act. A caregiver is “connected to a patient” through the caregiver
registry system when he or she registers them with the State using a “Caregiver
Attestation Form.” As previously noted, a Caregiver may resister up to 5 patients with
the “Caregiver Registry System.” However, while the broad Section 4 immunity requires
registering with the State, the Section 8 Affirmative Defenses may still provide a
defense if the “marijuana was not more than was reasonably necessary to ensure the
uninterrupted availability of marijuana for the purpose of treating or alleviating the
patient’s serious or debilitating medical condition.”
The problem then becomes that Section 8 requires a “bona-fide doctor-patient
relationship.” Therefore, the issue of what constitutes a “bona-fide relationship” has
been the deciding issue in several dispensary cases (c.f. People vs. Redden, id; People
vs. Feezel et al). In brief, to determine the legality of a particular medical marijuana
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transaction, some Courts go back to the legality of the original certification and whether
legitimate medical need existed in the first place.

This, in turn, depends on the

existence of a bona-fide doctor-patient relationship between the certifying physician and
his or her patient. Therefore, the requirements to establish a bona-fide relationship with
the certifying medical marijuana doctor may be crucial to some cases, particularly cases
involving medical marijuana centers that distribute outside the caregiver registry
protections provided by Section 4 and rely on the affirmative defenses of Section 8.
The same question was asked by more than ½ of the participants and all but 2 of
the Caregiver interviews:
I just want to know what type of medical records they need. I mean, you know,
what is valid? How are we supposed to know if the doctor is legitimate and
who the hell are they to say that somebody is not really in pain when they say
so? (P7).
Every single care caregiver and patient who discussed the issue of the medical
marijuana certification provided by the medical marijuana doctor thought the scope of
the doctor-patient relationship needed clarification.
The questions about how the courts might view the adequacy of the registered
patient’s medical examinations were hardly spurious. Only a total of two patients and
caregivers were even given a hands-on examination by the certifying medical marijuana
physician and two others were certified via their family physician or specialist rather
than the medical marijuana physician. Even the most serious patient cases, including
both Stage IV cancer patients were not certified by their oncologists or their family
physicians. Instead, one was given a note by her oncologist and referred to a medical
marijuana physician while the other was given her typewritten medical records and
referred by her family doctor to a medical marijuana physician. Among the most serious
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patient cases, only the single M.S. patient interview was certified by her treating medical
specialist.

According to the patients even the treating physicians of dying patients

would not certify them due to concerns with DEA or because the agreements granting
them hospital privileges prevented them from formally recommending the use of
marijuana. This issue clearly needs further research as this finding suggests it could be
an important barrier to adequate medical treatment.
The scope of the doctor-patient relationship and what the doctor needs to do to
establish this relationship was clarified in House Bill 4851 in 2012 which defines a “bona
fide physician-patient relationship…[requires]…review and maintenance medical
records…[and]… reasonable expectation of follow up care” (MCLA 333.26423 and
333.26428 as amended). However, it is not clear whether this legislation solved the
ambiguities expressed by the interviewees in this study since the bill was passed within
a couple of weeks after the interviews in this study were completed. Again, further
research on this particular topic, including the barriers to access and the fears of
recommending a substance banned by the same agency that issues the physician’s
controlled substances license permitting them to prescribe pain killers and other drugs
regulated by the Controlled Substances Act.
All but the four caregivers and patients mentioned above who discussed the
issue of the medical marijuana certification provided by the medical marijuana doctor
thought the scope of the doctor-patient relationship was a problem. One called the
certification system “A joke” (P 6). Four called the system “inadequate” and over onehalf did not believe they even had a legitimate doctor-patient relationship with their
medical marijuana certifying doctor.

The lack of a legitimate doctor’s visit for their
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medical marijuana certification was primarily prefaced on the fact that no hands-on
examination was done. Again, only two interview participants reported that they had
what they considered a “hands-on” or “normal” or “traditional” medical examination. Of
the other 29 interviewees, none even had their blood pressure checked, only 6 of 31
believed they had an adequate medical examination.
One Caregiver interview participant was a doctor’s manager who had handled “at
least 400” interviews of prospective patients.

Part of his job was to “pre-screen”

patients before bringing the patient to the doctor for his or her medical marijuana
certification. He expressed considerable concerns about the viability of most doctor
certifications under the Michigan Medical Marijuana Act stating:
The law does not provide physicians any guidelines. We have had one guy
telling people to slip $100.00 under a door along with the filled out form. He
would take the money, sign the form, and slip it back under the door. That is
not a legitimate doctor-patient relationship (Participant 11).
All of the patients interviewed would agree with the Michigan prosecutors and the
medical ethics board that a legitimate patient doctor relationship should be part of
medical marijuana treatment and that the law needed to be clarified in this regard.
Several discussions with professionals and activists prominently featured
concerns about the Section 8 defense and the scope of the requirement of a “bona-fide
doctor-patient relationship.”

One physician informally interviewed argued that, at a

minimum, an actual doctor-patient relationship required a “level 1 medical examination.”
However, there is disagreement on whether an actual physical examination is required
or whether a records review and a consultation type of appointment met the criteria of a
bona-fide doctor-patient relationship.
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Patient 11, the office manager and conference organizer, argued that a “bonafide” relationship does not require a physical exam but merely a consultation since “a
bona-fide relationship does not require the doctor to take on the person as a patient.”
For example,
Nobody would contest that a radiologist who views a CT Scan and
diagnoses a patient without ever having seen the patient has, in fact,
established a bona-fide doctor-patient relationship by virtue of interpreting
his medical tests for the treating doctor (P11).
Similarly, the manager argued, a medical marijuana certification doctor should be able
to make a recommendation based on adequate medical records without even seeing
the patient. More than half of the participants, and all of the doctors, and lawyers,
informally interviewed agreed that any diagnosis based on medical records and not an
actual physical examination of the patient would, at a minimum require medical records
showing three separate doctor’s visits, treatments, and/or diagnosis of a condition for
which marijuana may provide actual or palliative relief.
Another issue in the certification process was the viability of “Skype” and remote
or internet certifications. There was broad agreement during all formal interviews and
information gathering discussions (except one physician who gave his opinion during a
discussion) that Skype or internet certifications were not valid.

This lone physician

holdout argued, like the office manager, that the situation was similar to a radiologist,
perhaps in India, making a remote diagnosis. However, all other respondents did not
agree, claiming that medical marijuana certification doctors, unlike radiologists, were not
diagnosing or interpreting detailed imaging data. Several participants did agree that
renewals of certifications could potentially be done by Skype provided the patient’s
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condition was relatively stable and updated records were provided and reviewed by the
doctor’s office.
“Internet Certifications” where the patient never even sees the certifying
physician, were considered substandard medical care by everybody who was
interviewed who discussed the issue. However, there was disagreement on whether a
substandard level of medical care removed the protections of a medical marijuana
certification based on a bona-fide doctor-patient relationship as the Redden court had
held.

As of summer, 2013, this issue has still not been resolved by the Michigan

Supreme Court.
Obtaining opinions on this issue was not always easy. Very few patients and
caregivers were interested in the precise details of the requirements for a medical
examination to receive protections under Section 8.

Patients, and caregivers, were

much more concerned with obtaining clear instructions that could be followed than in
precisely what the doctor was supposed to do to at their medical examination. Many
seemed to take the attitude exemplified by one patient: “If they will just tell us what to
do and stop playing games, I will be glad to do it” (P 9). This frustration with the law was
universal in the interviews. The illegality of marijuana and its reputation in the popular
media make it important to medical marijuana users to make sure they stay within the
laws. However, with the laws amorphous and unclear, this is not always either easy or
even possible.
Conclusion of Findings on Legal Concerns:

Several legal issues and

concerns were expressed by the participants during the course of the interviews
especially about uneven and ambiguous enforcement of the Michigan Medical
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Marijuana Act. These included the problem of receiving certification cards from the
State of Michigan which in turn created a problem of access which was a concern of
nearly one half of the patients interviewed.

The legality of dispensary operations was

also a major concern, particularly for the dispensary owners and operators and a
number of measures were taken by these operators to insulate them from criminal
liability. The dilatory practices of the State government in refusing to consider inclusion
of additional medical conditions as required by the Act was another concern along with
the lack of direction on the proper scope of the doctor-patient relationship.
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Chapter 6: DISPENSARIES AND MEDICAL MARIJANA PROVIDER
ORGANIZATIONS UNDER THE MICHIGAN MEDICAL MARIJANA ACT BEFORE
MCQUEEN
Introduction:

The writers of the Michigan Medical Marijuana Referendum

removed all the dispensary language at the last minute because dispensaries were not
polling well with Michigan voters (MPP 2013). Although the Michigan Medical Marijuana
Act legalized the use and possession of marijuana, it was left deliberately unclear on the
scope and structure of the distribution system. As a result, a number of organizations
arose to provide access to the newly legalized marijuana. However, the legality of such
organizations remained in question until the Supreme Court opinion in People vs.
McQueen in February, 2013. The issue was the legality of transactions outside the
“Caregiver Registry System” between Caregivers and Patients who were not registered
with the Caregiver with whom they were conducting a transaction. With McQueen, such
transactions were effectively made illegal under the Michigan Medical Marijuana Act.
The organizational structures that preceded this ruling are the subject of these
findings and this section.

The organizational structures included the “Traditional

Compassion Club” where phone numbers and contact information rather than marijuana
were exchanged, “Farmer’s Markets” where marijuana was freely exchanged, and
several other structures to be covered in more detail in this section.
More than one third (11/31) of the interviews were with owners and operators of
these entities. Therefore, since these structures have now been made clearly and
unambiguously illegal under the Michigan medical marijuana act, this is the first and
probably only study that will investigate patients and caregivers as they responded to
the ambiguous developing case law that culminated in the definitive McQueen case
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which declared that any transfers of marijuana between any patient and any caregiver
are not protected by Section 4 immunity unless that patient and caregiver are registered
together in the State system. The interviews for this study took place when most of the
case law was being actively argued and decided. Dispensary owners and operators
and other caregivers attempting to comply with these cases and an unclear law amidst
a variety of ambiguities is the main story of this finding.
Findings on Dispensaries: A Functionalist Report: Until the end of the 1960’s the
discipline of sociology was dominated by the functionalist perspective. Functionalists
claim that sociology should be concerned primarily with describing, explaining,
improving, and predicting the structure and function of social institutions, traditions and
norms, and their place in the larger society. The findings on alternative medical care
providers and the description provided by the participants is undisputedly derivative of
this rich tradition in sociology research. It examines the traditions and beliefs of the
dispensary operators, the institutions of the dispensaries and their function in the
medical marijuana community of Michigan as well as their place in the ambiguous laws
of today’s society. The confusing state of the law on medical marijuana has become
both the norm and tradition of the political atmosphere when dealing with marijuana. In
explaining the function of the dispensaries, and the ideas of the dispensary operators,
the functional approach makes the most sense.
The structure of alternate medical care providers or medical marijuana centers
and the delivery of marijuana to Michigan patients after the Medical Marijuana Act
before McQueen is important for several reasons. First, it is a great example of the
nebulous world in which medical marijuana users and providers find themselves
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functioning. Second, there is active legislation pending in Michigan and in other states
to regulate dispensaries, and this report demonstrates what type of structures are
available, how patients and caregivers interact within them, and how organizations
deliver marijuana to patients in an unregulated environment. These results suggest
organizational structures that work for patients and caregivers, and structures that do
not work for them.

Most important, this provides considerable direction for future

regulation and legislation of marijuana distribution centers.
Results on the formation, operation, and structure of medical marijuana providers
are derived from three distinct sources: First, Results from “Patients” are from recorded
and transcribed Interviews; Second, Results from Caregivers are also from recorded
and transcribed interviews. Third, descriptions of the operation of alternate health care
provider networks and facilities in Michigan are from personal observations and
inspections as well as from formal recorded interviews and informal discussions with
Patients and Caregivers (Producers and Activists). Consent for all discussions was
obtained verbally in the same manner as with formal interviews, and each participant
was given a copy of the HIC approved Information Sheet if notes were taken after or
during the interaction.

Dispensary Models Before McQueen: The data permits us to describe the types
of medical marijuana centers and dispensaries in the State of Michigan before the
Supreme Court case of McQueen effectively outlawed all transfers of marijuana except
between patients and caregivers connected through the registry system. Observations,
recorded interviews with patients and caregivers, and dozens of informal conversations
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with dispensary owners and operators suggest there were five main dispensary models
in Michigan before McQueen.
The first medical marijuana dispensary model to arise was the Traditional
Compassion Club.

These organizations function less like medical marijuana

dispensaries or delivery organizations than as advocacy groups and information
clearing houses.

A person who contacts a Traditional Compassion Club will be

screened and interviewed. The patient is then provided with a list of available caregivers
and growers with whom they can register through the State and obtain their marijuana.
The often thinly veiled cover for most of these groups was that they were not directly
involved in the transfer, sale, or delivery of marijuana and so they are perfectly legal
under the law.

However, many Traditional Compassion Clubs also held “Private

Events” that function more like “Farmer’s Markets” (see below) where transfers of
marijuana do occur.

So long as no transfers of marijuana occur, this is the only

organizational structure that is still legal in Michigan after McQueen.
The Farmer’s Market was the model endorsed by the Michigan Medical
Marijuana Association, the main medical marijuana patient advocacy organization.
Before McQueen, they conducted several weekly “Farmer’s Markets” throughout the
State with the consent of local governmental authorities.

Several other “Farmer’s

Markets” not organized by the MMMA were also held, some of them almost every day of
the week. A medical marijuana Farmer’s Market functions in the same way as a more
traditional themed Farmer’s Market except, instead of a choice of corn, soybeans, and
wheat the patient is given a choice of different strains of marijuana. As at a traditional
Farmer’s Market, a Caregiver or grower at a medical marijuana Farmer’s Market
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typically rents a table for a nominal fee, displays the product of their own hands and
skill, and these are then acquired for value from a public eager for fresh produce, and
the ability to talk directly to the farmer.
The experience of walking into a bustling medical marijuana Farmer’s Market is
interesting and informative. The patients are much different than the hippie stereotype,
and almost always are dressed in work casual clothing with only a scattering of tie-dyed
shirts and only rarely does one see the stereotypical John Lennon sunglasses. The
tables are arranged similar to any large farmer’s market except the farmers in these
facilities display their wares in large glass containers arranged on the tables in front of
them.

Patients circulate through the room speaking to various growers about their

product, often sampling it, and then negotiating the price with the individual farmer.
There are several advantages to the Farmer’s Market. First it appears to fall
within the intent of the Michigan law, which limits a grower/caregiver to 12 plants per
patients (maximum 5 patients or 60 plants) and thereby takes away power from large
agribusiness. If there are large 1,000 plant grows in Michigan they were certainly not
approved by voters under the Michigan medical marijuana act. Second, many patients
appreciate the bustling market with a wide variety of choices and a friendly, often
decidedly smoky atmosphere.

Related to this is the third advantage which is that

patients and growers often are able to speak directly to one another about the product,
and in many farmers markets patients would even have the opportunity to sample the
product before purchase.

Finally, and perhaps most important, the farmers market

model cuts out the large scale distributor and the prices for patients is often dramatically
lower than at medical marijuana dispensaries.
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However, farmers markets were not without problems.

Almost one half of

participants complained about insects, pesticides, stems, and leaves, and poor quality
marijuana they had purchased from farmer’s markets. The complaints from this plurality
were primarily about poor quality control and inaccurate information from caregivers and
growers about the quality and expected effects of the marijuana they were acquiring.
There were also concerns about the lack of legally enforceable remedies against a
grower or a vendor’s false statements.
Yah man, what are you gonna do, call the cops when they cut you a bag of
dope that is full of chemicals and gives you a headache? Now don’t get me
wrong, I am not saying the health department needs to inspect but they gotta
control that (medical marijuana). We need testing for all marijuana that is
sold and standards. With dispensaries, like in Colorado, it is a free market
with competition. You can just stop going there if they don’t have good sh*t
but all kinds of people sell at the farmers markets (P7).
No Farmer’s Market organizer consented to a formal interview and no interviews were
recorded at Farmer’s Markets.

However, in attending more than fifteen to twenty

different Farmer’s Markets throughout the State of Michigan, there was the opportunity
to circulate and gather formative information from dozens of vendors at these events,
including the original organizer and Michigan Medical Marijuana Association President.
In addition, several of the Caregivers who were formally recorded and interviewed
stated they routinely rented tables at these events:
I: So you get rid of your overages at Farmer’s Markets also?
P: I do like the Farmer’s Market format better because, you know, some
dispensaries will just take bull crap and try to pawn it off. You know, seeds,
stems, fertilizer, insecticide, the whole 9 yards. With the Farmer’s Market you
can often get a better price when you sell, I mean, provide the marijuana to them
and you can talk directly to the patient (P24).
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After the Farmer’s Markets, there is also the Provider Network Dispensary.
This model is a reaction to the law and an attempt to comply with the ambiguities.
Specifically, they attempted to limit the interaction between patients seeking to acquire
marijuana and the retail vendors. On the surface, these organizations functioned like a
Traditional Compassion Club. However, in this type of club, several caregivers “hang
out” and wait to be paged as patients arrive. Each caregiver is responsible for his/her
own supply of marijuana, and hours are coordinated through the club so that a core
group of growers and caregivers is available at the club during business hours. This
insures variety and choices for any patients who “drop by” the club. Transactions are
between the individual patient and the individual caregiver or grower who is in
possession of the type of product the patient wishes to acquire. For example, the
Interview P1 was with a young female who specialized in baking THC laced
confectionaries. During the one hour interview, we were interrupted no less than five
times as her name was paged on the club intercom. She disappeared behind a private
screen for several minutes each time and confirmed, off the record, that she was in
charge of “medibles” for the club that day. Medibles are marijuana laced food products,
often delivered as candy or the stereotypical brownies and other confectionaries. Other
provider’s names were frequently called over the intercom during this interview
indicating there were other caregivers at the club ready to provide the varieties and
types of marijuana demanded by patients.

The details of how these organizations

functioned such as percentages paid to the club by the various caregivers, if any, and
the specific financial arrangements were not a subject of these interviews as any
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reporting on this information was considered to be potentially harmful to the subject
population.
The California Style Dispensary is a well-known structure that was first seen in
California and involves a dedicated facility where marijuana is exchanged between
growers, caregivers, and patients. In Michigan, this model manifested in a few different
ways before McQueen.
The California Storefront Model Dispensary typically has a large display case
with several different kinds of marijuana visible in jars behind a retail counter. Several
Caregivers on duty share the weight limits, or the Caregiver on duty behind the counter
simply disregards the weight limits. Again, the scope of this practice was considered
potentially harmful to the research participants and was not pursued during the recorded
interviews but the subject was discussed in unrecorded interviews.

In Michigan, a

Caregiver may possess a maximum of 15 ounces if the Caregiver behind the counter is
a patient and has five additional patients registered to him under the Caregiver Registry
System. In order to comply with the weight limits, a few of these dispensaries function
like Amsterdam dispensaries and attempt to keep below the applicable weight limits via
deliveries conducted several times a day by other Caregivers. More often than not,
however, these dispensaries were small businesses that featured one or two proprietors
on duty at the same time who were obviously in possession of well over the 15 (or 30
with two caregivers) ounces allotted to them under the Act. These proprietors offered a
variety of justifications for exceeding the allowable weight limits under Section 4 of the
Act. Most relied on Section 8 which permits excess amounts beyond the maximum 15
ounces that any one individual caregiver can possess so long as it is necessary “to
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insure an uninterrupted supply of marijuana to treat their qualifying medical condition
(MCLA 333.2724).”
The Private Club Model blends the Provider Network Dispensary and the
California Storefront Model. In a Private Club Model with one caregiver on duty, there
are no display cases in front. Members sign in as if at a doctor’s office, and wait to be
called to the back. In a private room, a display of marijuana and the single caregiver
who is wholly responsible for and in possession of a maximum of 15 ounces of
marijuana permitted under Section 4 works with the patient.

Interview P16 was a

Private Club Model dispensary operator and a Lansing lobbyist who also runs the
second largest medical marijuana advocacy group in Michigan. He explained:
Our model is better (than a California style storefront dispensary) because all
of our caregivers are in possession of only the amounts they are allowed to
possess and no more. We don’t always have the variety some of the other
stores have but we are trying to be legal…at least the weight limits are clear
in the law.
The Private Club Mixed Model features mixed caregivers who share the
allowable weights and commingle the marijuana for display and may also rely on
deliveries to keep below the total allowable amounts. This is useful for a medical
marijuana user who wants to be able to choose from many different types of marijuana.
Dispensaries argue they are the same basic model as Farmer’s Markets, in that
they are relying on Section 4 to protect a transaction outside the caregiver registry
system since it allows transfers between a Caregiver and a patient. They argue that all
models of distribution are perfectly valid under the law even though a number of
dispensaries have been closed down in Lansing and throughout the State of Michigan
and several dispensary owners and operators are currently facing State prosecutions.

142
Finally, the Delivery Service operates like a Private Club dispensary,
occasionally in conjunction with such a dispensary, delivers the product directly to the
patient’s living room. Interview P 11 was a Delivery Service operator who traveled the
State of Michigan with a briefcase he called his “pot-in-a-box.” This method is especially
useful for those medical marijuana users who are unable to travel, or are bedridden due
to their condition.
Each of these models involve patient-to-patient or caregiver-to-patient distribution
of marijuana functioning mostly outside the caregiver registry system. The Supreme
Court of Michigan held in People vs. McQueen that the Michigan Medical Marijuana Act
does not provide for any distribution of marijuana outside the caregiver registry system.
However, these models, even though they have been invalidated by the court, are still
important because some are still functioning and the legislature is considering laws to
modify the distribution system in Michigan, and these are the only models in Michigan.
Most interviews felt the model of distribution they used was valid under the
marijuana act and many defended their preferred model whether it included
dispensaries, home delivery, or Farmer’s Markets. However, most patients were not
aware of the variety of models that were available.

If a patient was aware of a

dispensary, for example, it was very uncommon for them to also be aware of how
farmer’s markets operated. The large majority of medical marijuana users, regardless
of the system they used to obtain their marijuana were interested in changing something
about the system. Only eight participants favored the State of California model of
completely unregulated dispensaries. However, almost all participants discussed the
problem with access and in particular access to marijuana distribution centers whatever
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form they took. They wanted better regulated marijuana distribution and more open
access.

They talked about the involvement of the criminal element without legal

distribution centers, and universally wanted safe, public, legal access, and the provision
of regulated locations to acquire marijuana rather than in the black market. The primary
issue was access to varieties and different strains of medical marijuana and most
participants’ primary concerns centered on practical issues such as quality control,
availability, and access rather than legal issues such as the specific defects in the law.
This concern for quality control in medical marijuana was supported by twenty
three of the participants. These patients and caregivers, wanted specific, clear
guidelines for dispensaries, and substantially increased government control and
regulation over marijuana cultivation and delivery, quality control, testing, and inspection
of medical marijuana and production/growing facilities.

Approximately one-third of the

recorded interviews expressed the desire to see the entire process of marijuana
cultivation and medical use regulated from the original grow operation to the sale and
distribution with most of this group citing the State of Colorado as a model.
The bottom line for patients and caregivers alike was the desire to have a safe,
regulated, legal place to obtain different varieties of high quality, potent, medical
marijuana. Most were not concerned with the precise structure of these facilities and
most individuals, even the dispensary owners and operators, were only aware of one or
two distribution models in the State.

Most interviewees were not even aware of

Farmer’s Markets if they usually purchased their marijuana at a dispensary and most
that frequented Farmer’s Markets were not aware that dispensaries were still open.
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The ability to find a variety of quality medical marijuana was a concern when
multiple sources were available for medical marijuana users. Now, with the decision in
McQueen and the current system allowing only a primary caregiver allowed per patient
those concerns are likely to be greatly increased. Supply interruptions, quality issues,
and a lack of variety in the medical marijuana following McQueen are likely to be the
major issues in the medical marijuana community today and further research on this
topic is warranted.
Before McQueen, Patients wanted the ability to speak with the grower or a
knowledgeable seller about the expected properties of the marijuana being acquired
and, most important, to have a variety of choices. These options were available in the
dispensaries models, but not in the current caregiver system.
Chemical Testing of Marijuana: One particularly desirable feature of some
medical marijuana centers was the availability of chemical testing for the samples of
marijuana. This was benefit of dispensaries was cited by patients and caregivers.
I: Can you talk about that what strains work for you best?
P: I like the strains that have high cannabinoids.
I: We are here at the (dispensary name withheld) so we have these testing
sheets with all the percentages of chemicals in the testing results and…
P: Yes I like to look at the numbers I like them because they say it is the
cannabinoids that attack the cancer cells. They either repair or destroy so you
know, I always go for the highest cannabinoids, especially CBD (P28).
The ability to know the chemical composition of the medical marijuana, which was only
available at larger dispensaries, was mentioned as benefit to the patient in order to have
a better understanding of what works best for their condition.
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State and Federal Provider Advocacy Organizations
Several organizations in the state of Michigan and at the Federal level have
developed to help Caregiver and medical marijuana users. These organizations vary
from groups that offer support to those that actively advocate for the users of medical
marijuana.
Michigan NORML (National Organization for the Reformation of Marijuana Laws),
MPP (Marijuana Policy Project) and the MMMA (Michigan Medical Marijuana
Association) were all organizations known before this dissertation research began.
However, the MACC (Michigan Association of Compassion Clubs) was not formed until
just before the interviews for this dissertation began.

Most of the information that

follows comes from discussions with various “Compassion Club” (dispensary) owners
and operators, and was confirmed using public sources to the extent possible. The
patient and caregiver perceptions about the precise operational structure, goals, and
membership activities of the organizations were actively sought from the participants
throughout the interviews.
The largest medical marijuana advocacy organization in Michigan is the MMMA:
The “Michigan Medical Marijuana Association” is devoted to preserving and protecting
patient rights under the Michigan Medical Marijuana Act. The purpose of the MMMA
was articulated in an informal interview with a high ranking official in MMMA. He is a
fiery individual who served in the armed services and who brings his passion for gritty
city and jungle battles to the fight for medical marijuana and gave a long and detailed
informal, unrecorded interview for this paper:
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We are a grass roots organization of patients, and our main goal is to protect the
marijuana act, and make sure patients have access which is our right under the
law no matter what the Attorney General says (MMMA Official).
The large group boasts thousands of members, and the official stated several times the
primary goal of the MMMA was to protect patients and the caregiver registry system.
The interview took place at a Western Michigan Farmer’s Market sponsored by the
MMMA. A major topic of discussion was the Farmer’s Market model and why it is the
preferred distribution advocated by the MMMA because “it empowers the small grower
and preserves the caregiver registry system. The relationship between the MMMA and
other provider organizations was also discussed. The MMMA maintains an exceptional
web site (www.Michiganmedicalmarijuana.com) which is devoted to legal and practical
discussions about the medical marijuana act.

Besides State-wide information and

organizing, the MMMA is concerned with local, grassroots efforts such as turning out
patients to appear in the court rooms and to protest during important court cases and
during legislative sessions where the Act is being debated.
By 2009, several medical marijuana centers and dispensaries in Michigan joined
together to form a competing organization, the MACC (Michigan Association of
Compassion Clubs). A prominent member of the MACC was recorded interview P 16.
Unlike the MMMA, this is not a grass-roots organization, but an organization of
professional centers who banded together in order to engage in lobbying activities. The
MACC arose from one of the first medical marijuana centers in Michigan, and at the
time of the interviews, had several dozen dues paying centers, and two full time
lobbyists in Lansing at the State legislature.

Several pieces of legislation are and

continue to be advocated by this organization, including a bill allowing local control of
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medical marijuana centers, and bills to better define the scope and requirements of the
medical marijuana law such as better defining “bona-fide doctor-patient relationship”
and the meaning of “locked enclosed facility” which has been the subject of unresolved
litigation and several criminal prosecutions.
P16 discussed MACC’s relationship with the MMMA:
I:

What about the MMMA?

P:

We do a lot of the same type stuff, but we are different at the point where
we are pooling money to go do this type of lobbying, the capital and stuff.
Where they would be the masses and show up at the rallies. And their
leadership of course is pretty cool, and they have similar philosophies.

Despite the show of unity, the relationship between the MMMA and the MACC has
been, at times, quite acrimonious, tending to divide the medical marijuana community
between patients represented by the MMMA and dispensary organizations represented
by the MACC. In fact, relations between the MMMA and the MACC could even have
been called openly hostile.

For a time there was a split in the medical marijuana

community between patient advocates in the MMMA and the “big money lobbyists” in
the MACC.
However, this split was largely patched together after the Michigan Attorney
General Bill Shuette began raiding and prosecuting patients, caregivers, and
dispensaries:
Sure, we are at odds, as it happens in a few of these emerging things. You
know, the details of how we distribute this new legal product, but we had this
rally September 7th where about 3,000 people showed up in Lansing. That
was a community effort, and what we did (is) work together, and as I say,
look, and obviously, I will tell you what else made it easier for us to get along
was Bill Schuette who made himself known as the real enemy. What he was
bringing to us was so much bigger than our inner community squabbles that
we just said, ‘Okay, this is obviously kind of stupid right now when we just
kind of have this serious threat hanging out here.’ So, we said ‘Let’s identify
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three, four things here that we absolutely iron clad agree on, and this will be
the basis of our unity efforts’ (P16).
There was an obvious attempt to “smooth over” differences between the
organizations and present a united front. Both the MMMA leader (who was interviewed
informally and not recorded) and P16 denied any current friction between the two
organizations, and both strongly emphasized how their different goals and objectives
were complementary.

In fact, both used almost the same words to describe their

relationship and both talked about collaboration efforts:
I have no problem with [MACC]. They are doing their thing which is organizing
and lobbying and protecting their business model, and we are all about grass
roots organization and making sure the will of the people is heard. There is no
conflict at all between us, no problem at all (Informal Interview Notes).
Similarly, in his recorded interview P16 stated:
Well [the MMMA leader] is quite an advocate, and we certainly don’t have any
conflict with the MMMA at all. They are doing their community organizing thing,
and we are focused on the business and access side. There is no conflict
between our groups at all. We are in total agreement about the overall goals and
objectives (P16).
The interviews confirm a well-known result from the sociology and social psychology
literature that a clearly definable common enemy increases inter-group coherence by
providing a singular direction (Fisk 2012).
A third advocacy organization is the Michigan chapter of NORML: The National
Organization for the Reformation of Marijuana Laws, which predated the medical
marijuana law and advocates for the complete legalization of marijuana. NORML's
mission is to “move public opinion sufficiently to legalize the responsible use of
marijuana by adults, and to serve as an advocate for consumers to assure they have
access to high quality marijuana that is safe, convenient and affordable” (NORML
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2013). The Michigan Chapter of NORML (www.MINORML.org) has a lead attorney who
is an old friend of this dissertation author. This researcher worked for him in his first job
as an attorney between1992 - 1994 and has maintained some contact. This contact was
renewed after he had become lead counsel for MI-NORML and learned about my
dissertation topic.

He was corresponded with several times for this paper about

ongoing cases, the developing case law, the likely interpretations, and various legal
issues that arose during the pendency of this dissertation.
A fourth organization which also predated the Act is the MPP (The Marijuana
Policy Project). This group actually wrote the referendum that was placed on the Ballot
and passed by the people which became the Michigan Medical Marijuana Act.9 It is a
national advocacy organization with offices in Lansing, Detroit, and Washington D.C.
and around the country. The organization has been instrumental in getting medical
marijuana legislation passed in 17 States and the District of Columbia, and legalized
completely in two States. However, this organization was heavily criticized by several
participants in the interviews because of ambiguities in the legislation and for their
failure to include dispensaries in the original referendum because they “were not polling
well” (Interview 11, 16, et al).
The MMMA leader stated:
We are trying to clean up the mess these people [MPP] left with even
though the intent of the law is clear.
P16, the MACC leader had similar thoughts:
P:

9

Well these people [NORML and MPP] don’t agree with us. They think
specifically that anything of medical marijuana is useless because they
keep on fucking with it and finding new ways to subdue it. So you got to

Full disclosure necessitates revealing that the author has been a dues paying member of the MPP since 2008.
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go straight to decriminalization [of marijuana]. Some people think that is
the problem with the referendum [written by MPP]. If they wanted to
screw it up so bad the only alternative was full legalization and…well
they….
I:

They would have written the same legislation?

P:

Yeah, basically (P16).

Other participants were less diplomatic:
Those fuckers ruined my life. Why did they have to put all this ambiguous
shit in there when it could have been clear and still passed? We had two
thirds of the people vote for this thing (defendant in a prominent Michigan
medical marijuana case informally interviewed).
Nobody from the MPP was interviewed for this dissertation, and the leadership has
moved their activities to other States, passing medical marijuana laws in Arizona (2010),
New Jersey (2010), Washington D.C. (2010), Delaware (2011), Massachusetts (2012),
Connecticut (2012) and full legalization in the States of Washington and Colorado (ProCon, 2013).
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CHAPTER 7: STRAINS: THE PERCIEVED EFFECTS OF DIFFERENT VARIETIES
OF MARIJUANA
Introduction: Marijuana has over 100 components that act together within the
human body and brain. Growers, patients, seed banks, and others have long claimed
that different marijuana strains and cultivation techniques produce strains that have
different psychoactive and medicinal properties (Rosenthal 2004). However, the claim
is unsupported by clinical research due to the restrictions and obstacles to research that
were previously discussed.
Therefore, explaining the effect of these different substances in the human body
has been missing from the literature. The most well characterized and best known
chemical component in marijuana is delta-9 Tetrahydrocannibinol (THC) which has well
known psychoactive properties through its activation of CB1 and CB2 receptors in the
nervous system.

This effect in isolation is fairly well characterized given the fairly

substantive body of research on orally delivered synthetic THC such as Marinol,
Nabilone and Cesamet (Armentono, 2011). The second best characterized component
in marijuana is Cannabidiol (CBD) which is increasingly known for its anti-inflammatory
and other potentially medicinal qualities (Project CBD 2013). However, as we have
seen, federally approved research employs marijuana with an average potency of 1-3%
THC ,but marijuana available to a medical marijuana patient (at least before McQueen)
was often more than eight to twenty-five times as potent at over 25% THC (Canalytics
2012). Almost no government approved or funded research has ever measured CBD
levels, but commonly available medical marijuana has a wide range of CBD from 0% all
the way up to 15% in some samples (Rosenthal 2004). The effect of these chemicals
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present in the remarkable array of strains available to the medical marijuana consumer
has been problematic for those on the anti-marihuana side of the argument and
government organizations such as NIDA have worked hard to prevent any systematic
research into those effects.
Findings on Strains of Medical Marijuana is Intepretevist and Critical:
In order to investigate this huge gap in the literature about the effects of different
strains of marijuana, without the ability to conduct double blind, randomized clinical
studies, sociological methods commonly employed to study hidden or other difficult to
study populations were employed. Patients and growers were interviewed and several
“Farmer’s Markets” and dispensaries were visited. In discussions with dozens of high
volume growers, all experienced growers acknowledged a difference in varieties, and
only three of the dozens of growers and vendors interviewed were not able to clearly
articulate those differences. The remainder were in almost total agreement and spoke
about “up” vs. “down” or “daytime” vs. “night-time” or most commonly “Indica” vs.
“Sativa.” The basic claim from patients agreed with the growers and producers, and the
literature on growing marijuana (Rosenthal 2002) that a product with a higher THC
content has a more euphoric effect. Conversely, there was broad agreement that a
product with a higher CBD content has sedative effect, known on the street as “couchlock” which (in the highest dose) imparts the classic “stoner” effect of sitting on the
couch practically unable to move, staring off into space.
The astounding variety of strains in medical marijuana currently available is an
entirely new area of research that does not have very many predicates in modern social
research, or medical research because of marijuana’s unique social history.

The
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closest analogy would be the strictly medical question of pharmaceutical choice. For
example a medical sociologist would probably not choose to design a study to
determine whether morphine or oxycontin provided better pain relief since this does not
concern the social causes of disease and is not related to the study of the medical or
legal systems.

There is usually no direct nexus that can be studied between the

sociological and biological causes of disease and medication preference. However, in
the case of medical marijuana there is a direct nexus between the sociology and biology
of strain preference. This nexus is the methodological approaches that sociology offers
which can circumvent the legal and social barriers to research on marijuana. As a
scientific discipline, Sociology is both methodological and theoretical and, given the
barriers to research, indirect qualitative methodologies aimed at hypothesis generation
are the only way to study issues like the proposition that different types of marijuana
may have different effects and therefore different medicinal properties. When social,
ethical or legal barriers impede research, another way to engage in the search for
scientific truth is to query the experts on the issue in question (Westfall 2004).
As this research evolved from the question of whether “medical” marijuana is
actually being used as medicine to a more advocacy oriented critical perspective, the
goals increasingly sought to provide a voice to this disenfranchised population. This
social group is marginalized and by bringing them to the light it is hoped it might
empower them to destroy myths about the dangers of marijuana and especially about
the self-fulfilling anti-marijuana argument regarding proof of medical benefits in different
types of marijuana. The population of medical marijuana users has been the subject of
intense legal and social discrimination.

Marijuana patients are lampooned as lazy,
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antisocial, hippie pot smokers in the popular media.

Yet the types and strains of

medical marijuana, as well as the use of these strains indicates considerable rational
thought, and provides objective evidence of medical need on the part of the medical
marijuana users. The preferences that were consistently indicated by patients about the
effects of certain types of medical marijuana for specific illnesses suggests that this
group is not only using marijuana as medicine, but the group is in fact using different
types of marijuana for different types of medicinal effects.

By investigating these

different types of marijuana and the perceptions that their use evokes, the hope is to
discover the rationale behind the use of medical marijuana in this group and to provide
evidence for the existence of different medicinal effects in different types of marijuana.
In turn this enlightens, in part, why so many would subject themselves to possible legal
action and produces testable hypotheses for future medical, clinical, and sociological
work.
The “Orchestra Effect”:
Marijuana contains more than 100 ingredients in different concentrations
depending on the strain and the harvest techniques (Rosenthal, 2002). According to
one unrecorded participant who was a tireless advocate for the cause of marijuana
activism and a prominent blogger and public speaker for the Michigan Medical
Marijuana Association, the heterogeneity of psychoactive components creates the
“Orchestra Effect.” He claims that all or almost all strains contain the same essential
components, but different strains contain different quantities and concentrations of
those components. Therefore, by analogy one strain might have a stronger “trumpet”
section while another might have a stronger “percussion” section “and this unique
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mixture in each strain produces that beautiful music we all love so much.” Even though
both strains (Indica and Sativa) contain basically the same components, albeit in
differing concentrations, the effect of the overall “composition” (i.e. the effect
experienced by the user) can be very different. The extended musical analogy is an
interesting way to conceptualize the different strains as different varieties of music
where different genres produce very different music even while using basically the same
instruments. Continuing, this participant provided the example of a Rock band and a
Blues band which both use a guitar, a bass, and drums but the music that is produced is
markedly different and unique to each genre. Like an orchestra, or a particular type of
music, different marijuana strains and cultivation techniques use the same building
blocks to produce strains that have different perceived psychoactive properties
(Rosenthal, 2002).
Medical Marijuana is different and much more potent than the illegal Marijuana
used before the change in the law:
Besides different medicinal effects, potency differences were also a prominent claim.
Most patients reported that “medical” marijuana available at dispensaries and other
vending locations was much different than the marijuana that was available before the
Michigan Medical Marijuana Act passed. The most prominent claim identifying this
difference was about the potency of the marijuana which most (except for two interview
participants who came originally from California) claimed was much higher with medical
marijuana than the marijuana previously purchased on the street.
I:

When did you start using medical marijuana instead of Vicodin most of the
time?

P:

I would say this happened when it got better, you know, when we passed
the law.
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I:

What got better?

P:

The pot got better

I:

What do you mean the pot got better?

P:

Stronger, more variety, much, much stronger than most of the ditch weed
you could get before. That did not help me like the stuff we have now.
(P5).

Caregivers agreed that “medical” marijuana was much more potent than most of the
marijuana available before the law passed.
P:

We test all of our medical marijuana here and, you know, the government
reports that most of the weed seized on the streets is 7% or 8% THC.
Just about the weakest stuff we carry is 12% THC, but that has a lot of the
Terpenes and CBDs that make it more medicinal. A lot more!

I:

So, your inventory, the weakest strain in your inventory is half again as
strong as the average strain on the street?

P:

No. Our weakest is probably two three or four times stronger than the
average ditch weed you get on the street. You have to consider more
than just the THC because the other chemicals control how much is
absorbed, how fast it is absorbed, how long the body takes to break it
down.

I:

And if it takes the body longer to break down then…

P:

[interrupting] Right, you feel it is, you know, a lot more potent. Our best
strain is almost 30% THC and one hit of that is like smoking an entire joint.
There is no comparison.

Far from the characterizations of the dangers of potent marijuana (NIDA, 2013) the
more potent marijuana was viewed by patients and caregivers as more effective
medicine which, paradoxically, also let patients decrease their overall use of marijuana.
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Medical Marijuana patients titrated their dosages of marijuana depending on
the potency:
Along with the claim of greatly varying subjective potency, patients and
caregivers consistently reported that they titrated the dosage depending on the potency
in order to achieve the desired effect. That is, when the marijuana was strong then the
patients smoked less to achieve the same “high” while when the marijuana was not as
strong they smoked more to achieve the same “high.”
I:

Has your use of marijuana increased or decreased since you became a
legal certified patient?

P:

Yes, I am able to find much better product, so I don't have to use as much.

I:

You are suggesting that potency means less use?

P:

That is exactly what I am saying, yes (P3).

Patients consistently reported that it was desirable to use less marijuana and therefore
inhale less smoke in order to achieve the same psychoactive or medicinal effect.

Different Strains of Marijuna Were Associated with Different Perceived Effects:
Most patients, and all of the recorded caregiver interviewees were aware of the
“Indica/Sativa distinction,” and most claimed agreement with the known literature that
Indicas provided a sedating effect while Sativas provided a more uplifting effect. In an
interview with a Caregiver, the differences were briefly outlined:
I:

Could you give us a primer on Indicas and Sativas, and medical use?

P:

OK, cannabis comes in two primary strains, one is Indica. Which comes
from South East Asia, the Indus river valley, and Sativa comes from more
equatorial Central America and South America. So, the nature of the
plant, Sativa has a greater impact on the person’s mental health in terms
of THC in Sativa particularly helps elevate mood, uplifts mood, creates a
mental relaxation state and is calming.
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I:

So the calming version is more of an equatorial plant?

P:

Yes, now in contrast, Indica as a plant comes from Northern Pakistan,
Southern Afghanistan, Indus River valley, same part of the world. And uh,
this the border region of Pakistan and India. The Indica plant naturally
produces a higher level of CBD which is Cannabidiol (P11).

Overall patients agreed that Indicas were preferred at night for the more “sedating”
qualities while
Sativas were preferred during the day for the more “uplifting” qualities.
There was Disagreement between the Limited Available Literature and Two of the Most
Serious Patient Cases Who Claimed Indicas Gave them More Energy While Sativas
Were Not As “Uplifting”:
One very interesting result, which should be viewed as very preliminary, but
which certainly deserves future attention was that while almost all patients and
caregivers consistently reported that even though different strains of medical marijuana
were associated with different perceived effects, and that they actively sought out the
preferred effects by choosing specific types of marijuana, there was NOT universal
agreement about how those effects were perceived. It is possible saturation could be
achieved on this topic given enough targeted interviews, but it is certain that saturation
was not achieved on this topic during the course of this study.
Some of the growers thought that Indica/Sativa hybridization and controlled
breeding had essentially erased the categories of “Indica” and “Sativa.”
No…it is not that simple…you can make an Indica with real high THC that
makes you wired, not couch-locked; and you can make a Sativa put out more
CBD and things like CBN just by waiting to harvest for a few days. Every
strain is different, sure, but every harvest is different, every grower is different.
We are all different. Everybody is different (P3).
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Several dispensary owners and growers agreed with this analysis and thought this was
a primary reason to allow dispensaries, so that patients could have access to different
strains so they could find “what works for them” (P3, P11, P16, and P25).
However, some minimal evidence was uncovered suggesting it is also possible
the factors giving rise to what “works for the patient” could be related to the qualifying
medical condition. The two most serious participants, both in considerable pain with life
threatening diseases did not agree with the common formula of uplifting Sativas and
sedating Indicas. In fact they totally disagreed about the uplifting qualities of Sativas
and the sedating qualities of Indicas. One was a terminal cancer patient, and the other
had Multiple Sclerosis, and both were in considerable pain. They both suggested that
Indicas were more “uplifting” for them even though the other recorded Interviews either
speculated that the effect was “individual (P11, P16) or agreed that Indicas were more
sedating.
Sure I know what they say [about Sativas] but Indicas give me energy, I
don’t know why. Isn’t that weird? (P27).
I prefer Indicas because they make me feel better. I can just do more
activities when I smoke an Indica (P14).
Based on the limited data collected in this study on this topic, a reasonable hypothesis
can be offered which requires further elucidation:

Medical marijuana patients with

terminal cancer or M.S. might perceive the effects of marijuana differently than medical
marijuana patients with less serious conditions.

Even more significant, patients in

significant pain appeared to prefer high CBD while those with mental or emotional
trauma preferred high THC. As a preliminary matter, this suggests that CBD may be
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associated with decreased pain sensation which, if true, significantly undercuts the
argument that medical marijuana is a mere “ruse.”
Conclusion of Strains:
The ultimate goal of medical marijuana is to be able to develop strains specific
for specific conditions.

The heterogeneity of marijuana and the heterogeneity of

responses to different types of marijuana that is identified in this study also suggest that
different types of marijuana might be developed for different medical conditions. These
results suggest that patients with chronic pain are likely to respond to different strains of
marijuana differently than patients with anxiety or depression.

Further research is

clearly needed on whether it might be efficacious to identify medical condition specific
strains and this requires relaxing federal regulatory obstacles so actual clinical studies
on actual medical marijuana can be conducted.

The preliminary results from

interviewing knowledgeable caregivers and patients about their experiences with
different strains of medical marijuana suggest that a focused scientific program to
develop specific strains and identify specific psychological and medicinal components in
marijuana is long overdue.
In addition to the potential medical benefits, the identification of medicinal
properties in marijuana is an important piece of evidence in the ongoing Cannabis
Dialectic.

The amount, degree, and character of the heretofore documented

governmental resistance to legitimate scientific inquiry and any findings of the potential
beneficial and medicinal effects of marijuana suggests this evidence may exist, and that
it may be an important factor in influencing public opinion and claims making on behalf
of medical marijuana. As we have seen, this intractable social dispute has been a
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problem for many decades with two highly polarized sides.

One side claims that

“medical” marijuana is a “ruse” to legalize all drugs for all purposes while the other
claims marijuana has significant medicinal properties.

This section presents some

evidence towards the hypothesis that different types of marijuana have different
perceived effects.

If confirmed, this could be a highly persuasive argument that

marijuana does, at least some of the time for at least some types of patients, actually
have medicinal properties. Evidence that different patients perceive different types of
marijuana as more or less medically beneficial depending on both the patient’s medical
condition and the concentration of various compounds in the marijuana is even more
persuasive evidence that marijuana is “medical.”
warranted.

More research on this topic is
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CHAPTER 7: LIMITATIONS AND CONCLUSION
Research Problem and Significance:
The War on Drugs, and on marijuana, has remained contentious since even
before the 1937 Marijuana Stamp Act (P.A. 238, 75th Congress, 50 Stat. 551, Aug. 2,
1937) with some 700,000 arrests for marijuana possession each year in the United
States. This amazing figure has remained fairly constant, year after year, despite the
fact that marijuana was common and grown throughout the early history of the United
States as a commodity that provided oil, fiber, food, and medicine. Recently there have
been increasing claims about claimed medical uses for marijuana. By 2013, despite
federal opposition, medical marijuana was approved in 17 States and the District of
Columbia while full legalization of marijuana was approved in two States, Washington
and Colorado.
The courts, law enforcement, and other government agencies have subjected
marijuana users to penalties and thereby marginalized them while making research on
the population of users, and on the banned substance, marijuana itself, extremely
difficult. This social split between the pro and anti-marijuana forces which was identified
as the “cannabis dialectic” is obvious and has been fueled by nearly 80 years of legal,
social, and media dogma. The major social actors from government, to the media, to
the courts, policing, and corrections disproportionately favor the anti-marijuana position,
often enforced by harsh legal penalties, well-funded research programs, and directed
media campaigns of social opprobrium. Until very recently the perspective of marijuana
users has been almost completely ignored and marginalized by the popular culture,
including in the media, academia, medicine, and scientific research.
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In order to address this lack of balance, the research question in this study was
initially whether marijuana was actually being used as medicine, as claimed by many
advocates, or whether “medical” marijuana was actually a “ruse” to legalize drugs for all
purposes as claimed by many opponents.

The advertising flyers used to attract

participants in this study asked for interviews with medical marijuana patients who were
willing to talk about their use of marijuana as medicine, and from the earliest interviews,
it became apparent that the answer was an unequivocal yes. Beyond doubt, some
patients were using marijuana medicinally.

Therefore, the major aim of the paper

became the presentation of the patient and caregiver perspective of the medical
marijuana issue. Given the large amount of research expended on drug treatment, and
the social, psychological, and physiological harms of marijuana, it was believed that the
perspective of those committed to the use and provision of marijuana as medicine was
needed, and this was the primary purpose of this study. If marijuana is actually being
used as a medicine and not always being “abused” as an intoxicant, then the validity,
safety and efficacy of marijuana as medicine is the pivotal issues for medical marijuana.
If marijuana is a safe and legal drug that treats a number of medical conditions, then the
arguments of the anti-marijuana groups is compromised.
Methods:
This study employed in-depth, recorded interviews of medical marijuana patients
with a total of 31 medical marijuana patients giving recorded interviews.

Twenty

recorded participants who were “regular” patients and eleven were patients and also
producers or “Caregivers” under Michigan law. Several dozen shorter, often impromptu
discussions were also conducted but not recorded for various reasons. Pursuant to IRB
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protocols, all persons who gave interviews from which data was collected via
handwritten notes during or afterwards, or who were recorded and transcribed, were
provided IRB approved information sheets. Often impromptu discussions took place
while awaiting the scheduled recorded interview or while visiting a medical marijuana
club or dispensary. Other discussions were held with medical marijuana physicians,
and attorneys specializing in medical marijuana law.
Interpretive Research Methods:
Qualitative research is often the interpretive task of finding individual meaning
that empowers “certain agents to create representations and thereby to authoritatively
pronounce on the shape and structure of the world” (Hess-Biber & Levy, 2004). The
interpretive researcher views the world as the participants view the world and attempts
to see and convey what the participants see. In short, the fundamental characteristic of
qualitative research, whether used to study “primitive” cultures or contemporary cultures
and groups, is the “commitment to viewing events, actions, norms and values from the
perspective of the people being studied (Bryman 1988). This task was simplified by the
fact that the writer is himself a registered medical marijuana patients and an “insider”
with this population.
Recruitment:
Prospective participants were recruited using IRB approved flyers posted at
Compassion Clubs and other sites where medical marijuana patients were known to
congregate and by referrals. Efforts were made to obtain a recorded interview sample
population that roughly looked like the Michigan medical marijuana population on the
categories of gender and qualifying medical condition although proper caution must be
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taken in interpreting these results since the sample in no way represents a probability
sample.

Interviews:
The recorded interviews were transcribed while the unrecorded interviews
involved either note-taking or subsequent dictation of the findings. Most of the recorded
patient interviews took approximately an hour while most of the caregiver interviews
took one to two hours. The unrecorded interviews varied from a few minutes to more
than 1-hour. Each recorded interview was conducted in a private, safe location of the
participants choosing and conducted using an eight page Interview Guide as a
template. However, they were not heavily structured and the topics drifted depending
on the interests and concerns of the participant. The unrecorded interviews were totally
unstructured.

The main purpose of the interviews was to identify the patient and

caregiver perceptions about the effects, use, acquisition, and provisioning of marijuana
in light of their qualifying medical condition.
Each recorded interview began with the question:
condition to use medical marijuana in Michigan?”

“What is your qualifying

This was followed by a detailed

medical history, and then the participant’s perception about his/her use of medical
marijuana, including beneficial and harmful effects, method of use and how often they
used medical marijuana, as well as, an interactive discussion of the certification
process, and each individual’s visit to the medical marijuana doctor. The topics of
stigma, dealing with the children of patients, use of different medical marijuana strains,
and initiation into the use of marijuana and medical marijuana were added later to the
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interview guide.

Finally, demographic information such as income, class, political

affiliation, work and school history, and religion were briefly discussed. The Interview
Guide was changed and adapted as new information became available from
participants. Four topics were chosen to present as findings for this paper: reduced
opiate usage, unequal enforcement and stigma, availability, and quality. Each chosen
topic or theme (as well as subtopic and themes) is given a separate Chapter in the
“Results” section. Narrative passages from the transcripts provide multiple perspectives
that were used in a discussion of the interconnected themes (Creswell 2003).
Data Analysis:
Transcript excerpts were coded and place into one or more of 12 initial
categories (Table 4). Qualitative data analysis is iterative and reflective which means
that data analysis is circular with new information feeding back and causing the
researcher to change tone and the questions for the next interview.

The process

continues until saturation of the data is achieved. Some of the findings reported in this
study were obvious almost immediately and saturation of the data occurred relatively
quickly.

For example, the first four interviewees spent some time talking about their

perception that marijuana use let them decrease their opiate use, and this continued
throughout every single one of the thirty one interviews where the patient’s complaint
was chronic pain.

However, it was not until very late in the interview process

(specifically interviews 25 and 26) that the structure of dispensaries and alternate
marijuana delivery organizations came into focus. Saturation of the data on this topic
did not occur until the final two interviews. Saturation of the data for different strains of
medical marijuana did not occur during this study and this report is very preliminary.
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Results:
Four major results are reported in this study: The first finding was that medical
marijuana patient consistently claim that the use of marijuana by Michigan patients
reduced or eliminated their need for prescription painkillers.

The second finding

provides evidence of patient concerns of ambiguity, unfair, and unequal enforcement of
the Medical Marijuana Act. The third finding provides a description of the structure and
functions of medical marijuana centers in Michigan before the McQueen decision
outlawed transfers of marijuana in February, 2013. The final finding addressed by this
research is suggestive that different strains of medical marijuana have different effects
and are both perceived, and used differently by different patients, possibly depending
on the patients qualifying medical condition.
Finding 1: Reduced Opiate Usage was the primary, overwhelming finding in this
study. Patients and caregivers agreed that the use of marijuana by Michigan patients
reduced or eliminated the need for prescription painkillers. This result was obtained
from the final codes on “Beneficial Effects,” the “Cannabis Dialectic,” and “ReverseGateway” along with several comments from the category “Hippy Talk.”
Finding 2 Unequal enforcement and Stigma (Ambiguity and unequal enforcement
of the Medical Marijuana Act) was the main topic of the interviews. Many participants
volunteered to be interviewed so they could speak with a licensed attorney about the
Michigan Medical Marijuana Act so this topic was front and center in both the recorded
portions of the interviews and even more so in unrecorded and/or preliminary
discussions.

The legal concerns were ubiquitous and focused on availability of

marijuana, and government regulation of distribution in light of the developing case law
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on the topic in Michigan. Most of these results were synthesized from the final codes on
the “Cannabis Dialectic,” “Doctor’s Visit,” “Michigan Marijuana Act,” and “Stigma.”
Finding 3: Dispensaries, Availability and Access (Medical Marijuana Center
structures before the McQueen outlawed transfers of marijuana) was another common
discussion, particularly with dispensary owners and operators and for the same reason
as finding 2 (i.e. because the interviewer was an attorney in Michigan).

Several

marijuana distribution strategies were pursued in several different functional
arrangements with different dispensary structures, delivery services, and farmer’s
markets.

This topic was chosen as a finding to report because it was considered

socially important with considerable relevance to how future legislation could be
structured and because of the unprecedented access to and cooperation from
dispensary owners in Michigan this author gratefully received. Paradoxically, this topic
becomes even more salient with the Michigan legislature, and other State legislatures
considering dispensary options. Most of this information was taken from the sections on
“Dispensaries.”
Finally, Finding 4: Effectiveness of different strains of medical marijuana was
taken from the section on “Strains.” The finding was that different patients pursue
different strains of marijuana for the different perceived effects and that this perceived
difference may be related to the patient’s qualifying medical condition. This was a very
difficult topic to pursue and, in fact, it is a topic that has never been explored in any
systematic way, and certainly not in any clinical way.

The new medical marijuana

strains are extremely potent and have a variety of effects but most are just a few years
old and cannot be studied in the United States due to NIDA restrictions. The results

169
from this topic should be viewed as very preliminary and further research is urgently
needed.
Limitations: This study presents a very unique set of data: The actual words,
beliefs, and thoughts of a sample of medical marijuana patients and caregivers in the
State of Michigan.

However, this was not a probabilistic sample of patients and

participants were obviously over-represented by volunteers with strong, often very
articulate beliefs in the efficacy of medical marijuana. All but four of the participant
patients had (at least) a small personal grow as permitted under Michigan law as did all
of the caregiver participants.

No African Americans and only one Hispanic were

interviewed. Four African American interviews were scheduled but unfortunately none
were completed.

The medical marijuana law was strongly opposed by the State

Attorney General and several local prosecutors and a number of prominent patient
prosecutions occurred during the time this research was ongoing. Therefore it is not
surprising that the rate of last-minute cancellations was very high in this sample with
approximately 80 interviews scheduled over a 2 year period and only 31 completed and
recorded. After the first few interviews there were so many volunteers that cancellations
were generally not followed up. This sample does approximate both the gender ratios
found in the medical marijuana population and the types of qualifying conditions in the
population, but there is no representation that it is probabilistic. Appropriate caution
should be exercised in interpreting these results and generalizing them to the population
of medical marijuana patients and caregivers in Michigan.
Based on the tone of the interviews, and conditions reported by the State of
Michigan (LAR, 2012) it is believed that the sample in this study included those with
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more defensible medical conditions than the general population of patients. In other
words, it is reasonable to assume that if patients had a question about whether their
medical condition rose to the level of “serious or debilitating” (MCLA 333.26424)
required under Michigan law it is likely they did not volunteer to be interviewed for this
convenience sample about their “use of marijuana as medicine.”

Certainly no

“questionable” cases were referred by any of the Caregiver referral sources. These
results are qualitative and should certainly not be interpreted to suggest anything about
the degree of seriousness that would be found in a probabilistic sample of medical
marijuana patients. The results from the caregiver interviews contain excerpts from
highly educated professionals and individuals with considerable specialized knowledge
of the patient population. However, they also had a pecuniary interest in the medical
marijuana industry. Obviously they were not an unbiased group and were in a position
where they would be more likely to support the idea of beneficial effects from the use of
marijuana. Therefore, their results deserve particular and skeptical scrutiny. Many
were tireless advocates for the cause of medical marijuana and could only be described
as true believers.
Qualitative Hypotheses and Future Research Directions:
In depth, qualitative interviews of 20 medical marijuana patients and 11
“Caregivers” (producers, growers, vendors, and activists) were conducted resulting in a
wide range of findings. Shorter, informal interviews were held with approximately 100
participants including 9 medical marijuana attorneys, 4 medical marijuana certifying
physicians and (in addition to the 11 recorded interviews of caregivers) 16 growers, or
dispensary owners and operators who were not recorded.

The most important and
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most obvious and clear finding was that medical marijuana patients report substituting
marijuana for prescription drugs, particularly opiates.

A variety of concerns about

access, legal issues, and enforcement of the Medical Marijuana Act were also
discussed during the interview process along with the structure of medical marijuana
centers and the bewildering varieties of medical marijuana strains that are available.
This is the first reported study on the medical marijuana population in Michigan.
Qualitative results allow the formation of testable hypotheses.

Based on the data

provided by this research, the following hypotheses are offered as potential subjects for
further research:
1.

Some medical marijuana users may be using marijuana as a substitute or

replacement for opiate narcotics. In particular this data suggests an avenue for clinical
research using medical marijuana for adjunctive pain treatment, especially in those
patients with persistent opiate addiction, or with those individuals resistant to more
standard forms of analgesic treatment.
2.

Medical marijuana may be more effective than some types of narcotics by

providing analgesia without the side effects associated with opiates. Randomized and
blinded clinical trials need to be permitted by the government and performed by
researchers to provide evidence or falsification of this hypothesis.
3.

Patients and caregivers agree that law enforcement and courts hostile to

the medical marijuana act have used the statutory ambiguities to engage in uneven
enforcement activities contrary to the will of the people as manifested in the referendum
that created the Michigan Medical Marijuana Act.
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4.

Most medical marijuana patients were concerned about access to

marijuana before People vs. McQueen outlawed dispensaries in Michigan. Without
dispensaries, it is not clear how patients are obtaining their medical marijuana. The
legal caregiver registry system that is still in place may be the vehicle for marijuana
distribution or patients may have returned to the black market practices common before
the Marijuana Act. Further research on this topic is warranted.
5.

Before McQueen groups formed to distribute marijuana in a variety of

structures from Farmer’s Markets, to Compassion Clubs, to dispensaries, in order to
provide access to marijuana. These structures can no longer be easily studied because
they are illegal in the State of Michigan but there spontaneous organization and the
structures that formed and operated before McQueen provides a path for other States to
follow and for the Michigan legislature as it considers a legal distribution system for
medical marijuana patients.
6.

Patients and providers formed a variety of advocacy groups and have

taken other measures to advocate for medical marijuana, protect themselves from law
enforcement, and help insure access to marijuana.

Private relationships with local

government officials protected and authorized local distribution networks while
marijuana advocacy organizations such as the Michigan Medical Marijuana Association,
the Michigan Association of Compassion Clubs, the Marijuana Policy Project, and the
National Organization for the Reformation of Marijuana Laws advocate for patients,
caregivers, dispensaries, and other medical marijuana providers.
7.

The literature from grow manuals and seed bank publications claim that

indica strains of marijuana have a different effect than sativas and that indicas are
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associated with sedation while sativas are associated with a more uplifting effect.
Patients and caregivers generally agreed about the expected and perceived effects of
these different strains of marijuana. However, a few caregivers denied the arbitrary split
between indicas and sativas and claimed the effects are “individual” to each specific
patient or there are too many factors involved to identify the categories.
8.

Two of the most serious patient cases gave different answers than the rest

of the patients and claimed that indicas gave them more energy while sativas did not
which suggest there may be something medicinal (like CBD) in the indicas which are
making them feel better and providing more energy. Interviews focusing on the most
serious cancer and M.S. patients should be conducted.
The results in this dissertation do not provide evidence or proof of these
hypotheses but they do raise the questions, offer solid hypotheses for future research,
and provide ample justification for that further research. Research is needed on the
possibility that medical marijuana might aid the treatment of persistent opiate addiction
and that marijuana can act as an adjunct or even a replacement to opiate use. Clinical
trials comparing opiates with medical marijuana are needed and long overdue. Future
work could also survey or interview larger patient samples, or focus on medical
marijuana patients who are current or former opiate addicts.

There is a need for

research into the issues of medical marijuana efficacy and patient characteristics.
Despite regulatory barriers to medical marijuana research, qualitative interviews
of patients provides a viable alternative to understanding the population, untangling the
cannabis dialectic, describing the alternative provider distribution network, and providing
evidence for the medical use and efficacy of marijuana.

However, since all the
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interviews in this study were before People vs. McQueen outlawed dispensaries in
Michigan, further work is needed to determine if the legal concerns of patients and
caregivers and in particular the concerns about access to medical marijuana have
increased since dispensaries were legally closed by the Michigan courts. Further work
could also investigate the scope of dispensaries that remain open in opposition to the
court ruling and the impact and reaction to the ruling by the State-wide advocacy
organizations. Finally, considerably more work is needed on the different strains of
medical marijuana. The findings in this dissertation suggest that more serious patient
cases might prefer high indicas which are higher in CBD which has been shown in cell
lines and animal studies to have anti-inflammatory, analgesic, and anti-pyretic effects
which could be important clue to finding the “medical” in medical marijuana.

Disclosure of Interests: The author certifies that he has no commercial, proprietary, or financial
interests in the subject, companies, or products mentioned in this manuscript. This PhD Dissertation in
medical sociology is with the Department of Sociology, Wayne State University. The author did not
receive payment, grants or consulting fees to conduct this study and has no prior or existing pecuniary or
financial relationship with any participants or organizations who participated in this study or who assisted
in obtaining interview leads. Interviewees were volunteers and were not paid for their time.
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APPENDIX 1: INTERVIEW GUIDE
Introduction:
This is the interview Transcript of Participant _________ who has kindly given his/her (hereafter
generic male pronoun) permission to record his statement is that correct?
Your identity will remain confidential and you are free to skip or refuse to answer any
question(s) for any reason. You may stop the interview at any point, and refuse to answer any
more questions. Do you have any questions for me before we begin?
OK, this is for a PhD program in medical sociology so I am primarily interested in the reasons
why people are using medical marijuana, what is the range of patients and medical conditions
that are treated and what are some of the problems people experience with this new treatment. So
I am interested in your medical condition, your qualifying condition, what went into your
decision to become certified to use medical marijuana, and your personal thoughts, ideas, and
beliefs about how marijuana works for you.
So I would like to ask you some questions about your medical history.
Medical History/Qualifying Condition
•

What is your qualifying condition?

•

How long/When diagnosed

•

Who diagnosed (physician specialty- PCP, specialist or medical marijuana clinic doctor?

•

Could you just give me a narrative of your condition, and the treatment you have
received?

•

History of medical providers seen for condition

•

How does this condition affect you?

•

Describe daily routine

•

Any impairments, symptoms, signs, etc.

What type of treatment have you had for this condition?
•

Any major surgeries?

•

other drugs

•

invasive treatments

•

non-invasive treatments
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Other medical conditions besides your qualifying condition?
•

get into detail

Use of medical marijuana
How does marijuana help your qualifying condition?
•

Describe in detail: Specifically WHAT does marijuana do for this condition?

Does using marijuana help any of your other conditions besides the qualifying condition?
Have you been able to decrease other treatments since you started using medical marijuana?
•

narcotics decreased?

•

Gateway or Reverse-gateway drug?

* Reverse Gateway is a new term derivative of several conversations with physicians
specializing in medical marijuana certifications. There is a large body of well-funded
psychological research suggesting that marijuana is a “gateway” to “harder” drugs such as
heroin and cocaine. Some certifying physicians criticize this methodology and characterize
medical marijuana as a “reverse-gateway drug.” In other words, far from serving as an
initiation and introduction to “hard” drugs the experience suggests the precise opposite. The
physicians claim that medical marijuana patients are able to use marijuana to stop using or at
least reduce the need for harder drugs such as oxycontin, vicodin and opiate pain relievers.
Have you been able to reduce or discontinue any medications as a result of having medical
marijuana available to you?
•

frequency of doctor visits and treatment

How would you rate your ability to function in everyday life before you started using medical
marijuana and after you became a patient?
•

improved or not?

•

able to work now but could not before?

•

comfort level?

•

Are you able to do any activities now (or more frequently) than you could before as a
result of medical marijuana?

•

driving

•

work
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•

physical or mental activities?

•

MM vs. other medical tx.

Has your use of marijuana decreased, increased, or stayed about the same since you became a
legal certified patient?
Adverse Effects of M and MM
Some research suggests that marijuana causes memory impairment and a-motivational syndrome
or laziness, and that marijuana smoke has a much higher level of cancer causing chemicals than
cigarette smoke. Have you noticed any physical, cognitive, or mental problems from your use of
marijuana?
"How important is medical marijuana for your health?"
"What are your feelings about the legalization of medical marijuana?"
Drug History, Past and Current use patterns, before & after registered MMM status
Now I would like to ask you some questions about your Drug History, Past and current use
patterns, before & after registered MMM status
Do you drink alcohol?
•

approximately how much per week?

•

have you ever felt or feared that you might have a drinking problem?

Have you used other illegal drugs in the past?
•

Cocaine (crack, powder, mainline)

•

Heroin

•

Hallucinogens

•

Meth

•

Nicotine/Cigarettes

•

others

•

Prescription drugs (depending on qualifying condition)

As you know marijuana is still considered a Schedule 1 drug by the federal government with no
legitimate medical use and a high abuse potential:
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What are your thoughts about that?
How would you personally compare marijuana to these other drugs given your personal
experiences?
•

dangers

•

abuse potential

•

medicinal value of any other drug (including alcohol and prescription drugs)

•

benefits

Did you have experience with marijuana before you developed your qualifying condition?
•

when

•

how often

•

how used

•

for how long

Without being specific or providing any identifying information, how do you get your medical
marijuana?
•

Grow your own

•

You have a Registered Caregiver

•

Purchase on the street

•

Friend

•

Dispensary

•

Co-op/club or farmer’s market

•

Other source- please be specific without providing any specific identifying information.

How do you use marijuana?
•

medibles

•

vaporize

•

smoke

•

regular pipe

•

joint
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•

water pipe

In what type of social setting do you consume marijuana?
•

are you usually with other people/friend/family?

•

are you usually alone?

How often:
•

Several times a day

•

Every day

•

Every night 4. About every other day

•

A few times a week

•

A few times a month

What kind?
Why did you go through the trouble of getting certified to use medical marijuana?
Was going through the certification process worth it?
Will you get recertified next year?
Stigma:
Ask: what do you think means before reading definition:
(1) a mark of shame or discredit, disgrace or infamy; a stain or reproach, as on one's reputation.
(2)Medicine/Medical. a mental or physical mark that is characteristic of a defect or disease: the
stigmata of leprosy.
•

Family, Parents

•

Social

•

Medical Professionals (see also ‘certification’)

Dealing with Children
Strain Preferences Indica/Sativa etc.
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Initiation- M and MM
Demographics: Age, Gender, Family, Size, members, status,
Now I would like to ask you some general demographic family, and employment history
questions. In your answers please do not be specific enough so that a person reading this
transcript would be able to identify you personally.
You are a (male/female) in you (20’s, 30's)
Did you grow up in a small town, the country, or the city?
Are you married?
•

Any kids; how many; also other marriages/marital history

How would you rate your economic status?
•

less than $20,000.00 for a family of 4

•

25-35K for a family of 4

•

35-55K

•

60-150

•

over 150K per year

How have you been employed?
•

disabled (due to qual. condition?)

•

management

•

temporarily unemployed (for how long) –

•

Professional (doctor/lawyer/executive)

•

office worker

•

sales

•

retail –

•

small business owner

•

construction

•

other

•

manufacturing
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How are you currently employed?
If unemployed where were you employed?
Please tell me about your employment history?
•

go through in detail depending on time

What is/was your income during your best year? When was that?
What did your family (parents/spouse/kids) think about you becoming a medical marijuana
patient?
•

do your kids know about your patient status?

•

approximate ages

•

how did you tell them

•

any barriers or obstacles from family such as parents or spouses opposing?

•

do you feel you have ever been stigmatized or discriminated against, or treated differently
because you are a medical marijuana patient?

Politics, Religion:
Finally, I would like some general information on your political and religious orientation.
Are you a member of an organized religion?
On a scale of 1-10 with 10 being the most religious person you have ever met, how would you
rate yourself in terms of your dedication to your religion?
•

Do you go to church (etc.) regularly?

•

pray?
o Every day?
o Every week?
o About what?

Is there a conflict between your religious beliefs and your use of marijuana?
Do you consider yourself a liberal, or a conservative?
•

abortion

•

GWOT
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•

Same sex marriage

Republican or Democrat?
Based on your status as a patient, what do you think about the full legalization of cannabis? Have
your attitudes changed since becoming a patient?
Are you satisfied with MMM Law? How would you change?
I am going to read to you a statement from Appellate court Judge O’Connell. Are you aware of
his concurring opinion?
--he basically said the law is unclear and that anybody in Michigan who uses medical marijuana
for any reason can expect the DEA to come knocking at their door.
I would like to get your reaction to a quote from his opinion:
“I do not direct my critical comments toward those qualifying patients who do in fact have a
serious debilitating condition and seek some solace in medical marijuana. This act was intended
to help those individuals. My comments are directed at those who are currently abusing the
written certification process, i.e., the majority of the persons who are becoming certified at this
time… medical marijuana users “who proceed without due caution” could “lose both their
property and their liberty.”
Based on your observations, do you think the vast majority of medical marijuana patients are
abusing the certification process and do not have a legitimate medical need?
Conclusion
Is there anything else you would like to tell me that I did not cover?
Do you have any questions for me?
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APPENDIX 2: ADVERTISING FLYER

RESEARCH PARTICIPANTS WANTED FOR
MEDICAL MARIJUANA STUDY

Do you have your medical marijuana card in Michigan? Are you willing to
help with some important research sponsored by the Sociology Department
and the School of Medicine at Wayne State University?
We are looking for patient and caregiver VOLUNTEERS to sit down and
interview about your personal views, and experiences with marijuana as
medicine.
We will follow standard research procedures for interviews. They will be
recorded and transcribed but identifying information is masked or deleted
to protect patient confidentiality. The tape will be deleted after
transcription. You have the option of receiving a copy of the transcript and
providing your additional comments.
You may terminate the interview at any time and refuse to answer any
question. There is no funding to compensate participants and participation
is voluntary. Interviews will take approximately 1-hour.
Contact Dave: dpeters@med.wayne.edu or leave message at
734-765-6212. Thank you so much for your help!
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ABSTRACT
QUALITATIVE REPORTS OF MICHIGAN MEDICAL MARIJUANA
PATIENTS AND CAREGIVERS INCLUDING
REDUCED OPIATE USE, DISPENSARY OPERATIONS,
LEGAL CONCERNS, AND MARIJUANA STRAINS
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After hundreds of years of use the medical properties of Marijuana have been
marginalized in our society. Qualitative interview data was collected from medical
marijuana patients and knowledgeable producers and activists in Michigan about their
perceptions and observations on the medical use of marijuana. Patients consistently
reported using marijuana to substitute or wean off prescription drugs. All patients and
producers who were taking opiate narcotics claimed they reduced overall drug use,
especially opiates, by using medical marijuana. Patients and caregivers also claimed
medical marijuana was preferred over opiates, eased withdrawal from opiates, and in
some cases was perceived as more effective at relieving pain. Other issues explored
included the operation of the Michigan Medical Marijuana Act, the formation and
operation of medical marijuana centers in the face of countervailing State and federal,
opposition, and the varieties and effects of different strains of medical marijuana.
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State and Federal Marijuana Laws
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